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ABSTRACT 
 
Objectives: To develop a prototype decision aid used to assist ulcerative colitis patients 
when deciding between ileal pouch-anal anastomosis (IPAA) and ileostomy. 
Methods: Three separate systematic reviews (quality of life studies, IPAA studies, 
ileostomy studies) were conducted to populate the decision aid with outcome 
probabilities. Meta-regression was used to select appropriate pooled outcomes.  
Results: Of 3920 studies reviewed, 9 studies reported on quality of life, 67 on outcomes 
following IPAA, and 11 following ileostomy. No difference in quality of life was found 
between procedures. Among IPAA patients, pooled pouch failure rate was 5.5%, with 
pouchitis being the most common complication (22%). Among ileostomy patients, the 
pooled rate of ileostomy revision was 17.1%.  
Conclusions: No surgical option is clearly superior and patients must weight specific 
risks and benefits in deciding between procedures. This newly developed decision aid 
may help patients decide which option is best for them.  
 
KEYWORDS: Ulcerative Colitis; Decision Aid; IPAA; Restorative Pouch; Quality of 
Life; Ileostomy 
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CHAPTER ONE-INTRODUCTION 
 
1.0 Overview 
  
 Some therapeutic decisions faced by patients are easy for example, use of 
antibiotics to treat an infection or having surgery to remove a cancer. Few patients would 
find difficulty deciding between leaving an ultimately fatal cancer to grow or removing it 
with surgery. Other decisions in medicine are not as clear with the benefit of one 
treatment option over another depending on the balance of differing complications and 
outcomes associated with each treatment. One example is the decision between a 
lumpectomy and radiation after lumpectomy (breast conserving surgery) or a mastectomy 
faced by women with localized breast cancer. Both treatment options are associated with 
equivalent survival
1
 but the implications of the treatment and its consequences for the 
patient are different. Women faced with this decision must balance the increased 
locoregional recurrence rate and need for adjuvant radiation associated with breast 
conserving surgery versus the more invasive mastectomy entailing the removal of the 
entire breast but sparing the need for radiation. This is a difficult decision as it comes at 
an emotionally charged time and requires the assimilation of complex medical 
information to properly weigh the risks and benefits of each option.  
In an effort to enhance and support this decision making process, researchers at 
McMaster University developed a decision aid to assist patients and their clinicians when 
discussing these treatment options
2
. Their decision aid consisted of a visual aid and 
written material systematically developed to present the information based on the best 
available evidence to the patient during the surgical consultation. This decision aid was 
subsequently tested in a randomized controlled trial involving women who faced the 
2 
 
 
decision of breast conserving surgery or mastectomy. Use of the aid was not only 
associated with improved patient knowledge about the two treatment options, but also 
improved satisfaction and reduced decisional conflict
3
. Thus, the use of the aid not only 
enhanced the decision making process but left women more satisfied with their chosen 
treatment.  
 A similarly complex decision faces patients with ulcerative colitis. Approximately 
one third of patients with ulcerative colitis will ultimately undergo a proctocolectomy 
(removal of the entire colon and rectum) for the management of their disease
4
. Following 
the removal of the colon and rectum, patients have two main reconstructive options. Both 
options involve trying to overcome the loss of the reservoir function provided by the 
rectum which is pivotal to maintaining control of bowel function on a day to day basis. 
One is to restore intestinal continuity by fashioning a neo-rectum using the ileum and 
anastomosing (joining) it to the anus, a procedure known as ileal pouch- 
anal anastomosis (IPAA). This strategy results in a new rectum formed by the small 
bowel, thus patients continue to have bowel movements via their anuses, but the 
frequency of movements is increased (6-20 times per day). The other surgical option is to 
bring the end of the ileum out to the skin as an ileostomy. This procedure results in 
patients passing feces through the ileostomy and into an appliance. Both of these options 
result in very different experiences, complications, and implications for day to day life. 
This is a complex decision with  lots of factors to consider for patients, and as no option 
has been shown to be superior to the other
5
, patient preference for either procedure guides 
the therapeutic decision
6
. 
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1.1 Objective  
To our knowledge, no decision aid has been developed to support and facilitate 
the decision between surgical options faced by patients with ulcerative colitis.  The 
objective of this thesis was to develop a prototype decision aid for patients with 
ulcerative colitis who are undergoing an elective proctocolectomy and have to choose 
between IPAA and ileostomy. This work represents the first step in developing a decision 
aid that will ultimately be refined and evaluated by patients with ulcerative colitis. In 
order to appreciate the necessity for the aid, background information detailing the role of 
surgery in the management of ulcerative colitis and the different surgical options will be 
presented in the first chapter. This introductory chapter will also include information 
about decision aids and will outline the process of decision aid formation. Subsequent 
chapters will deal with the literature review and meta-analyses necessary to populate the 
decision aid with information based on the best available evidence. Finally the prototype 
decision aid and its plan of refinement will be presented.   
 1.2 Ulcerative Colitis 
 Ulcerative colitis is one of two major forms of inflammatory bowel disease (IBD), 
the other being Crohn’s disease, and together they affect approximately 0.5% of 
Canadians
7
. Although often lumped together, Crohn’s disease and ulcerative colitis 
represent distinct clinico-pathologic entities. Ulcerative colitis is limited to the mucosa of 
the bowel wall, while Crohn’s disease involves transmural inflammation. They differ in 
their distribution as well, with ulcerative colitis being limited to the rectum and colon, 
while Crohn’s disease can occur anywhere along the gastrointestinal tract8.   
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In ulcerative colitis, chronic inflammation of the colon and rectum induces 
symptoms of diarrhea, abdominal pain, bloody stools, and weight loss. In its most severe 
form, the disease results in a life-threatening colonic emergency (fulminant colitis) 
characterized by systemic sepsis and multi-organ failure. In addition to these effects, it 
also places patients at increased risk of colon cancer. Medical treatment may temporarily 
control symptoms but the only definitive treatment is surgical removal of the entire colon 
and rectum. What follows is a brief look at the epidemiology, risk factors, clinical 
features, diagnosis, and treatment of ulcerative colitis with specific emphasis on the role 
of surgery and the surgical options. 
1.2.1 Epidemiology  
  
 Ulcerative colitis is a disorder of the developed world, with the highest annual 
incidences being found in Europe (24.3/100 000 person-years) and North America 
(19.2/100 000 person-years) when compared to Asia and the Middle East (6.3/100 000 
person-years)
9
. Although first described in the 19
th
 Century, the incidence and prevalence 
of ulcerative colitis have been increasing
10, 11
. In Canada, the estimated prevalence of 
ulcerative colitis is 211.2/100 000 with an annual incidence of 12.9/100 000 person-
years
7
. With an estimated population of 34 million in 2010, there were approximately 
4000 new cases of ulcerative colitis diagnosed in that year alone
12
. Ulcerative colitis is 
considered to have a bi-modal age distribution with most patients developing the disease 
in early adulthood and a second peak of incidence in the 50-60 age range
13
. Mean age of 
diagnosis of inflammatory bowel disease in North America ranges from 33-45 years
14
, 
with ulcerative colitis developing 5-10 years later than Crohn’s disease15. The gender 
distribution of ulcerative colitis is fairly even, however, men are more likely to develop 
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disease later in life
16
. In Canada, the incidence ratio between females and male is roughly 
1.05, while Crohn’s disease displays a female predilection with a ratio of 1.337.   
 Given its chronic nature and increasing incidence, ulcerative colitis represents a 
large burden on the Canadian health care system. The direct yearly cost of caring for a 
patient with ulcerative colitis on the Canadian health care system is estimated at $3500 
per patient. This number is much higher for those who require surgery with an estimated 
yearly cost of $18,749 during the year of surgery
17
. Contributing to this cost is the 
frequency of hospitalization which is twice that of the normal population, with an average 
cost of $5000 per hospitalization
12
. Added to this is the indirect cost of lost productivity 
as patients with ulcerative colitis missed on average 7.2 days of work in 2008, 
contributing to approximately $150 million dollars in lost productivity due to 
inflammatory bowel disease
18
. Despite its significant societal and economic impact, the 
exact cause of ulcerative colitis remains elusive. 
 The most established theory on the etiology of inflammatory bowel disease is one 
of an environmental trigger inducing an inflammatory response in a genetically 
susceptible host
19
. According to this concept a luminal trigger, whether it be an infectious 
agent (bacteria/parasite/virus) or some environmental or nutritional antigen, induces a 
dysregulated, chronic, inflammatory response within the colon and rectum
20
. The 
evidence for this theory comes largely from epidemiologic and clinic-pathologic studies 
of risk factors and genetic associations. 
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1.2.2 Risk Factors 
 Congruent with the environmental trigger-susceptible host theory of pathogenesis, 
risk factors for ulcerative colitis and inflammatory bowel disease can be divided into 
genetic factors and environmental factors.  
Genetic Factors 
 Evidence of a genetic predilection for inflammatory bowel disease comes from 
studies showing clustering of cases within families. Family members of patients with 
ulcerative colitis have a 10 fold increase in contracting the disease when compared to age 
and sex matched controls
21
. Further evidence is garnered from twin studies where the 
monozygotic concordance rates are 18% for ulcerative colitis and 58% for Crohn’s 
disease
22
. Families with multiply affected kindred also show a pattern of disease type 
with 75% of those affected having one type of IBD only
23
. Although not consistent with 
classical patterns of genetic inheritance (autosomal dominant, x-linked, etc) these 
associations suggest a myriad of genes interplaying to produce a variable level of 
susceptibility to IBD.  
 Currently, over 60 distinct genetic susceptibility loci have been linked with IBD
24
. 
The most established genetic link has been made with genes encoding for the major 
histocompatibility complex (MHC) on chromosome 6, known as the HLA genes
25, 26
. 
MHC is a protein complex found on the cell membranes of all cells in the body. They 
mediate the interaction between white blood cells and other cells, and are implicated in 
immune function and autoimmune diseases. The most consistent association with 
ulcerative colitis has been the DRB1*0103 allele. Found in less than 2% of the Caucasian 
population, studies have identified the allele in up to 15.8% of patients with extensive 
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colitis requiring surgery, suggesting it may also be associated with disease severity
26, 27
. 
Other genes associated with ulcerative colitis include cellular signalling pathway genes 
(JAK2, STAT3)
28
 and intestinal barrier function genes (ECM1,HNF4A)
29, 30
. The latter 
group of genes encode for cell-adhesion molecules that help maintain the integrity of the 
intestinal mucosa. Their association with ulcerative colitis supports the long-held belief 
that compromised, “leaky”, mucosa is part of the pathogenesis of the disease31. It is 
genetic attributes such as these that make a patient susceptible to the development of the 
disease which is thought to result from exposure to some form of environmental trigger.  
Environmental Factors 
 One of the strongest links to the importance of environmental factors in the 
pathogenesis of ulcerative colitis comes from the consistent finding of an increasing 
incidence of IBD in Western developed countries when compared to developing 
countries
32
. When immigrants from a low incidence, developing country, travel to a 
Westernized country, it is their children that develop an increased susceptibility to 
inflammatory bowel disease suggesting childhood exposure to the environmental triggers 
is key. It is these associations which have lead some credence to the so-called hygiene 
hypothesis or “dirty” hypothesis of autoimmune diseases. According to this theory, 
children that have limited exposure to bacteria from living in “sterile” modern 
environments have abnormally developed immune function and are unable to 
differentiate between pathogenic and non-pathogenic antigens. This results in non-
pathogenic antigens, whether their own or from commensal bacteria (gut flora), inducing 
chronic inflammatory reactions leading to autoimmune diseases such as IBD
33
. The 
dysregulation of the immune system is thought to arise from dysfunction of regulator T-
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cells resulting from limited exposure to both commensal and pathogenic bacteria during 
childhood and infancy
34
. Many features of life in a modern society are linked to reduced 
bacterial exposure: improved sanitation, decline in endemic parasitism, life on concrete 
with reduced exposure to soil, increase in antibiotic use, vaccination, and less crowded 
living conditions
32
. Despite ample evidence for the hygiene hypothesis, the specific 
environmental trigger(s) for IBD remain elusive. Many dietary or infectious agents have 
been proposed but none have been conclusively linked
16
.  
  The specific trigger(s) and pathogenesis of IBD remain unclear, although 
most of the evidence supports the environmental trigger-susceptible host theory and the 
hygiene hypothesis as potential mechanisms. Given its purported autoimmune nature, 
many of the therapeutic measures have been aimed at altering the immune response 
within the colon and rectum.  
 
1.2.3 Clinical Features and Diagnosis 
 Ulcerative colitis is characterized by inflammation affecting the mucosa and 
submucosa of the rectum and colon. It progresses from the rectum proximally along the 
colon, with the extent and severity of inflammation dictating the symptomatology of the 
patient. The most common findings are bloody diarrhea, urgency, and tenesmus. As the 
disease progresses proximally patients may complain of abdominal pain and fever. Most 
patients have disease limited to the left colon and rectum (80%), while 20% will develop 
inflammation throughout the colon
40
. Patients may also develop extra-intestinal 
inflammatory manifestations involving the skin (pyoderma gangrenosum, erythema 
nodosum), eye (uveitis, scleritis), joints (ankylosing spondylitis, sacroilitis), and 
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hepatobiliary system (sclerosing cholangitis). These manifestations occur in 
approximately 30% of patients, with the joint complications being most common
41
. Some 
ocular and skin disorders will improve following colectomy while hepatic and articular 
disorders do not, with some patients requiring a liver transplant for sclerosing 
cholangitis
42
.  
 The disease course and severity is variable with some patients experiencing a 
waxing and waning course with occasional disease flares and periods of remission, while 
others experience severe un-remitting disease. Diagnosis is usually accomplished via 
endoscopy of the rectum and colon demonstrating mucosal inflammatory changes 
(redness, exudates, ulceration, loss of mucosal folds), and biopsies of the rectal/colonic 
wall displaying signs of chronic inflammation (cryptitis and crypt abscesses) and 
architectural distortion (crypt branching, loss of goblet cells)
43
. Other diagnostic 
considerations include Crohn’s disease, infectious colitis, radiation colitis, and ischemic 
colitis. In its most severe form, ulcerative colitis can present as fulminant toxic colitis 
with associated systemic sepsis and evolving organ failure. Other urgent complications 
include gastrointestinal haemorrhage, perforation, and severe dilatation of the colon 
(megacolon).  
 One chronic consequence of long-term inflammation in the colon and rectal 
mucosa is a predilection for the development of colorectal adenocarcinoma. This risk is 
first materialized at approximately the 8-10 year mark following disease onset with an 
associated risk of colon cancer of approximately 2%
44
. This risk increases with length of 
disease activity to roughly 20% at 30 years
45
. The development of cancer is preceded by 
pre-cancerous changes in the mucosa (low and high grade dysplasia), the detection of 
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which usually mandates the removal of the entire colon and rectum as up to 40% of 
patients with dysplasia will harbour a malignancy. This forms the rationale behind 
colonoscopic screening guidelines which recommend that patients with ulcerative colitis 
have a colonoscopy every 1-2 yrs with random biopsies to assess their risk of having 
colon cancer starting at 8-10 years of disease activity
46, 47
.  
1.2.4 Treatment Overview 
 Most cases of ulcerative colitis can be treated medically with anti-inflammatory 
medications. Medical therapy is aimed at either the control of acute symptoms with 
induction of remission or the maintenance of disease remission. The specific agents 
chosen depend on the severity and location of disease. Mild disease limited to the recto-
sigmoid area (distal colon and rectum) is usually treated with topical therapies, either 5-
ASA compounds or steroid enemas. More severe proximal disease may require systemic 
therapy, again with either 5-ASA compounds or steroids. Mild diffuse colonic disease 
usually necessitates systemic therapy with 5-ASA compounds, while severe acute disease 
is often treated with steroids
48
. Most cases will respond to steroids, but a small subset will 
require emergency surgery for severe steroid-refractory disease. Once a patient recovers 
on steroids, they are slowly weaned off and disease activity is monitored. Because of 
severe side effects, long-term steroid therapy is not recommended to maintain remission, 
thus other immunomodulators are used to treat steroid-dependent disease, where 
symptoms persist or recur following steroid taper. Compounds such as 6-mercaptopurine 
and azathioprine are used to blunt the body’s immune system and allow the tapering of 
steroids. Other newer biologic medications, antibodies designed to target specific 
molecules in the inflammatory cascade, are also used to treat steroid refractory disease. 
11 
 
 
Infliximab, a monoclonal antibody active against tumor necrosis factor alpha (TNF), is 
used to treat steroid dependent or resistant disease, to both induce and maintain 
remission
49
. Most patients can be successfully managed with medical treatment alone but 
up to 25% will ultimately require surgery for the treatment of their disease
4, 50
.  
1.2.5 Role of Surgery 
 One of the major differences between Crohn’s disease and ulcerative colitis is the 
ability to cure ulcerative colitis with removal of the rectum and colon (proctocolectomy). 
The indications for surgery can be grouped by urgency with both elective and emergent 
conditions requiring surgery. The most common elective indication for surgery is failure 
of medical management
4, 51
. These are patients who have ongoing symptoms despite 
medical management, or who are unable to tolerate the withdrawal of steroids.  The use 
of newer agents, such as infliximab, has not reduced the need for colectomy
52
. Another 
elective indication for surgery is increased risk of cancer. Total proctocolectomy is 
recommended for patients with ulcerative colitis who have a current colon cancer, 
dysplasia associated lesion or mass (DALM), or high grade dysplasia. Both DALM and 
high-grade dysplasia are associated with high risks of concurrent adenocarcinoma with up 
to 40%  rates of concurrent cancer identified when the specimens are reviewed 
pathologically
53
. The recommendations are less clear for patients with low grade 
dysplasia, as the risk of concurrent cancer is less well defined with risks of developing 
future high grade dysplasia or cancer ranging from 18-54%
54-56
. Most practitioners would 
recommend surgery in a good risk patient but obviously the decision is highly 
individualized based on patient factors
51, 57
.  
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 Severe acute colitis affects 10-15% of patients with ulcerative colitis and is 
characterized by frequent bloody bowel movements, fever, tachycardia and anemia. Such 
patients may progress to develop fulmitant colitis characterized by systemic sepsis and 
evolving organ failure, or develop megacolon defined as transverse colonic dilatation 
greater than 6 cm. Both of which are generally considered indications for emergent 
surgery
4, 51
. Approximately 20-30% of patients with severe acute colitis will require 
surgery
58
. The surgical options considered in the emergent setting differ from the elective 
situation. The sole priority during emergent surgery is to remove the source of systemic 
toxicity, the colon, thus subtotal colectomy with ileostomy is the procedure of choice
51, 59
. 
This entails leaving the rectum in-situ as removal of the rectum entails a more involved 
procedure with increased risks of morbidity and potentially mortality, and disease of the 
rectum alone is rarely life-threatening. Reconstructive options such as an ileal pouch-anal 
anastomosis are not appropriate in the acute setting given the increased complexity of the 
surgery. Removal of the rectum with IPAA can be considered electively months later 
once the patient has recovered from their acute illness. Patients who develop colonic 
perforation are also treated with a subtotal colectomy and ileostomy, although they carry 
a much higher mortality
60, 61
. Patients with acute colitis who fail to respond to medical 
management within 72-96 hours should also be offered colectomy
62
. Following a subtotal 
colectomy and ileostomy, these patients have the option to choose from either keeping 
their ileostomy or undergoing a restorative pouch procedure. Electively, patients have 
options to choose from, these will be described in the following section.  
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1.2.6 Elective Surgical Options 
 Patients who have elective surgery for ulcerative colitis, whether it is for 
intractability or cancer risk, have options to choose from. The main options are either a 
total proctocolectomy (removal of entire colon and rectum) and ileostomy, or total 
proctocolectomy with ileal pouch-anal anastomosis (IPAA). Other options such as the 
continent ileostomy (Koch pouch) and ileoproctostomy have very limited roles in the 
modern surgical management of ulcerative colitis and have largely fallen out of favour. 
The Koch pouch has been associated with a high rate of revision and re-operation (up to 
50%), while the ileoproctostomy leaves the rectum insitu which is at risk of malignancy
4
.  
Total proctocolectomy and ileostomy 
 This procedure involves the removal of the entire colon and rectum, and the 
connection of the end of the small bowel to the skin (ileostomy or stoma). Digested 
material passes through the small bowel and is emptied into a bag that is worn on the skin 
with the aid of an appliance. It is the conventional, benchmark procedure for ulcerative 
colitis to which all others are compared. It is well established as being safe and allows 
patients to continuing living active lives
63
. It is considered the first line procedure in those 
who choose to undergo it rather than IPAA, or those who are not candidates for IPAA 
(impaired fecal continence, peri-anal disease, multiple comorbidites)
51
. It has the benefit 
of only requiring one procedure whereas restorative proctocolectomy (IPAA) is often 
done as a staged procedure. Complications following this procedure include stoma related 
complications (prolapse, retraction, peri-stomal hernia), small bowel obstruction, 
unhealed perineal wound, and sexual and bladder dysfunction
64-67
. The most distressing 
feature of this procedure for patients is the creation of the ileostomy. This necessitates 
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emptying the bag of small bowel feces roughly 6-10 times per day. Although the idea of a 
stoma seems difficult to accept for patients, most patients who undergo the procedure are 
satisfied with their result
6, 68, 69
. A systematic review of outcomes following this 
procedure will be presented later in the thesis, while a separate chapter will be devoted to 
a quality of life comparison between this procedure and IPAA.  
Ileal  pouch-anal anastomosis (IPAA) 
 During this procedure, the small bowel (ileum) is used to construct a pouch that 
functions as a neo-rectum allowing patients to defecate via their anus. The only true 
advantage it has over the traditional therapy is the avoidance of an ileostomy and the 
restoration of anatomic defecation. This advantage does come at a cost of a more lengthy 
procedure with its own set of complications and risks. Most of these complications are 
related to the creation and malfunction of the ileal pouch, which does not function 
perfectly as a new rectum. In this option patients typically have a staged surgery where 
the colon and rectum are removed, the pouch created and the fecal stream diverted 
proximal to the pouch with a loop ileostomy. This ileosotmy is later closed during a 
second procedure. Chapter three will summarize a detailed systematic review of trials 
comparing the quality of life between ileostomy and IPAA, while Chapter four will 
review the outcomes following IPAA.  
 
1.3 Decision Aids 
 
 Most clinical decisions faced by patients and surgeons involve the balance of risks 
and benefits.  The uncertainty of potentially poor outcomes at the patient level makes this 
process difficult and distressing to patients and surgeons alike. Traditional models of 
clinical decision making, namely paternalistic ones where surgeons simply determined 
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what they felt was the best option for the patient and proceeded with such have been 
abandoned in favour of a shared-decision making process
77
. At the conceptual level, 
shared-decision making has four necessary characteristics: 1) Both the physician and  the 
patient are involved in the treatment decision making process. 2) Both the physician and 
the patient share information with each other. 3) Both the physician and the patient take 
steps to participate in the decision making process by expressing treatment preferences. 
4) A treatment decision is made and both the physician and patient agree on the treatment 
to implement
78
. Within this framework are three well-defined stages: information 
exchange, deliberation, and deciding on a treatment. The utility of decision aids are built 
into this framework by facilitating the information exchange between the patient and the 
surgeon; and by clarifying a patient’s preferences during the deliberative stage of 
decision making
77
.  
But do patients want to be involved in their treatment decisions? Two studies have 
addressed this issue in patients with IBD. In a survey of over 1000 patients with either 
Crohn’s disease or ulcerative colitis, 81% of patients indicated they wanted to be actively 
involved in their treatment decisions
79
. In a second study of over 1000 patients with IBD,  
80% of patients indicated they wanted more information about treatment options when 
discussing treatments with their physicians
80
. With an obvious desire for more 
involvement, and with IBD patients being often young and knowledgeable about their 
condition, this is a population ideally suited for the use of decision aids.  
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1.3.1 Objectives of a Decision Aid 
 The main goal of decision aids is to facilitate informed, preference-sensitive 
decision making
81
. Not all clinical decisions are necessarily “preference-sensitive” and 
thus some clinical decisions are better suited to the use of decision aids. Wennberg has 
divided clinical decisions into those that are “effective”, meaning decisions where the 
benefit is clear to both the patient and the physician (antibiotics for an infection) and 
those that are “preference-sensitive”, where the optimal strategy is unclear and depends 
on the preferences and values of an individual patient
82
. The decision between a 
restorative pouch procedure or an ileostomy is clearly a “preference-sensitive” decision. 
Both options result in a similar control of disease, but one avoids the need for an 
ileostomy at a cost of different complication profile and the need for more procedures. 
The process of shared-decision making should respect a patient’s individual values, 
personal resources, and capacity for self determination
83
. It is built upon a therapeutic 
alliance where responsibility for the decision and outcome are shared by the care team
84
. 
Patients can often find complex medical decision making troubling, a phenomena known 
as decisional conflict
85
. Uncertainty around the decision and its potential outcomes results 
not only from the inherent complexity of balancing various risks and benefits, but also 
from modifiable factors such as lack of information, lack of understanding, unclear 
values, and inadequate support during the decision making process. O’Connor has 
developed nine objectives that have been adopted as pillars for the development and 
design of decision aids: 1) Improve knowledge of the clinical problem, options, 
outcomes, and variation in patient or practitioner opinions and practices. 2) Create 
realistic expectations of outcomes, consistent with available evidence. 3) Clarify personal 
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values for outcomes and promote congruency between patient values and choices. 4) 
Reduce patients’ and practitioners’ decisional conflict (uncertainty) about the course of 
action to take. 5) Promote implementation of choices. 6) Improve patients’ and 
practitioners’ satisfaction with decision making. 7) Promote patients’ persistence with 
choice. 8) Reduce patients’ distress from the consequences of decisions. 9) Improve 
patients’ health-related quality of life and promote informed use of resources by patients 
and practitioners
86
. It is along these objectives that decision aids should be designed and 
evaluated.  
1.3.2 Design of a Decision Aid 
 To develop a decision aid, the first step is the consolidation of the best evidence 
for the individual treatment options explored. In order to gather the necessary data, a 
systematic review of outcomes following both IPAA and ileostomy will be undertaken in 
order to populate the prototype decision aid with data. This will form the rough prototype 
that will be further refined by input through surgeons, ostomy wound care specialists, and 
patients themselves. A Delphi conference of experts in the field of decisional support, the 
International Patient Decision Aid Standards Collaboration, established 12 quality criteria 
for the development of decision aids which were used as a guide to the development of 
our aid: 1) systematic development process; 2) providing information about options; 3) 
presenting probabilities; 4) clarifying and expressing values; 5) using patient stories; 6) 
guiding or coaching in deliberation and communication; 7) disclosing conflict of interest; 
8) delivering patient decision aids on the internet; 9) balancing the presentation of 
choices; 10) using plain language; 11) basing information on up to date scientific 
evidence; and 12) establishing effectiveness. The only criterion that we do not consider 
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significant is the use of patient stories. Some literature has shown the inclusion of patient 
stories can bias patients’ preferences and potentially unduly influencing their decision87. 
Thus patient stories were not included in the development of the aid.  
 Following the collection of outcome probabilities from the literature, the 
prototype aid will further be refined by three sets of focus groups, one with colorectal 
surgeons, one with enterostomal therapists, and one with patients. The resulting refined 
prototype will then be tested for validity and reliability on healthy volunteers, as it is 
clinically inappropriate and potentially unethical to manipulate information concerning 
therapy and outcomes to patients at the decision point
88, 89
. Finally with a valid and 
reliable decision aid, it will be tested on patients for effectiveness. Various outcomes 
have been proposed for the evaluation of decision aids. Demonstrating an increase in 
knowledge about the treatment options by the use of a decision aid is an obvious first step 
in evaluating the effectiveness of the aid, and is fairly straightforward with the use of pre 
and post questionnaires. Moving beyond a demonstration of improved knowledge 
acquisition, the purpose of the decision aid is to enhance the overall decision making 
process and ultimately result in an improved quality of life for the patient.  Various scales 
have been developed to test the conceptual aspects of an enhanced decision making 
process. One of the most studies is the Decisional Conflict Scale, developed by 
O’Connor. This scale operationalizes the degree of uncertainty patients experience when 
facing a treatment decision. This scale consists of 16 questions with Likert scale 
responses that explore three domains: decisional uncertainty, factors contributing to 
uncertainty, and perceived effective decision making. This scale has been validated
85
 and 
used in the evaluation of different decision aids
3
. Other metrics that have been used to 
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evaluate decision aids include measures of anxiety, satisfaction with the decision
2
, and 
preference for independent decision making
90
. Ultimately the goal of the decision aid is 
to improve a patient’s quality of life. This has been difficult to demonstrate reliably as 
current generic and even disease-specific measures of health-related quality of life may 
not be sensitive enough to capture the specific aspects of decisional uncertainty. Thus 
most of the literature has typically utilized a mixture of patient knowledge, decisional 
conflict, and satisfaction assessments in combination with the degree of patient 
participation as ways to establish the effectiveness of these aids. In a systematic review of 
over 30 trials examining the effectiveness of decision aids, the use of these aids was 
found to improve patients knowledge, improve the proportion of patients with realistic 
perceptions of the risks and benefits of the therapies, lower decisional conflict, reduce the 
proportion of patients who are passive decision makers, reduce the proportion of patients 
who remain undecided after counselling, and improve the agreement between a patient’s 
values and the option chosen
91
. It is along these metrics that our aid will ultimately be 
evaluated by.  
1.4 Overview of the Thesis 
 This thesis is designed in the integrated article style, following the introductory 
chapter, chapter two will describe the methodology behind the systematic literature 
review and quality assessment necessary for the creation of the prototype decision aid. 
Chapter three will present the results of the systematic review of quality of life literature 
comparing ileostomy and IPAA treatment options. Chapter four will summarizes the 
results of the systematic review and meta-analysis of outcomes following the IPAA 
option, while chapter five will discuss the results of the outcomes following the ileostomy 
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option. Finally, chapter six will outline the methodology behind the refinement and 
validation of the prototype decision aid.  
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CHAPTER TWO - SEARCH STRATEGY AND STUDY INCLUSION FOR 
SUBSEQUENT SYSTEMATIC REVIEWS 
 
2.0 Introduction  
 
  In order to populate our decision aid with information, a systematic review was 
undertaken of the literature reporting on surgical outcomes following proctocolectomy 
with either an ileal pouch-anal anastomosis (IPAA) or an ileostomy. Concurrent with this 
systematic review, studies reporting on the differences in quality of life between the two 
approaches were also reviewed. Rather than conduct three different searches of the same 
literature, we combined the three searches into one broad literature search. This allowed 
the inclusion of a large number of studies in our index search, and eliminated the 
redundancy of having to undertake three separate searches of the same databases for 
studies reporting on outcomes following proctocolectomy. The implications of this broad 
approach resulted in a very large number of abstracts reviewed, allowing the abstract 
reviewers the ability to apply apriori study inclusion criteria over a wide range of 
screened articles. This chapter serves as part of the methods for the subsequent three 
chapters which report on the specific results of the systematic reviews of three groups of 
articles: studies comparing quality of life between IPAA and ileostomy, studies reporting 
on outcomes following IPAA, and studies reporting on outcomes following ileostomy.  
 
2.1 Search Strategy 
 Studies were identified by searching the following databases in conjunction with 
the help of a professional librarian experienced in systematic reviews (Erin Boyce):  
- Medline (1978-2009) 
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- Embase (1978-2009) 
- CINAHL 
- Cochrane Database of Systematic Reviews  
The search strategy used was a combination of MESH (medical subject heading) 
terms and key words. For example, when searching Medline, the following strategy was 
used:  
MESH terms 
Disease identifiers:  
ulcerative colitis, inflammatory bowel disease,  
 
Procedure identifiers:  
restorative proctocolectomy, ileostomy,  
 
Key words:  
 
Disease identifiers:  
Inflammatory bowel disease, ulcerative colitis, IBD, colitis  
 
Procedure identifiers:  
Proctocolectom$, colectom$, ileal pouch-anal anastomosis, IPAA, ostom$,  
 
The disease identifiers were combined with the procedure identifiers and the 
“explode” function was used to further broaden our search. No limits were placed on 
language at this stage of our search. A similar strategy was employed when searching the 
other databases mentioned above with modifications taking into account the differences 
in MESH terms and key words inherent to each specific database. The search was limited 
to papers published in 1978 or later as this was the year when Parks published the first 
report on IPAA
1
. The search was last updated on January 30, 2009. In addition to these 
electronic searches, the references of included studies were hand searched for any 
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additional studies that met our inclusion criteria. A broad search strategy with no limits 
on type of outcome was selected in order to minimize the risk of missing studies that had 
been improperly indexed. The specific search strings are included as Appendix A.   
 
2.2 Study Inclusion Criteria 
 The study inclusion criteria were formulated along a framework encompassing the 
population of interest, the intervention of interest, and outcomes of interest. For a study to 
be eligible for inclusion in the review, it had to meet all three criteria. Table 2.1 lists the 
specific inclusion criteria.  
Table 2.1 Inclusion Criteria for Studies  
Population  Patients with ulcerative colitis ≥ 18 yrs of age  
 
Intervention  Proctocolectomy with ileostomy 
 OR 
 Restorative pouch procedure (regardless of type of 
pouch) with or without protocolectomy 
Outcomes  ONE OR MORE OF 
 Post-operative mortality 
 Post-operative complications  
 Early: wound infection, intra-abdominal sepsis,  
anastomotic dehiscence, perianal sepsis 
 Late: pouchitis, anastomotic stricture, parastomal 
hernia, pouch failure, bowel obstruction 
 
 Re-intervention/ re-operation (excision of pouch, 
revision of ileostomy)  
 
 Bowel function (fecal incontinence, number of bowel 
movements/day, need for pad, number of appliance 
changes per day, need for incontinence pads, need for 
anti-diarrheal medication)  
 
 Sexual dysfunction  
 
 Female: dyspareunia, reduced fertility  
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 Male: impotence, retrograde ejaculation 
 
 Quality of life 
 
Methodologic   Study with more than 100 patients OR comparing 
quality of life between pouch and end-ileostomy    
 Year of publication ≥ 1978 
 No previous publication with the same patients from 
same institution 
 Report on baseline characteristics of the patients 
undergoing procedure 
 English only language 
 
In addition to the content specific inclusion criteria listed above, specific 
methodologic criteria were applied to refine the inclusion of studies. The specific 
inclusion criteria relating to population, intervention, and outcome need not be justified 
given their self-evident nature, but methodologic criteria require some justification. For 
the studies looking at clinical outcomes following either the IPAA procedure or 
ileostomy, inclusion was limited to studies that reported on 100 patients or more. Larger 
studies are more likely to provide a stable estimate of outcomes (complications), but 
limiting the inclusion to studies with even higher numbers (> 1000) would likely result in 
the inclusion of only a few studies from high volume centers which could bias the results, 
as not all patients who would ultimately be using the decision aid would have access to 
high volume centers. Outcomes following IPAA have been linked to surgeon and 
institution volume, with lower volume centers having poorer results
2
. Thus limiting the 
inclusion to studies with 100 patients or more strikes a balance between the desire to 
include as many studies as possible, but also to include those with the most stable 
estimates of outcome probabilities. Far fewer studies comparing quality of life between 
33 
 
 
the two procedures have been published and no study size limitation was placed on the 
inclusion of these studies.    
Inclusion was also limited to studies that reported on baseline characteristics (age, 
sex, underlying diagnosis) as it was necessary to assess these factors in order to assess 
whether or not the patients undergoing the procedure met the other inclusion criteria 
(population, intervention). Publications from the same institution reporting on the same 
cohort of patients were also excluded. In cases where there were multiple publications 
from the same institution, the most recent publication with the highest number of patients 
was included, unless different outcomes were reported.  This review was also limited to 
publications reported in English. Given the large number of studies published on this 
topic, we felt the added benefit of translating articles would not improve the conclusions 
of the systematic review. Also there is evidence to suggest that the exclusion of non-
English language publications does not influence the ultimate conclusions of meta-
analyses
3
, and that non-English language publications are often of poorer quality
4
.  
No limitations were placed on study design (retrospective vs prospective), rather 
this was included in the quality assessment of the studies. The use of broad inclusion 
criteria with few limitations on study design has been recommended as the preferred 
strategy when carrying out a meta-analyses of observational studies
5
.  
All abstracts generated by the search strategies were reviewed independently by 
two reviewers. Each reviewer indicated whether or not the study met the inclusion criteria 
and agreement was measured using the kappa statistic. Any disagreements were resolved 
by consensus, and if consensus was not met then a third reviewer was asked to decide. 
Measurement of reviewer agreement has been recommended by the PRISMA statement 
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as a way of enhancing the transparency and reliability of the methods used to screen and 
select studies for inclusion into systematic reviews
6
.  
 
2.3 Study Quality Assessment 
 Assessing the quality of included studies is an essential part of a systematic 
review
5, 6. There are two basic approaches to the assessment of study quality or “risk of 
bias”, namely the use of scales or rating scores that reduce the assessment of a study’s 
quality into a score, or the examination of key components of a study’s design and 
relating individual elements of study design with quality. The attractiveness of the scale 
or score approach lies in its ease of reporting, by attributing a number or rating to each 
individual study. This rating can then be used as a weight in adjusting any subsequent 
meta-analysis. Although attractive from a practical perspective, the use of scales and 
scores has been criticized as over-simplifying the assessment of quality and potentially 
introducing bias into the results when used as weights in analysis
7, 8
. Most scores are 
constructed in an “ad hoc” fashion and lack validity, with various study elements being 
combined that may or may not have an effect on study validity
5, 9
. An approach where 
individual elements of study design are assessed and evaluated rather than summarized 
into a score is the preferred method of study quality assessment
5-7
. 
 The assessment of study quality is not as well established for observational studies as 
it is for randomized controlled trials
5, 10
. Within controlled-trials, specific elements of 
study design including: concealment of allocation; blinding of outcome assessors, 
participants, and patients; and proportion of patients lost to follow-up have all been 
empirically linked to validity of results
11-13
. Although many tools for assessing study 
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quality of observational studies exists, with one systematic review identifying 86 such 
tools
10
, no one tool can be recommended over others given the lack of empirical evidence 
relating specific design elements to study validity
10, 14
. As no consensus exists on the 
specific method of quality assessment for observational studies, individual elements of 
the included studies were evaluated for their impact on study quality.  
Two systematic reviews on the topic of quality assessment in observational studies 
came to similar conclusions about which items should be included in the quality 
assessment of observational studies: methods of selecting patients, methods of measuring 
outcome variables, adjustment for confounding, and completeness of follow-up
10, 14
.  
These elements formed the basis of our assessment of study quality (Table 2.2). As most 
of the studies ultimately included in the systematic review of outcomes following either 
the IPAA or the ileostomy procedures were single center reports of case series with no 
comparator, it was important to determine whether a significant selection bias was 
occurring, namely that authors were only including their “best” cases as opposed to 
including all patients that underwent a procedure when reporting their rates of 
complications. To identify potential for selection bias, studies were classified as 
consisting of consecutive patients or non-consecutive patients depending on the method 
of patient recruitment. Studies were also classified as either prospective or retrospective 
depending on the timing of patient recruitment relative to when the outcome occurred. 
Studies that included consecutive patients recruited prospectively were considered to be 
at less risk of selection bias compared with non-consecutive or retrospective studies. 
Studies that did include a comparator group (quality of life studies comparing IPAA and 
ileostomy) were evaluated as to whether or not the authors adjusted for confounding 
36 
 
 
either in the design or the analysis of the study. Studies that adjusted for confounding 
were considered to be at less risk of bias. Given the large number of outcomes of interest 
to the systematic reviews (most complications following IPAA or ileostomy) it was 
impractical to evaluate specific definitions for specific outcomes. Rather, studies were 
classified based on whether the outcomes listed were clearly defined. Studies that applied 
specific definitions when assessing outcomes were considered to be at less risk of bias, as 
specific definition of outcomes allows the application of systematic outcome assessment, 
and limits subjective interpretation by the individual outcome assessor. Although blinded 
outcome assessment has been linked to study validity
12, 13
, this measure was not 
applicable to most studies in our review given the predominance of single group case 
series. 
For the group of studies reporting on quality of life comparisons between IPAA and 
ileostomy, whether or not the study utilized a validated quality of life measure was 
recorded. Studies that utilized a validated measure of quality of life and made reference to 
the method of validation were considered to be of less risk of bias when compared to 
studies that utilized non-validated measures of quality of life
15
.  
Loss to follow-up was also considered a quality measure, as controlled-trial literature 
has shown it to be associated with study validity. Length of follow-up was also included, 
as many of the important outcomes following either procedure can be time dependent. 
For example, 45% of patients who will ultimately develop pouchitis, an important 
complication following IPAA, will only do so at least 6 months following the 
procedure
16
.  Along with completeness and length of follow-up, we considered studies 
that had a standardized protocol for follow-up, meaning routine clinical assessments at 
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pre-specified time points, to be more likely to accurately detect and report complications 
following either procedure and thus be at less risk of bias.  
 
Table 2.2 Study Elements Evaluated for Quality  
  
Quality Criteria  Categories 
Selection   Non-consecutive: if patients were recruited from a 
specific clinic/ institution but no mention is made if they 
are consecutive or represent all patients from that clinic 
over a specified time period 
 Consecutive: if patients were recruited in a consecutive 
manner OR represent all patients who presented to a 
specified clinic/institution over a specified time period 
 
 Retrospective: If the study reports on patients whose 
outcomes occurred before the study began 
 Prospective: If the study reports on patients whose 
outcomes occurred after the study began 
 
 
Confounding   Adjustment: if the authors adjusted either in the design 
(matching) or analysis (multivariable methods, 
stratification) of their study for the presence of 
confounders. 
 No adjustment 
 No comparator group: if the study did not include a 
comparator group 
 
Outcome 
 criteria clearly 
defined 
 All: if the authors defined their criteria for all the 
outcomes reported in the study 
 Some: if the authors only defined some of the outcomes 
reported in the study  
 None: if none of the reported outcomes were defined 
 
 
Quality of life 
instrument 
 Validated: If study reports on the validation method or 
referenced a study which details the validation method 
used 
 Not Validated: No mention of validation of the 
instrument/ measure 
 
Loss to follow-up  % of patients not accounted for in the results 
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Length of follow-up  mean or median length of follow-up reported in months 
 
Follow-up protocol  Standardized: Standardized follow-up protocol with 
routine visits at pre-specified time points 
 Non-standardized: Follow-up was not completed in a 
standardized fashion or no mention of follow-up 
procedures 
 
 
 Each element of study quality was reported for the individual studies and their 
influence on the results was explored using sensitivity analyses.  
2.4 Results of Study Search 
 The search strategy outlined previously was last updated on January 30, 2009. In 
addition to these electronic searches, the references of included studies were hand 
searched for any additional studies that met our inclusion criteria. Figure 2.1 summarizes 
the results of the searches. Once duplicates were removed, 3920 distinct abstracts were 
independently reviewed by two reviewers and any study that either party felt met 
inclusion criteria was selected for full text review
1
.  Of the 3920 abstracts, 411 were 
ultimately selected for full text review. Of these 411 abstracts, the majority were 
excluded from final study inclusion. The most common reason for exclusion was a 
publication dealing with the same cohort of patients published at different time points. In 
cases were multiple publications dealt with the same cohort of patients, the study with the 
inclusion of the larger number of patients was used in the review. Studies meeting 
inclusion were divided into three groups that form the basis of the three meta-analyses to 
follow. Chapter three of this work will deal with the results of the literature review 
surrounding quality of life comparisons between IPAA and ileosotmy, while chapters 
                                                 
1
A file containing the list of abstracts reviewed is available from the author as it was too large to included 
as an appendix. 
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four and five will summarize the results of the meta-analyses of studies reporting on 
outcomes following IPAA, and ileostomy respectively. The first review is necessary as 
part of the justification process for a decision aid, if one strategy is clearly superior to the 
other in terms of quality of life then it throws the very idea of a decision aid into question, 
and at the very least, any important difference in quality of life must be included in the 
aid. The other two meta-analyses are necessary to populate the decision aid with outcome 
probabilities.  
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Figure 2.1 PRISMA
6
 Flow Diagram of Identified Studies  
  
CINAHL (n =127) Embase (n =2529) Medline (n =1938) 
Records identified through 
database searching 
(n =4659) 
Cochrane (n =65) 
Full-text articles excluded 
(n = 324)        
Reasons for exclusion: 
Paper with duplicate cohort of patients (n = 124) 
Paper with < 100 patients (n = 57) 
Review paper only (n = 41) 
Report on subgroup of patients only (n = 38) 
Non-English language paper (n = 22) 
Did not report on the outcomes of interest  
(n = 25) 
Wrong intervention (n = 17)                                
 
Records excluded 
(n = 3509) 
Records screened 
(n = 3920) 
Records after duplicates removed 
(n = 3920) 
Studies included in 
systematic review of 
ileostomy outcomes 
(n = 11) 
Studies included in 
systematic review of 
Quality of life between 
IPAA and ileostomy  
(n = 9) 
Studies included in 
systematic review of IPAA 
outcomes 
(n = 67) 
Full-text articles assessed 
for eligibility 
(n = 411) 
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CHAPTER THREE-A SYSTEMATIC REVIEW OF STUDIES COMPARING 
QUALITY OF LIFE BETWEEN IPAA AND ILEOSTOMY  
 
3.0 Introduction 
 
 Whether ulcerative colitis is treated with a proctocolectomy and ileostomy or with 
an ileal pouch-anal anastomosis (IPAA), the resulting control of disease, namely the 
removal of the diseased colon and rectum is the same. What differs is the post-operative 
experience of the patient and the impact each option has on the patient’s day to day life. 
In patients with inflammatory bowel disease who have not had surgery, fears and worries 
surrounding surgery and the potential need for an ostomy appliance are most prominent 
when compared to other concerns
1
. Patients with active, symptomatic ulcerative colitis 
generally have worse health-related quality of life (HRQOL) than healthy controls
2-4
. 
Severity of disease activity is one of the most important determinants of health-related 
quality of life in patients with ulcerative colitis
2, 5-7
. Removing the colon and rectum in 
patients with ulcerative colitis is often curative, and several studies have documented 
similar HRQOL between patients following colectomy and the general population
8-11
. 
Studies examining changes in HRQOL between preoperative and postoperative patients 
have similarly shown an improvement following colectomy
12, 13
. Muir et al in a 
prospective study of patients undergoing IPAA showed an improvement in both disease-
specific and generic measures of health-related quality of life when pre and post-
operative scores were compared
12
. These findings have not been universal as Berndtsson 
and Oresland showed no difference in generic HRQOL between preoperative and 
postoperative patients undergoing IPAA, and only a modest gain in disease-specific 
HRQOL
14
. With intractability of disease as the most common indication for 
proctocolectomy, most patients can expect to have improved HRQOL following surgery. 
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The question becomes: Does the form of intestinal reconstruction, IPAA or ileostomy, 
influence the HRQOL of these patients or is the gain in HRQOL independent of which 
procedure patients receive?  
 In order to justify the design and application of a decision aid to help patients 
select which reconstructive option they would prefer, it is necessary to explore the 
specific effects each has on HRQOL. If one option is clearly superior in regards to 
HRQOL, then perhaps the role of a decision aid becomes less important as one option 
may be recommended over the other on the basis of improved HRQOL. If, on the other 
hand, they are shown to be largely equivalent then helping patients make the choice that 
is most in keeping with their values and expectations is of paramount importance and the 
role of a decision aid becomes vital in facilitating such a process. What follows is a 
systematic review of studies comparing proctocolectomy with IPAA or ileostomy and 
their effects on HRQOL. Before describing the methodology and results, a brief 
introduction to the concept of health-related quality of life is necessary to provide context 
for the remainder of the chapter.  
 
3.1 Health-Related Quality of Life 
 Health-related quality of life seeks to measure the functional impact a disease and 
its therapy have on a patient’s day to day life15. It moves beyond measuring the specific 
disease state (symptoms, complications) by encompassing behaviours, emotional 
attitudes, and perspectives of an individual and how they related to their current state of 
health
16
. Measuring HRQOL is important as two patients may have identical disease 
severity yet one will have a job and a healthy social life, while the other is unemployed, 
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depressed, and on disability. Capturing and measuring these differences is the purpose of 
HRQOL assessment.  
3.1.1 HRQOL Measurement 
 HROQL instruments can be classified into three main types: global, generic, and 
specific
16
. Global measures consist of a single question or score used to summarize 
overall quality of life. Often consisting of simple questions like “How is your quality of 
life?” these measures, although easy to administer and report, are often insensitive to 
smaller changes in quality of life and do not provide any information on specific areas of 
dysfunction
17
. Generic and specific instruments are questionnaires containing items that 
are grouped into domains. A domain or dimension is a specific area of 
experience/behaviour that the instrument is attempting to measure
15
. The items 
(questions) forming the individual domains are combined into scores representing each 
domain, thus allowing the researcher the ability to assess the impact of a therapy or 
disease on a specific domain. These domain scores are then combined to provide a 
summary score for that patient’s HRQOL.  
The classic example of a generic measure is the Medical Outcomes Survey Study 
36-Item Short Form (SF-36)
18
. The SF-36 is a self-administered health survey composed 
of 36 items organized among 8 domains: bodily pain, general health, mental health, 
physical functioning, role-emotional, role-physical, social functioning, and vitality. The 
resulting score ranges from 0 (worst) to 100 (best). The advantages of such a scoring 
system lie in its applicability across patient populations and disease states.  
Another type of generic instrument is one that measures utility, which is defined 
as a patient’s preference for a specific disease state and/or treatment19. These measures 
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are rooted in decision theory and are typically used in economic analyses as they 
summarize HRQOL into a single number, usually from 0 (death) to 1 (perfect health). 
They can be combined with cost data to produce cost-utility analyses and are useful when 
evaluating health care programmes. Although useful, utility measures are often 
unresponsive to subtler changes in HRQOL and they do not show in which domain 
improvements or deteriorations occur
15
.  
 Bernklev et al showed that when the SF-36 was applied to patients with 
ulcerative colitis, scores were significantly lower in 6 of the 8 domains when compared to 
normal population values
4
.  Although useful in patients with ulcerative colitis, generic 
measures such as the SF-36 have been criticized for their lack of responsiveness, namely 
the ability to detect smaller changes in HRQOL related to disease activity or therapy over 
time
4,15,20
. To overcome this limitation, disease specific instruments have been developed 
to detect smaller yet clinically meaningful changes in HRQOL among patients with 
inflammatory bowel disease. The most commonly used disease specific instrument is the 
Inflammatory Bowel Disease Questionnaire (IBDQ)
21
. The IBDQ is an interviewer or 
self-administered questionnaire consisting of 32 questions organized along 4 domains: 
bowel symptoms, emotional functioning, social functioning and systemic symptoms, with 
each question being scored 1-7 resulting in a range of 32-224; with higher scores 
indicative of better HRQOL. The recommended approach is to utilize both a generic 
measure and a disease specific measure when evaluating the impact of a disease or 
therapy on HRQOL
4, 15, 17, 20
. Table 3.1 summarizes the most common instruments used 
in evaluating quality of life in inflammatory disease patients.  
 
47 
 
 
 
Table 3.1 Quality of Life Instruments Used in Ulcerative Colitis 
Instrument Items/Domains Scoring 
Generic   
SF-36
18
  36 questions organized into 8 domains: 
bodily pain, general health, mental health, 
physical functioning, role-emotional, role-
physical, social functioning, and vitality. 
 
0 (worst)-100 (best) 
Sickness impact 
profile (SIP)
22
 
136 questions evaluating every day 
activities among 12 categories: sleep and 
rest, emotional behaviour, body care, home 
management, mobility, social interaction, 
ambulation, alertness, communication, 
work, recreation, eating, these are further 
grouped along 2 domains, physical and 
psychosocial.  
 
0 (most dysfunction)-
100 (no dysfunction) 
Utility   
Time Trade-Off 
Technique 
(TTOT)
23
 
Based on standard gamble theory, patients 
are asked to trade-off time spent in a 
disease state with time spent being 
perfectly healthy, the resulting point of 
indifference (amount of time being healthy 
equivalent to normal life span in disease 
state) is translated into an index between 0-
1.   
 
0 (death) – 1.0 (perfect 
health) 
Disease Specific   
Inflammatory 
Bowel Disease 
Questionnaire 
(IBDQ)
21
 
32 question interviewer or self-
administered questionnaire evaluating 4 
domains: bowel symptoms, emotional 
function, social function, systemic 
symptoms.  
 
 
Each question (1-7), 32-
224 total score (higher 
score = better HRQOL) 
Rating Form for 
IBD Patient 
Concerns 
(RFIPC)
24
 
25 questions evaluating 5 domains: impact 
of disease, sexual intimacy, complications 
of disease, body stigma. 
 
0-100 (higher score = 
worse HRQOL)  
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3.1.2 Characteristics of HRQOL Instruments 
 A methodologically robust HRQOL instrument must at the very least measure 
what it is intended to measure, namely quality of life. The difficulty arises as no “gold 
standard” exists for the measurement of quality of life15, thus newly developed 
instruments cannot simply be validated by a comparison to a gold standard. To overcome 
this issue, concepts surrounding “surrogate” measures of validity have been borrowed 
from the psychological literature and applied to the validation of instruments intended to 
measure HRQOL. Face validity implies that an instrument appears to measure what it is 
intended to measure, while content validity refers to whether an instrument 
comprehensively examines the domains of interest relating to the intended concept to be 
measured
25
. These aspects of validity are not quantitatively evaluated, rather they are the 
result of careful review and consideration of the items within the instrument often by a 
panel of experts or patient focus groups
16
.  Construct validity refers to how an instrument 
measures or behaves in relation to the theoretical construct it is supposed to measure
25
. It 
is evaluated by comparing changes in the instrument to changes in some other marker of 
disease, seeing if it behaves as predicted based on its theoretical construct. For example, 
an instrument used to measure pain (its theoretical construct) should correlate with 
changes in the amount of pain medication used. Criterion validity refers to an instruments 
ability to relate to a similar questionnaire intended to measure similar domains
16
. For 
example, a new disease specific measure of HRQOL could be compared to an established 
reference, such as the IBDQ, to see if the two are congruent. For a new instrument to be 
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deemed valid, it should satisfy these validity concepts. Table 3.2 summarizes properties 
of methodologically sound HRQOL measures. 
Table 3.2 Desirable Properties of HRQOL Measures. 
Property Concept 
Validity   
  Face validity Instrument evaluates intended concept 
 
  Content validity Instrument is representative of all areas of interest being made up 
of multiple domains comprehensively representing the concept 
being studied 
 
  Construct validity Instrument behaves as predicted by its theoretical construct when 
compared to some other marker of disease or therapy  
 
  Criterion validity Instrument behaves congruently when compared with some 
accepted reference standard that measures similar concepts 
 
Reliability  
  
  Test-retest reliability Instrument should have consistent results when applied 
repeatedly to the same patient and variation between patients 
should be greater than variability within patients  
 
  Internal Consistency Items within a domain should correlate with each other 
 
  
 
 An instrument must not only be valid but must also display reliability when 
repeatedly applied to the same patients (test-retest reliability), have internal consistency 
among its various domains, and be responsive to clinically meaningful changes in 
HRQOL
15-17
.  In a systematic review of instruments used for the measurement of 
HRQOL among patients with inflammatory bowel disease, Pallis et al identified two 
disease specific measures, the IBDQ and the RFIPC that have been shown to be valid and 
reliable
26
. As part of the systematic review of studies comparing HRQOL between 
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patients with an IPAA and patients with an ileostomy, we sought not only to summarize 
their results but also to evaluate whether they had measured HRQOL using a validated 
instrument.  
3.2 Methods 
Search Strategy  
The details of the search strategy are outlined in chapter two of the thesis. Given 
the smaller number of studies in this group we did not limit ourselves to studies with at 
least 100 patients, but rather included all studies that compared health-related quality of 
life between patients undergoing IPAA or ileostomy. All titles and abstracts were 
independently reviewed by two reviewers, and any study that either reviewer deemed as 
potentially eligible was selected for full text review. Study inclusion was then assessed 
independently with any disagreement resolved by consensus. Specific study inclusion 
criteria are detailed in chapter two of this work.  
Data Extraction 
  All information was extracted independently by two reviewers with any 
disagreements resolved by consensus. Data pertaining to details about the patients (age, 
sex), intervention (IPAA or ileostomy, complication rate), length of follow-up, and 
quality of life measures used were extracted. Numerical results of the various HRQOL 
instruments were also extracted along with their statistical significance (p-value) and the 
conclusions of the authors.  
Quality Assessment 
The method of assessment and justification for study quality evaluation is also 
found in chapter two of this work. However, this was expanded for the quality of life 
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studies to include an assessment of the validity of the instruments used in each study 
along the criteria in Table 3.2. HRQOL measures were evaluated based on whether the 
authors indicated in their study, or made reference to other studies, where the validity and 
reliability of their chosen HRQOL instrument had been established. Instruments were 
considered to have face validity if some description of the method used to decide on what 
elements to include in the measure were included in the work or in the references; while 
instruments were considered to have content validity if they were made up of multi-
domain scores comprehensively covering the concept of interest. Construct validity was 
established if the authors described or made reference to studies that compared the 
instrument to some marker of disease or therapy.  Criterion validity was established if the 
instrument was compared to some other established HRQOL measure. Where applicable 
the validation references were extracted. Instruments were considered to be overall valid 
if the authors displayed or made reference to the demonstration of construct and/or 
criterion validity, as these are the most rigorous methods of establishing validity
15
.  
Analysis 
 Although we had originally intended to meta-analyze the overall scores and 
domain specific scores of the included studies using weighted mean difference
27
, where 
the difference between two groups is adjusted for by study size. We deemed that there 
was too much heterogeneity across studies in terms of  different HRQOL instruments and 
the way the results were reported (some mean, some median) to allow for quantitative 
analysis. Instead, the individual study results are presented in a table with the conclusions 
reached by the authors of the studies.   
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3.3 Results 
 We identified 9 studies that compared HRQOL between patients with ulcerative 
colitis that had undergone either an ileal pouch-anal anastomosis procedure or an 
ileostomy. Agreement between reviewers for this subset of studies was excellent, with no 
disagreements about study inclusion (kappa = 1.0). Table 3.3 summarizes the study 
characteristics of included studies.  
3.3.1 Quality of Included Studies 
 The quality of the studies varied widely with only three studies including 
consecutive patients and only two being prospective. Two studies adjusted for 
confounding, one in their analysis using a logistic regression, and the other in their design 
through matching patients from both groups for known confounders of HRQOL. Losses 
to follow-up, or in this case response rates to HRQOL questionnaires, were generally 
poor with all but three studies having >20% non-response rates. Table 3.4 summarizes 
the differences in study quality.  
3.3.2 Validity of HRQOL Instruments Used 
Of the included studies, 5 used validated measures of HRQOL, while four studies 
used non-validated measures. Three studies used the validated, generic SF-36 measure, 
while three studies utilized the validated, disease-specific IBDQ measure. Of the non-
validated measures, most were global assessments based on a yes/no answer to a question 
related to either social restriction or overall satisfaction. Liddell et al used a self-
developed score measure to assess patient satisfaction
28
. This assessed the degree of 
improvement with surgery over eight domains: social activities, sports activities, 
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housework, recreation, family relationships, sex, travel, and work. Although this measure 
met the criteria for face and content validity, no mention of methods to test construct or 
criterion validity were described. In a similar self-developed, non-validated score based 
instrument, Pemberton et al used a questionnaire consisting of seven domains: sports, 
sexual life, social activities, recreation, work around the house, family relationships, and 
travel; to assess the impact of surgery on restrictions in each domain
29
. Again, construct 
and criterion validity were not assessed. McLeod et al utilized two validated utility 
measures to assess the impact of each procedure on overall quality of life, as well as a 
validated generic measure, the Sickness Impact Profile
30
.  
 
3.3.3 Comparison of IPAA to Ileostomy Patients 
 
Global instruments 
  Studies using global measures to compare HRQL between ileostomy and IPAA 
patients found there were no significant difference between patients overall satisfaction 
(95 vs 93%)
29
, ability to return to work or school (98 vs 94%)
29
, and overall quality of life 
(87 vs 93%)
31
.  Similar results were described using two validated utility measures with 
no difference between groups
30
. Emblem et al described significantly more societal 
restriction among ileostomy patients using a non-validated questionnaire (67% vs 0%)
32
.  
 
Generic instruments 
Of the three studies using the SF-36, no difference in overall scores was found 
between the two groups
3, 33, 34
. The only domain-specific difference was described by 
Nordin et al who found worse social functioning among the IPAA patients
3
. McLeod et al 
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found similar results with no difference in overall scores using the Sickness Impact 
Profile
30
. Two non-validated generic instruments showed mixed results. Liddell’s 
Lifestyle Satisfaction Score failed to detect a difference between the two groups, either in 
its summative score or in the individual domain scores
28. In contrast, Pemberton’s 
Performance Score, which contained similar elements to Liddell’s score, found 
significant worse performance scores among ileostomy patients among all seven domains 
(sports, sexual life, social activities, recreation, work around the house, family 
relationships, and travel)
29
.  
Disease-specific instruments 
Of the three studies using the IBDQ, no differences in overall scores were found 
between the two groups
3, 34, 35
. Only one study identified a difference in domain specific 
scores, Nordin et al described worse social functioning and systemic symptoms among 
the IPAA patients
3. O’Bichere et al using a self-developed, non-validated, disease 
specific visual analogue scale (VAS) found IPAA patient to have worse altered bowel 
habits and more restrictions on diet than patients with ileostomies; while ileostomy 
patients had worse body image
33
. Table 3.6 summarizes the study results and conclusions.   
3.4 Discussion 
 Health-related quality of life is a measure of a patient’s perception of the impact a 
disease or its therapy has on their illness experience and functional status
36
. We identified 
nine studies that compared HRQOL between ileostomy and IPAA patients. No study 
identified an overall difference in quality of life between the two groups. Overall markers 
of quality of life, whether they are global, non-validated, generic, or disease specific, all 
indicate that patients with ulcerative colitis who undergo proctocolectomy have good 
55 
 
 
HRQOL regardless of which reconstructive option they undergo (ileostomy or IPAA). 
This is in keeping with the concept that removal of the diseased colon is what improves a 
patient’s quality of life following surgery, not the restoration of anal defecation.  
Although the restoration of anal defection via an IPAA has been perceived to 
result in an improved quality of life when compared to an ileostomy, as indicated by 
some modern narrative reviews
37, 38
, this claim is not substantiated by a critical review of 
the literature. In fact, older literature indicates a high degree of satisfaction among 
patients with ileostomies. In a survey of 273 patients with ileostomies, Roy et al reported 
that 92% perceived themselves to have a normal lifestyle, and 89% indicated they had 
good or excellent health
39
. In a similar survey of 273 patients with ileostomies from the 
Cleveland Clinic, 74% of patients reported that they had normal lives
40
. Further evidence 
that removal of the diseased colon is the key to good post-operative quality of life comes 
from a study by Weinryb et al where patients having undergone a staged IPAA had their 
quality of life assessed before and after their temporary ileostomies were closed. Using a 
validated generic measure, the Psychological Adjustment to Illness Scale (PAIS)
41
, the 
authors found no further improvement in HRQOL following closure of ileostomy
42, 43
. 
 Studies have documented an improvement in HRQOL following proctocolectomy 
in patients with ulcerative colitis primarily related to control of their symptoms and 
disease
12, 30, 44
. Of note, these benefits are less apparent among patients with familial 
adenomatous polyposis (FAP) who undergo IPAA. FAP is an inherited disorder 
characterized by the development of hundreds of polyps and a high risk of colon cancer, 
often warranting a prophylactic proctocolectomy as most patients will ultimately develop 
colon cancer 
45
. These patients often receive an IPAA but they are not generally 
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symptomatic or ill prior to the procedure, unlike ulcerative colitis patients. Studies 
comparing postoperative quality of life among FAP and ulcerative colitis patients have 
consistently found a worse postoperative quality of life among FAP patients
46, 47
. In a 
study of 64 patients, 10 of whom had FAP, HRQOL assessed by the Cleveland Clinic 
Global Quality of life scale
8
 found significantly worse quality of life among FAP 
patients
46
, despite improved functional results in the FAP group. 
 Although we found no overall differences in HRQOL, some domain/item specific 
differences were observed between IPAA and ileostomy patients. Pemberton et al using a 
self-developed performance status score found more functional restriction among patients 
with ileostomies, particularly among the sexual activity, sports, social activities, and 
travel domains
29
. In contrast, Nordin et al, using the well validated IBDQ and SF-36 
found worse social functioning among the IPAA patients on both items
3
. These disparate 
findings may be explained by the effects of morbidity on quality of life. In Pemberton’s 
study, patients with ileosotomies had a much higher morbidity (complication) rate (22% 
vs 11%), which likely contributed to their worse functioning. The use of different 
instruments may also explain the contrasting results, although this is difficult to assess 
given the lack of validation of Pemberton’s performance score. O’Bichere also found 
worse domain specific scores with IPAA patients indicating that their procedure more 
negatively impacted on their bowel habits and diet when compared to ileostomy 
patients
33
. However, this was based on a non-validated self-developed score, and thus it is 
difficult to properly compare these results to those obtained using validated instruments. 
No study using a validated generic or disease specific instrument identified greater 
functional restriction among patients with ileostomies.  
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One consistent finding, however, was the reduced body image associated with an 
ileostomy. O’Bichere found a reduced body image among ileostomy patients when 
measured on their self-developed visual analogue score, although this did not result in a 
reduced overall quality of life when combined to produce a summative score, as it was 
offset by problems with pouch functioning among the IPAA patients
33
. Camilleri-
Brennan, using a self-developed, non-validated questionnaire also found reduced body 
image among patients with ileostomies
34
. Liddell et al using a validated multidimensional 
Body Self-Relations Questionnaire
48
 also found reduced body image among patients with 
ileostomies
28
. Despite these findings, no study identified any overall differences in 
quality of life, indicating that the overall impact of reduced body image is unlikely to be 
of any great functional consequence to these patients.  
 Ultimately, any systematic review is limited by the quality of its included studies. 
The quality of the nine studies varied widely, not only in their design (Table 3.4), but also 
in the quality of their method of HRQOL assessment (Table 3.5). These differences made 
comparisons between studies difficult to interpret. The most important aspect of quality is 
the use of validated measures of HRQOL. Statistical tests of the results of non-validated 
instruments are of little value and hazardous to interpret
36
. The studies of the highest 
methodological quality used both a validated generic and a validated disease specific 
instrument in their assessment of HRQOL; both identified no difference in HRQOL 
between IPAA and ileostomy patients. In the remaining studies, one used a validated 
generic measure and two validated utility measures, one used a validated generic measure 
combined with a non-validated disease specific instrument, one used a validated disease 
specific instrument only, and 4 used non-validated global measures. The design of studies 
58 
 
 
varied greatly with only three being prospective and six being retrospective. Only two 
studies adjusted for confounding. Pemberton et al adjusted the results of their 
performance score using a logistic regression accounting for differences in age, sex, 
duration of disease, and re-operation, although there performance score was not a 
validated measure
29
. Camilleri-Brennan’s study was of the highest methodologic quality 
as they combined a prospective design, adjustment for confounding, standardized follow-
up, and validated HRQL assessment (generic and disease specific)
34
. They matched 
patients in both groups for age, sex, socioeconomic status, and time since surgery and 
found no difference in HRQOL in either the generic or disease-specific instruments. 
 All but one study had suboptimal response rates to the questionnaires, with rates 
ranging from 98% to 58.1%. This is an important consideration as non-responders are 
often different in terms of characteristics than responders, and this can introduce bias into 
the results
49
. The only study to compare responders to non-responders identified no major 
differences in demographics or complications between the two groups
31
, thus the impact 
of this potential bias is difficult to determine.   
 The studies were generally limited by their small sample size with only one study 
containing greater than 100 patients per group. This may have resulted in under-powered 
comparisons. One way to overcome this would have been a quantitative meta-analysis of 
the results. This was not possible as the studies used different measures of HRQOL; and 
in the studies that did use similar measures, the results were reported differently (mean vs 
median), not allowing for meta-analysis. One approach would have been to combine the 
results of different measures through standardization, although this approach has been 
criticised for introducing bias as the most responsive instruments will carry 
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disproportionately more weight in the analysis
50
. Despite small numbers, disease-specific 
measures such as the IBDQ have been shown to be responsive enough to be suitable for 
even small trials (n=20)
36
.  
 This is the only systematic review looking specifically at the question of whether 
IPAA patients have improved health-related quality of life when compared to patients 
with ileostomies. Despite its systematic nature, this review does have several limitations. 
The first is the variable quality of the studies as discussed above. The second is the 
inability to quantitatively combine the results into a meta-analysis. Although this may 
have improved the power of the comparison, it may have introduced bias as the studies 
were fairly heterogeneous in terms of their clinical characteristics (morbidity rates), 
methods of HRQL assessment, length of follow-up, and methodological quality. Thirdly, 
no specific measures were taken to account for publication bias. Publication bias usually 
results from not including non-published studies that are more likely to have non-
significant results
51
. This is unlikely to be a factor as the major substantive conclusion of 
this review is that no difference exists between the groups. A final limitation is the 
inclusion of English-only language studies, the justification for and rationale can be 
found in chapter two of this work.  
 Although limited by variable study quality and small sample sizes, the current 
literature does not support the assumption that the more advanced IPAA procedure leads 
to an increase in quality of life when compared to the conventional ileostomy. Both 
appear equivalent in terms of overall quality of life, although ileostomy patients have 
poorer body image. These findings provide further rationale and justification for the 
development of a patient decision aid to help patients decide between the two 
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reconstructive options. This literature supports the concept that patients who select a 
certain option are satisfied with their choice and generally enjoy a good HRQOL. Despite 
high complication rates following IPAA, Skarsgard et al showed that 92% of patients 
would choose to undergo a pouch procedure again
52
. Thus empowering and facilitating 
this choice, rather than recommending one option over the other is the right way to 
approach the therapeutic decision between an IPAA and an ileostomy. 
61 
 
 
TABLE 3.3. Quality of Life Study Characteristics  
Study 
(author/year) 
Country HRQOL 
measure 
Groups N Age  
(mean, range, yrs) 
Male (%) Morbidity rate 
(%) 
Follow-up 
(mean, 
months) 
Emblem 
(1988)
32
 
Norway Social restriction IPAA 
Ileostomy 
19 
35 
27 (23-38) 
30 (26-35) 
53 
60 
21 
71 
48 
58 
Pemberton 
(1989)
29
 
USA Overall 
satisfaction, 
return to work or 
school,  
Performance 
status 
IPAA 
Ileostomy 
298 
406 
32* 
38 
51 
59 
11 
22 
47* 
104 
McLeod  
(1991)
30
 
Canada Time trade-off 
(TTOT) 
Direct 
questioning of 
objectives 
(DQO) 
Sickness-impact 
profile (SIP) 
 
IPAA 
Ileostomy 
37 
28 
36 ± 9 
39 ± 13 
49 
54 
 
8.1† 
18 
NR 
NR 
 
Liddell (1995)
28
 Canada Lifestyle 
satisfaction 
 
IPAA 
Ileostomy 
25 
10 
33.2 ± 7 
51 ± 14 
40 
40 
NR 
NR 
40 
47 
Jimmo (1998)
35
 USA Inflammatory 
Bowel Disease 
Questionnaire 
(IBDQ) 
IPAA 
Ileostomy 
55 
12 
31 
52 
 
45 
60 
49 
8 
12 
12 
O’Bichere 
(2000)
33
 
UK Visual analogue 
scale (VAS) 
 
Short-Form 36 
(SF-36) 
IPAA 
Ileostomy 
30 
30 
 
43 (22-71)‡ 
 
44 
 
NR 
 
13 
62 
 
 
Seidel (2000)
31
 USA Overall quality 
of life 
IPAA 
Ileostomy 
55 
31 
31.2 ± 1.3 
44.8 ± 3.7 
55 
48 
63 
16 
 
30.6 ± 3.5‡ 
Nordin (2002)
3
 Sweden SF-36 
IBDQ 
IPAA 
Ileostomy 
57 
42 
 
46 (20-70) 
 
48 
 
NR 
 
NR 
Camilleri-
Brennan 
(2003)
34
 
Scotland SF-36 
IBDQ 
IPAA 
Ileostomy 
19 
19 
41* 
41 
63 
63 
21.1 
42.1 
41* 
43 
* median; † rate of re-operation; ‡for both groups combined; NR not recorded 
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TABLE 3.4 Study Quality Assessment 
Study 
(author/year) 
Consecutive 
patients 
Study type Adjustment 
for 
confounding 
Response 
Rate 
Validated QOL 
measure 
Emblem (1988)
32
 
 
No Retrospective No 100% No  
Pemberton (1989)
29
 
 
Yes Retrospective Yes
2
 81% No 
McLeod  (1991)
30
 
 
No Retrospective No 98% Yes 
Liddell (1995)
28
 
 
No Retrospective No 87.5% No 
Jimmo (1998)
35
 
 
Yes Prospective No 79% Yes 
O’Bichere (2000)33 
 
No Retrospective No 68.9% Yes 
Seidel (2000)
31
 
 
Yes Retrospective No 58.1% No 
Nordin (2002)
3
 
 
No Retrospective No 69.3% Yes 
Camilleri-Brennan 
(2003)
34
 
No Prospective Yes
3
 76% Yes 
 
 
 
 
 
 
 
 
 
                                                 
2
 Pemberton et al adjusted for confounding in their analysis using a logistic regression for performance scores, adjusting for age, sex, duration of disease, and 
subsequent re-operation. 
3
 Camilleri-Brennan et al adjusted for confounding in their design by matching the two groups for age, sex, time since surgery, and socioeconomic status,  
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TABLE 3.5. Properties of Quality of Life Instruments  
 
Study 
(author/year) 
HRQOL measure 
(type) 
Face 
validity 
Content 
validity 
Construct 
validity 
Criterion 
validity 
Internal 
consistency 
Reliability Validation references 
Emblem 
(1988)
32
 
 
 
Societal restriction 
(global) 
No No No No NA No -  
Pemberton 
(1989)
29
 
Overall satisfaction, 
Return to work or 
school,  
Performance status 
(generic) 
No 
 
 
Yes 
No 
 
 
Yes 
No 
 
 
No 
No 
 
 
No 
NA 
 
 
No 
No 
 
 
No 
-  
McLeod  
(1991)
30
 
TTOT (utility) 
 
DQO (utility) 
 
SIP (generic) 
(range 0-100) 
Yes 
 
Yes 
 
Yes 
Yes 
 
Yes 
 
Yes 
Yes 
 
Yes 
 
Yes 
Yes 
 
Yes  
 
Yes 
NA 
 
NA 
 
Yes 
Yes 
 
Yes 
 
Yes 
Bergner et al
22
 
Churchill et al
53
 
Detsky et al
54
 
Torrance et al
23
 
Liddell 
(1995)
28
 
Lifestyle 
satisfaction 
(generic) 
Yes Yes No No No No -  
Jimmo (1998)
35
 IBDQ (disease 
specific) 
Yes Yes Yes  Yes  Yes Yes Guyatt et al
21
 
Irvine et al
25
 
O’Bichere 
(2000)
33
 
SF-36 (generic) 
 
VAS (disease-
specific) 
Yes 
 
No 
Yes 
 
No 
Yes  
 
No 
Yes  
 
No 
Yes  
 
No 
Yes  
 
No 
Ware et al
18
 
McHorney et al
55, 56
 
Seidel (2000)
31
 Overall quality of 
life (global) 
No No No No No No -  
Nordin (2002)
3
 SF-36 (generic) 
 
IBDQ (disease 
specific) 
Yes 
 
Yes 
Yes 
 
Yes 
Yes 
 
Yes 
Yes 
 
Yes 
Yes 
 
Yes 
Yes 
 
Yes 
Ware et al
18
McHorney 
et al
55, 56
 
Guyatt et al
21
 
Irvine et al
25
 
 
Camilleri-
Brennan 
(2003)
34
 
SF-36 (generic) 
IBDQ (disease-
specific) 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Ware et al
18
McHorney 
et al
55, 56
 
Guyatt et al
21
 
Irvine et al
25
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TABLE 3.6 Quality of Life Study Results  
 
Study 
(author/year) 
Groups (n) QOL measure 
 
Numerical results p-value Conclusions 
IPPA Ileostomy 
Emblem 
(1988)
32
 
IPAA (19) 
 
Ileostomy (35) 
 
Societal restriction 
(%yes) 
  
0% 67% <0.01 Ileostomy patients suffered greater social 
restriction then IPAA patients  
Pemberton 
(1989)
29
 
IPAA (298) 
 
Ileostomy (496) 
Overall satisfaction 
(%yes) 
Return to work or school 
(%yes) 
Performance score
1
 
 
95% 
 
98% 
 
 
-  
93% 
 
94% 
 
 
-  
NS 
 
NS 
 
 
<0.05 
Overall satisfaction was similar between 
the two groups although IPAA patients 
had improved performance scores when 
compared to ileostomy patients
4
 
McLeod  
(1991)
30
 
IPAA (37) 
 
Ileostomy (28) 
TTOT (0-1.0) 
(mean ±SD) 
DQO (0-1.0) 
(mean ±SD) 
SIP (0-100) 
(mean ±SD) 
 
0.95 ± 0.15 
 
0.87 ± 0.18 
 
1.2 ± 2.3 
0.97 ± 0.08 
 
0.89 ± 0.15 
 
3.1 ± 5.0 
NS 
 
NS 
 
NS 
No difference in QOL using two utility 
measures and one generic measure 
between the two groups.  Even a 
subgroup analysis of ileostomy patients 
contemplating a change to IPAA showed 
no difference. 
Liddell 
(1995)
28
 
IPAA (25) 
 
Ileostomy (10) 
Lifestyle Satisfaction
5
 
Overall satisfaction (1-7) 
(mean ± SD) 
 
 
5.48 ± 1.56 
 
 
5.7 ± 1.34 
 
 
NS 
No difference in overall satisfaction 
between the two groups. Comparison of 
the seven sub-categories
2
 failed to reveal 
any differences as well.  
 
 
 
                                                 
4
 Pemberton et al used a self- developed, un-validated, performance score measure as a way to determine the impact of each surgical procedure on daily life. It 
consisted of seven categories (sports, sexual life, social activities, recreation, work around the house, family relationships, and travel) each assessed with a 5-
point Likert scale. The results were only presented graphically, thus they were not extractable. In each category, IPAA patients showed significantly less 
restriction than ileostomy patients.  
5
 Liddell et al used a self-developed, un-validated score-based questionnaire to assess patient satisfaction. Eight domains and an overall assessment were 
explored: social activities, sports activities, housework, recreation, family relationships, sex, travel, and work; and each was given a score based on a 7-point 
Likert scale (markedly worse to marked improvement). 
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Jimmo (1998)
35
 IPAA (55) 
 
Ileostomy (12) 
IBDQ (32-224) 
(mean ±SD) 
 
 
205 ± 20
6
 
 
200 ± 25 
 
0.49 
No difference in disease-specific quality 
of life between the two groups. No 
difference demonstrated when individual 
categories of IBDQ were compared 
O’Bichere 
(2000)
33
 
IPAA (30) 
 
Ileostomy (30) 
SF-36 (0-100) 
(median) 
Health perception 
Physical functioning 
Role-physical 
Role-emotional 
Social functioning 
Mental Health 
Bodily pain 
Energy/vitality 
 
VAS (1-10)
7
 (median) 
Body image 
Altered bowel emptying 
Odour 
Noise 
Sexual relationship 
Clothes 
Diet 
 
 
57 
90 
88 
100 
88 
68 
90 
43 
 
 
5 
8 
5 
5.5 
5 
3.5 
5.5 
 
 
 
55 
80 
75 
100 
88 
76 
80 
53 
 
 
8 
5 
8 
6 
7 
3 
2 
 
 
 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
 
 
NS 
<0.05 
NS 
NS 
NS 
NS 
<0.05 
No difference was found in HRQOL 
using the SF-36 instrument between the 
two groups. The negative impact altered 
bowel habits and problems with pouch 
functioning are highlighted by the 
differences in the VAS domain of bowel 
emptying. While the negative effects of 
the ileosotomy on body image are also 
evident as these patients scored worse on 
the VAS.  
Seidel (2000)
31
 IPAA (55) 
 
Ileostomy (31) 
Overall quality of life 
Better since operation 
(always %) 
87 93 NS No difference between groups in overall 
quality of life.  
Nordin (2002)
3
 IPAA (57) 
 
Ileostomy (42) 
SF-36 (0-100) 
(mean) 
Overall health 
Physical functioning 
Role-physical 
Role-emotional 
Social functioning 
Mental Health 
 
 
NR 
NR 
NR 
NR 
70.2 
NR 
 
 
NR 
NR 
NR 
NR 
89.3 
NR 
 
 
 
 
 
 
<0.05 
 
Patients with IPAA actually scored worse 
on some domains of both the generic and 
disease specific measures of HRQL. 
IPAA patients had worse social 
functioning, more bowel symptoms, and 
worse emotional functioning than 
patients with ileostomies. There were no 
differences in the remaining domains of 
                                                 
6
 Values extrapolated from figure.  
7
 O’Bichere et al used a self-developed, non-validated 10-point visual analogue scale to assess how problematic patients saw the surgery in relation to each 
domain: body image, altered bowel emptying, odour, noise, sexual relationship, clothes, diet. Each was given a score from 1 (least problematic) to 10 (most 
problematic).  
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Bodily pain 
Energy/vitality  
 
IBDQ (32-224) 
(mean) 
Bowel symptoms 
Systemic symptoms 
Emotional functioning 
Social functioning 
 
 
NR 
NR 
 
 
 
NR 
54.4 
NR 
64.8 
NR 
NR 
 
 
 
NR 
63 
NR 
72.2 
 
 
 
 
 
 
<0.01 
 
<0.01 
either instrument, although numerical 
results were not reported.  
Camilleri-
Brennan 
(2003)
34
 
IPAA (19) 
 
Ileostomy (19) 
SF-36 (0-100) 
(median) 
Overall health 
Physical functioning 
Role-physical 
Role-emotional 
Social functioning 
Mental Health 
Bodily pain 
Energy/vitality 
 
 
IBDQ (32-224) 
(median) 
Global score 
Bowel symptoms 
Systemic symptoms 
Emotional functioning 
Social functioning 
 
 
 
 
62 
95 
93.8 
100 
100 
85 
88.9 
62.5 
 
 
 
 
85.4 
81.7 
80 
84.7 
95.8 
 
 
 
77 
90 
100 
100 
100 
75 
88.9 
77 
 
 
 
 
80.7 
80 
83.3 
80.6 
91.7 
 
 
 
0.70 
0.24 
0.60 
0.57 
0.81 
0.14 
0.21 
0.49 
 
 
 
 
0.56 
0.32 
0.25 
0.76 
0.56 
There were no significant differences in 
overall or domain specific measures of 
HRQOL between the two groups. 
Although a small sample size, the study 
used matching to control for confounding 
adding methodologic rigor to their 
results. Body image was also explored 
with a non-validated, self-developed 
measure which did show inferior body 
image among patients with ileostomies.  
TTOT=Time Trade-Off Technique; DQO= Direct Questioning of Objectives; SIP = Sickness Impact Profile; NS = non-significant, NR = not recorded
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CHAPTER FOUR – A SYSTEMATIC REVIEW AND META-REGRESSION OF 
OUTCOMES FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS 
 
4.0 Introduction 
 
 Patients with ulcerative colitis who wish to avoid a permanent ileostomy have the 
option to undergo a restorative proctocolectomy with an ileal pouch-anal anastomosis 
(IPAA). This technique involves the formation of a reservoir using the small bowel 
(ileum) and joining it to the anus to form a neo-rectum. Originally described by Parks and 
Nicholls in 1978
1
, the procedure has undergone many modifications and in its most 
common form consists of a two-stage procedure where the colon and rectum is removed 
and the pouch created, and protected with a diverting ileostomy that diverts the fecal 
stream away from the pouch allowing it to heal
2
. Patients then undergo a closure of the 
ileostomy at a second operation. It is important to note that this procedure does not 
improve the control of ulcerative colitis, rather it is a procedure aimed at improving a 
patient’s quality of life and day to day functioning through the avoidance of a stoma.  
As explored in chapter three of this work, there is no conclusive evidence that it 
universally leads to better health-related quality of life when compared to the 
conventional proctocolectomy and ileostomy. Rather the decision to undergo a restorative 
proctocolectomy should be made by the patient and be in line with their values and 
expectations. In order to facilitate this decision, patients must be informed about the risks 
of serious complications following the procedure. In order to provide estimates of these 
complications for inclusion into our decision aid, a systematic review and meta-analysis 
of serious outcomes following IPAA was conducted. One previous meta-analysis 
published by Hueting et al in 2005 had several limitations
3
. They did not explore any 
study quality items, no formal tests of heterogeneity were conducted, there were minimal 
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efforts to explore heterogeneity among studies, no assessment of publication bias was 
undertaken, and the review was dated as it only included studies published up to 2000. 
We conducted an updated meta-analysis and took measures to explore and quantify 
heterogeneity among studies.  
 
4.1 Methods 
Search Strategy  
 The details of the search strategy are presented in chapter two of this work, along 
with the justification and listing of the specific inclusion criteria. Briefly, we included 
studies of at least 100 patients that reported on outcomes of interest regardless of pouch 
type, number of stages, and length of follow-up. All titles and abstracts were 
independently reviewed by two reviewers, and any study that either reviewer deemed as 
potentially eligible was selected for full text review. Study inclusion was then assessed 
independently with any disagreement resolved by consensus. When conducting our 
review, we followed the guidelines set out by the Meta-analysis of Observational Studies 
in Epidemiology (MOOSE)
4
 and Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA)
5
 groups. 
Data Extraction  
 All information was extracted independently by two reviewers with any 
disagreements resolved by consensus using standardized, custom designed, data-
abstraction sheets. Study characteristics including size; location; time period of patient 
enrollment; length of follow-up; mean age; proportion with Crohn’s, FAP, or 
indeterminate colitis; proportion with prior subtotal colectomy; proportion of stapled 
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anastomosis; proportion with J-pouch configuration; and proportion with diverting loop-
ileostomy were abstracted. Outcomes of interest included pouch failure (pouch excision 
or permanent diverting ileostomy,), pelvic sepsis (pelvic abscess, anastomotic leakage, or 
perineal wound infection), pouch-fistula (any fistula involving the pouch), stricture 
(anastomotic stricture requiring dilatation), small bowel obstruction (requiring 
laparotomy), and sexual dysfunction (erection disorder or dyspareunia). Functional 
results were also extracted including mean number of bowel movements per day, mean 
number of bowel movements at night, proportion with significant fecal incontinence, 
fecal urgency (inability to defer defecation), proportion with daily pad use, and 
proportion requiring daily anti-diarrheal medication use.  
Quality Criteria 
 The justification for and rationale behind the selection of quality criteria is 
discussed in depth in chapter two of this work, but a brief synopsis follows here. 
Although many tools and scales exist for the assessment of quality criteria of 
observational studies, no one tool can be recommended above others as there is no 
empirical evidence linking specific observational study design elements to validity
6, 7
. 
With that in mind, specific elements of study design reflective of quality were 
investigated individually with regards to influence on outcome measures rather than using 
summary scores of quality
8
. The study quality criteria examined included: whether or not 
the patients represented a group of consecutive patients having surgery over a pre-
specified time period, whether the authors used clearly defined outcome criteria, whether 
the study was retrospective or prospective, proportion loss to follow-up, and whether the 
authors employed a standardized follow-up procedure.  
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Meta-Analysis 
 Each study estimate of a given outcome was recorded and its 95% confidence 
interval was determined using Wilson’s score method9. In order to combine the 
proportions from individual studies, we converted the individual proportions into odds
10
, 
and the odds were transformed into the log scale using equation 4.1: 
 ln(odds) = ln (no of patients having event/ no of patients not having event)   (4.1) 
This allowed us to generate a variance term which was used in the weighting of studies 
for the meta-analysis (equation 4.2): 
 
var ln(odds) = 1/no of patients having event + 1/ no of patients not having event
10
   (4.2).  
 
Meta-analysis was then carried out using individual study proportions converted 
to the ln(odds) scale according to the random-effects model of DerSimonian and Laird
11
, 
accounting for both within-study variance and between-study variance. This model 
assumes that the outcome measures of each study come from a random distribution of 
outcomes, with the weighting of studies based on the reciprocal of the sum of between 
study variance and within study variance. The statistical package, STATA version 10 
(Stata inc, Texas, US, 2008) using the procedures meta and metan were used to meta-
analyse the data as described by Sharp
12
. This procedure estimates the between-study 
variance using the non-iterative weighted method of DerSimonian and Laird
11
. Pooled 
results were converted back to the proportion scale and presented along with their 95% 
confidence interval. In cases where the study had no events, a continuity correction factor 
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was added (0.5) in order to generate an outcome measure for the meta-analysis as ln(0) is 
not a real number. Adding a continuity correction is preferred over excluding studies with 
zero events
13
.  Each outcome was also graphically summarized using Forrest plots. The 
possibility of publication bias was explored using funnel plots of the individual 
outcomes, looking for asymmetry amongst the smaller trials. This was done assuming 
smaller trials might be more apt to get published if they have “better” results, i.e. lower 
rates of complications following IPAA. 
Heterogeneity 
 Heterogeneity was statistically assessed for each outcome using the Cochran’s Q 
chi-squared test which is calculated by adding together the squared deviations of each 
study’s outcome from the overall pooled outcome, and then adjusting each deviation by 
the study’s weight used in the meta-analysis14. This statistic, although widely used, is 
often under-powered
15, 16
. In an effort to improve the test`s power, some author have 
argued establishing a cut-off of 0.1 as the nominal level of significance for this test
17, 18
. 
However, we maintained a value of 0.05 for this analysis as we had a large number of 
studies which would improve its power. The degree of heterogeneity was also quantified 
using the I
2
 statistic, which is the percentage of total variation across studies that is not 
explained by chance
19
. The resulting value ranges from 0 (no heterogeneity) to increasing 
proportions of non-chance related heterogeneity as the % I
2
 increases.  
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Exploration of Heterogeneity 
 To explore the heterogeneity we conducted selective subgroup analyses on pre-
specified study characteristics, namely, 85% or greater proportion of pouches created 
with J-configuration, studies with 100% diversion at the time of pouch creation, follow-
up greater or equal to five years, and loss to follow-up of <10%. The most common 
pouch configuration in the modern era is the J-pouch
2, 20, 21
 thus looking at studies that 
include a majority of patients with this pouch configuration is most relevant to the 
modern patient. While routine use of a diverting ileostomy has been linked to reduced 
septic complications following IPAA and has been adopted by most surgeons
22
. Longer 
follow-up has been linked to increased complication rates following IPAA as 
complications such as pouch failure and pouchitis tend to occur over the long-term
3
, and 
losses to follow-up have been empirically linked to differences in outcome measures in 
meta-analyses of experimental literature
23
. Our other quality criteria, namely consecutive 
patients (protection against selection bias), outcome criteria definition, and standardized 
follow-up have not been shown in prior research to be linked with validity or outcome.  
Each methodologic and study characteristic was systematically tested against the 
outcome for its contribution to study heterogeneity using univariable and multivariable 
meta-regression. Those factors that significantly contributed to heterogeneity amongst 
studies were then considered for subgroup analysis provided there was a plausible clinical 
or pathologic rationale. This last step was necessary to reduce concerns about multiple 
testing and data dredging where associations may arise purely from chance alone
24
.  
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Meta-Regression 
 Meta-regression involves exploring the linear association between study level 
covariates and the pooled effect measure generated in the meta-analysis. It seeks to 
determine how much of the heterogeneity is explained by variations in a single or a set of 
given methodologic or study level factors
10
. It occurs at the study level with the outcome 
being the meta-analyzed variable (here the ln(odds) of each outcome), and the covariates, 
which include the study level factors (such as size, length of follow-up, etc).  
Exploratory meta-regressions were undertaken to identify study level factors that 
significantly contributed to the between-study variability. Study level factors explored 
included methodologic criteria: consecutive patients, outcome definition, losses to 
follow-up, study type (retrospective vs prospective), standardized follow-up, and length 
of follow-up. The following study characteristics were also explored: mean age of 
patients, mid-point year of patient cohort, proportion of patients with Crohn’s disease, 
proportion of patients with FAP, proportion of patients with indeterminate colitis, 
proportion undergoing diversion, proportion of stapled anastomoses, and proportion with 
j-pouch configuration. For each study level factor, the significance of its association with 
the outcome on the log scale and the proportion of outcome variability accounted for by 
the factor were reported. For those that significantly contributed to outcome 
heterogeneity, a plot of the study factor and the outcome on the log scale are presented 
with the symbol representing each study, proportionally sized to the weight of the study. 
Meta-regression was performed using the STATA command metareg, which carries out a 
random-effects meta-regression and estimates the between study variance using the 
iterative residual maximum likelihood method
12
. The use of a random-effects meta-
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regression is preferred as fixed-effects meta-regression would only be appropriate if all 
the heterogeneity was explained by the covariates. This is generally not possible and the 
residual heterogeneity must be acknowledged in the analysis
24
. In order to undertake a 
random-effects meta-regression some estimate of residual between study variance must 
be generated. Multiple methods exist, some based on empirical Bayesian estimates, 
others on iterative restricted maximum likelihood estimates (REML). Iterative methods 
are preferred as they do not require any subjective assumptions about prior 
probabilities
24
. Only studies that reported on a given covariate (study factor) could 
contribute to the meta-regression.  
 
4.2 Results 
 
4.2.1 Study Selection 
 
Our searches resulted in 3920 abstracts and titles, with 411 full-text papers 
retrieved for review and 67 studies ultimately met our inclusion criteria. There was good 
agreement beyond chance between the two independent reviewers for study inclusion (k 
= 0.87). The most common reason for exclusion were papers reporting on duplicate 
cohorts of patients who had been treated at the same institution over a similar time period 
(n=124). Other reasons for exclusion included studies with < 100 patients, review papers, 
papers reporting on sub-groups only, studies reporting on outcomes not related to our 
inclusion, and non-English language papers. Occasionally two papers from the same 
center were included if they reported on different outcomes or reported on patients from 
two non-overlapping time periods.  
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4.2.2 Study Description  
 The 67 studies included 21,882 patients treated in 19 different countries who were 
followed for a mean (SD) of 62.1 (34) months (range: 13-180 months). The studies 
reported on patients operated on from 1977 to 2005, with specific time span of cohorts 
differing from study to study (Table 4.1). The mean age at time of surgery was 34.9 
years, ranging from 23.8 to 40 years (Table 4.2). Study size ranged from 100 to 1885 
patients with an overall mean study size of 327 patients. Eighteen studies included 
patients with Crohn’s disease, with proportions ranging from 0.16% to 24%, while 20 
studies included patients with indeterminate colitis, ranging from 0.5% to 29.4%.  
Patients with FAP were included in 33 studies with proportions ranging from 2.3% to 
16%. The rate of proximal diversion (loop ileostomy) at the time of pouch creation varied 
among studies with 28 studies reporting universal diversion with every patient, while the 
rates of diversion varied between 20% and 99.3% among the other studies. The rates of 
stapled-anastomosis also varied between 0% and 100%. The most common method of 
pouch construction was the J-pouch configuration, with 17 studies reporting exclusively 
on J-pouch patients. While the rates of J-pouch configuration varied between 3.1% and 
99.5% among other studies.  
 
4.2.3 Study Quality Assessment    
 Of the included studies, 25 (37% )were prospective, 42 (61%) included 
consecutive patients, 30 (44%) studies used standardized follow-up, and 51 (76%) studies 
used clearly defined outcomes to assess rates of complication, with 18 (27%) studies 
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using clearly defined outcome criteria for all their reported outcomes. Fifty two studies 
(77.6%) reported losses to follow-up; the average loss to follow-up was 7.5% (range 0-
29%) and 36 studies reported less than 10% losses to follow-up.  
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Table 4.1 Characteristics of Studies Reporting on Outcomes Following IPAA  
 
Author Location Years of 
Surgery 
Consecutive 
Patients 
Type of Study Outcomes 
Defined 
Standardized 
Follow-up 
Fonkalsrud et 
al
25
,1988 
UCLA, US 1977-1988 No Retrospective None No 
Nicholls et al
26
, 1989 St Marks, UK 1976-1986 Yes Prospective None No 
Pescatori and 
Mattana
27
, 1990 
Multicenter, Italy 1980-1989 No Retrospective Some No 
Wexner et al
28
, 1990 Minnesota, US 1980-1988 No Retrospective None No 
Becker et al
29
, 1991 Harvard, US 1982-1990 No Prospective Some Yes 
Harms et al
30
, 1992 Wisconsin, US 1984-1991 No Retrospective Some No 
Fischer et al
31
, 1993 Cincinnati, US NR Yes Retrospective Some No 
Mathey et al
32
, 1993 Multicenter, Swiss 1980-1991 No Retrospective Some No 
Sagar et al
33
, 1993 Leeds, UK 1980-1990 Yes Prospective None No 
Atkinson et al
34
, 1994 Vancouver, Canada 1984-1992 Yes Retrospective None No 
Daude et al
35
, 1994 Paris, France 1983-1991 No Retrospective Some Yes 
Hulten et al
36
,1994 Goteborg, Sweden 1982-1992 No Retrospective Some No 
Lewis et al
37
, 1994 London, UK 1983-1991 Yes Retrospective None Yes 
Gorfine et al
38
, 1995 New York, US 1992-1994 Yes Retrospective Some No 
Hewett et al
39
, 1995 Brisbane, Australia 1981-1993 Yes Retrospective None No 
Sitzmann et al
40
, 1995 Baltimore, USA 1987-1992 Yes Retrospective Some Yes 
Stahlberg et al
41
, 1996 Huddinge, Sweden 1980-1993 Yes Prospective All Yes 
McCourtney and 
Finlay
42
,1997 
Glasgow, Scotland 1988-1995 Yes Retrospective Some Yes 
Romanos et al
43
, 1997 Oxford, UK 1983-1995 Yes Retrospective Some Yes 
Breen et al
44
, 1998 Lahey Clinic, US 1980-1996 Yes Prospective All Yes 
Belliveau et al
45
, 1999 Montreal, Canada 1981-1994 Yes Retrospective None No 
Fazio et al
46
, 1999 Cleveland, US 1986-1997 Yes Prospective Some Yes 
Neilly et al
47
, 1999 Auckland, NZ 1982-1997 No Retrospective None Yes 
Tiainen et al
48
, 1999 Tampere, Finland 1985-1995 Yes Retrospective None No 
Young et al
49
, 1999 Sydney, Australia 1984-1997 Yes Retrospective Some No 
Karlbom et al
50
, 2000 Uppsala, Sweden 1983-1996 No Retrospective Some Yes 
Keighley et al
51
, 2000 Birmingham, UK 1983-1999 Yes Prospective None No 
Mowschenson et 
al
52
,2000 
Boston, US 1989-1996 Yes Prospective Some No 
Simchuk and 
Thirlby
53
, 2000 
Seattle, US 1987-1996 Yes Retrospective Some Yes 
Sugerman et al
54
, 2000 Richmond, US 1989-1999 Yes Retrospective Some Yes 
Blumberg et al
55
, 2001 New Orleans, US 1982-1995 No Retrospective Some  No 
Heuschen et al
56
, 2001 Heidlberg, Germany 1982-1997 Yes Prospective All Yes 
Madiba and Bartolo
57
, 
2001 
Edinburgh, Scotland 1990-1999 No Prospective All Yes 
Regimbeau et al
58
, 
2001 
Paris, France 1984-1998 Yes Retrospective None Yes 
Dayton et al
59
, 2002 Salt Lake City, US 1982-2001 Yes Retrospective Some Yes 
Heuschen et al
60
, 2002 Heidlberg, Germany 1988-1999 Yes Retrospective Some Yes 
Lepisto et al
61
, 2002 Helsinki, Finland 1985-1999 No Retrospective All Yes 
MacLean et al
62
, 2002 Toronto, Canada 1981-1999 Yes Prospective All Yes 
Robb et al
63
, 2002 Cincinnati, US 1978-2001 No Retrospective Some No 
Rudolph et al
64
, 2002 Louisville, US 1991-1999 Yes Prospective Some No 
de Oca et al
65
, 2003 Barcelona, Spain 1985-2000 No Retrospective None No 
Fazio et al
66
, 2003 Cleveland, US 1983-2001 Yes Prospective Some Yes 
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Fowler et al
67
, 2003 Gloucester, UK 1984-2001 Yes Prospective Some No 
Michelassi et al
68
, 
2003 
Chicago, US 1987-2002 Yes Prospective Some Yes 
Gosselink et al
69
, 2004 Rotterdam, 
Netherlands 
1989-2001 Yes Prospective Some Yes 
Hueting et al
70
,2004  Utrecht,
 Netherlands 
1989-2000 No Retrospective Some No 
Ikeuchi et al
71
, 2004 Hyogo, Japan 1984-2002 No Retrospective All No 
Marciniak et al
72
, 
2004 
Poznan, Poland 1984-2002 No Retrospective All No 
Pishori et al
73
, 2004 Florida, US 1988-2000 Yes Retrospective Some No 
Arai et al
74
, 2005 Yokohama, Japan 1993-2003 Yes Retrospective Some No 
Brown et al
75
, 2005 Toronto, Canada 1982-2001 Yes Prospective Some Yes 
Hallberg et al
76
, 2005 Stockholm, Sweden 1990-1997 No Prospective All Yes 
Ikeuchi et al
77
, 2005 Hyogo, Japan 1999-2003 No Retrospective Some No 
Krausz et al
78
, 2005 Haifa, Israel 1984-2004 Yes Retrospective Some No 
Araki et al
79
, 2006 Paris, France 1998-2003 Yes Prospective None No 
Bengtsson et al
80
, 
2007 
Goteborg, Sweden 1984-2004 No Retrospective All No 
Berndtsson et al
81
, 
2007 
Goteborg, Sweden 1982-1995 No Retrospective All No 
Das et al
82
, 2007 St Marks, UK 1978-2006 No Retrospective All No 
Hahnloser et al
83
, 
2007 
Mayo Clinic, US 1981-2000 Yes Prospective Some Yes 
Nilubol et al
84
, 2007 New York, US 1988-1999 No Prospective All Yes 
Abdelrazeq et al
85
, 
2008 
York, UK 1988-2003 Yes Retrospective All Yes 
Ferrante et al
86
, 2008 Leuven, Belgium 1990-2004 Yes Retrospective All Yes 
Fleshner et al
87
, 2008 Los Angeles, US NR Yes Prospective All No 
Hoda et al
88
, 2008 Oregon, US 1993-2003 No Retrospective All No 
Lovegrove
89
, 2008 Sheffield, UK 1987-2006 No Prospective None No 
Tulchinsky et al
90
, 
2008 
Tel-Aviv, Israel 1986-2005 No Prospective All No 
Rink et al
91
, 2009 Guttenberg, Germany 1990-2002 Yes Retrospective Some Yes 
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Table 4.2 Characteristics of Patients in IPAA Studies  
 
Author N Patient Mean 
Age (Range) y 
% 
Crohn’s 
% 
FAP 
% 
IC 
% 
Diversion 
% Prior-
subtotal 
% Stapled 
 
% J-pouch Length of 
Follow-up  
Loss to 
Follow-up (%) 
Fonkalsrud et 
al
25
,1988 
172 23.8(7-58) 0 9.3 2.7 100 NR 44.8 87.5 NR NR 
Nicholls et al
26
, 1989 116 30 (14-52) 0 0 0 75.8 62.5 0 12.9 41 1.3 
Pescatori and 
Mattana
27
, 1990 
207 34 (8-67) 0 31.4 0 99.3 30 24.2 63.3 13.4 NR 
Wexner et al
28
, 1990 180 31 0 6.1 0 100 12.2 0 1.1 60 1.1 
Becker et al
29
, 1991 250 35 (11-67) 0 16 0 100 NR 100 100 NR 0 
Harms et al
30
, 1992 109 32.4 (11-67) 0 17.4 0 100 98.1 0 0 33.6 0 
Fischer et al
31
, 1993 200 NR 0 0 0 100 NR 0 3.5 NR 2.5 
Mathey et al
32
, 1993 157 33.5 (10-65) 0 19 0 100 56.7 12.1 82.8 37 26 
Sagar et al
33
, 1993 103 34 (14-64) 0 10.7 0 100 NR 66.9 13.6 NR 6.3 
Atkinson et al
34
, 1994 158 34 (19-59) 0 0 0 100 NR 100  NR NR 
Daude et al
35
, 1994 156 35 0 0 0 100 35 0 100 29 0 
Hulten et al
36
,1994 307 NR 0 0 0 100 NR NR NR 66 17 
Lewis et al
37
, 1994 115 35 1.7 6.1 0 67.8 35.6 0 10.4 34 0 
Gorfine et al
38
, 1995 143 34 0.7 9.8 0.7 48.3 46.8 0 100 18 6.3 
Hewett et al
39
, 1995 126 NR 0 0 0 100 NR 0 51.4 51 15 
Sitzmann et al
40
, 1995 105 NR 0 17.1 8.5 100 29.5 0 100 37.2 0 
Stahlberg et al
41
, 1996 149 34
*
 (8-64) 0 0 0 100 NR 100 100 54
*
 0 
McCourtney and 
Finlay
42
,1997 
103 31 (12-77) 0 8.7 0 73.8 26.2 100 100 31 3.9 
Romanos et al
43
, 1997 200 33 (6-67) 0 3.5 6.5 69.5 NR 73.5 71 27
* 
2.0 
Breen et al
44
, 1998 628 NR 0.3 8.3 7.5 100 NR NR NR 56 3.7 
Belliveau et al
45
, 1999 239 34 4.1 4.6 0 100 36.8 32.8 32.8 NR NR 
Fazio et al
46
, 1999 977 37 3.5 3.8 12.6 100 NR 100 80.1 60 15 
Neilly et al
47
, 1999 187 32 (14-63) 3.9 9.4 3.4 51.7 NR 74.1 65.2 73.2 7.9 
Tiainen et al
48
, 1999 136 35.5(19-63) 0 0 0 100 47.1 2.1 100 NR NR 
Young et al
49
, 1999 100 35
*
 (5-68) 0 20 5 100 42 50 100 68 0 
Karlbom et al
50
, 2000 182 32 (16-68) 0 0 0 70.8 56 45.8 45.8 29
*
 8 
Keighley et al
51
, 2000 202 35.6 (13-77) 0 0 0 100 57.4 90.6 90.6 91.3 0 
Mowschenson et 
al
52
,2000 
133 34.1  0 2.3 0 30.8 NR 100 100 NR 16.5 
Simchuk and 
Thirlby
53
, 2000 
114 39 (16-72) 2.6 11.4 0 100 NR 0 100 38 2.6 
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Sugerman et al
54
, 2000 192 38 (7-70) 2.6 4.2 0.5 0 88.5 100 100 61.2 11 
Blumberg et al
55
, 2001 145 34 (14-70) 0 23.4 0 83.4 15.2 NR 35.9 NR NR 
Heuschen et al
56
, 2001 210 34.4  0 0 0 100 NR 100 100 51 11.5 
Madiba and Bartolo
57
, 
2001 
139 38.2 (13-74) 0 0 0 100 25.2 0 97.1 60 NR 
Regimbeau et al
58
, 
2001 
172 36 (16-72) 24.4 27.9 0 100 NR 0 100 60 26 
Dayton et al
59
, 2002 565 37 0 0 0 100 14 100 100 78.5 11 
Heuschen et al
60
, 2002 494 34.2
*
 0 0 0 91 29.8 100 100 56.7
*
 3.2 
Lepisto et al
61
, 2002 486 NR 0 7.4 0 32.7 15 7.8 NR NR NR 
MacLean et al
62
, 2002 1178 40.7 0 5.6 0 66 50 NR NR 104.4 8.1 
Robb et al
63
, 2002 379 35.9 (5-84) 1.6 10.3 0 100 NR 10.8 10.8 103.3 14.2 
Rudolph et al
64
, 2002 120 38 (7-72) 11.7 0 29.2 76.7 5.8 NR NR 47 1.2 
de Oca et al
65
, 2003 100 32 (15-63) 0 0 1 100 78 NR NR 83 NR 
Fazio et al
66
, 2003 1965 37.5 3.8 7.3 27.9 86.7 35.1 85.3 87.4 49.2 24.2 
Fowler et al
67
, 2003 106 40(13-77) 3.8 10.4 1.9 41.3 NR 0 0 NR 1 
Michelassi et al
68
, 
2003 
391 33.7 (12-66) 0 0 3.3 65 NR 29.9 100 24
*
 9.7 
Gosselink et al
69
, 2004 127 35
*
 (14-67) 3.9 0 0 21.3 73.2 0 3.1 68
*
 0 
Hueting et al
70
,2004 111 35.4 0 0 0 NR NR NR NR 42
*
 18.9 
Ikeuchi et al
71
, 2004 521 NR 0 0 0 NR NR 5.7 100 NR NR 
Marciniak et al
72
, 2004 110 NR 0 34.5 0 NR NR NR NR 21.6 NR 
Pishori et al
73
, 2004 303 NR 1.6 0 4.3 97 36.3 100 100 40 NR 
Arai et al
74
, 2005 296 33.8 0 0 0 55.4 2.4 96.3 100 52.6 0 
Brown et al
75
, 2005 1135 34 0 0 0 64.7 57.2 71.2 81.6 98 0 
Hallberg et al
76
, 2005 100 32
*
(12-71) 0 0 0 71 NR 100 100 48
*
 10 
Ikeuchi et al
77
, 2005 242 33
*
(15-69) 0 0 0 38 NR 0 100 NR NR 
Krausz et al
78
, 2005 174 NR 0 16.1 0 87.4 NR 46 63.2 64.8 24.7 
Araki et al
79
, 2006 123 37.5(10-69) 0 0 5.7 66.7 41.5 0 100 NR 0 
Bengtsson et al
80
, 
2007 
620 35.5 (13-75) 1.8 4.7 0 NR NR NR NR 168 6.9 
Berndtsson et al
81
, 
2007 
399 34 (13-74) 0 0 0 NR NR NR 33.6 180
*
 7.3 
Das et al
82
, 2007 1822 NR NR NR NR NR NR NR NR 120
*
 NR 
Hahnloser et al
83
, 2007 1885 34 (12-68) 0 0 0 98.4 NR NR 96.8 129.6 0 
Nilubol et al
84
, 2007 138 36.1 1.4 7.2 5.8 100 NR 0 87.7 64.8 6.5 
Abdelrazeq et al
85
, 
2008 
198 38.3 (14-64) 0 0 0 68.2 NR 100 100 64 3 
Ferrante et al
86
, 2008 173 39 0 0 1.2 66.5 18.5 95.4 97.7 78 6 
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Fleshner et al
87
, 2008 238 38 (8-81) 0 0 29.4 100 NR NR 100 47 0 
Hoda et al
88
, 2008 167 36 0 0 0 91.5 34.7 NR NR NR 29.5 
Lovegrove et al
92
, 
2008 
199 37.6 0.5 5 8.5 20.1 43.5 99 99.5 NR NR 
Tulchinsky et al
90
, 
2008 
120 37 (13-75) 0 0 0 86.7 21.6 NR NR 65 16.1 
Rink et al
91
, 2009 131 33 (12-70) 0 0 0 84 23.7 0 100 85 3.1 
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4.2.4 Complications 
Pouch Failure 
 Forty-six studies totaling 15,793 patients reported on pouch failure with 
individual study estimates ranging from 1.0% to 16.7%
25-28, 32, 34-45, 47, 49-55, 58, 59, 61, 64, 66-69, 
73-76, 78, 80-83, 86, 89, 91, 93
. The pooled estimate including all studies was 5.5% (95% CI, 
4.7%-6.5%) with significant heterogeneity p=<0.001 and I
2
 at 77.3% (Table 4.3, page 
111). Figure 4.1 graphically summarizes each study’s estimate, 95% confidence interval, 
and the pooled estimate. Studies with ≥85% J-pouch and studies with ≥85% diverting 
ileostomy had lower rates of pouch failure when compared to the overall rate, 3.8% (95% 
CI, 2.9%-5.1%) and 4.6% ( 95% CI, 3.6%-5.9%) respectively (Table 4.4, page 111). 
Studies with at least 5 years of follow-up had higher rates of pouch failure at 6.3% (95% 
CI, 5.1%-7.7%) when compared to the overall rate. Restricting the analysis to studies 
with less than 10% loss to follow-up had little effect on the summary estimate (Table 
4.4). Despite division into subgroups, heterogeneity remained significant for all groups. 
At the study level, only the length of follow-up was associated with a statistically 
significant increase in the rate of pouch failure in both univariable and multivariable 
meta-regression, accounting for 16.83% of between study heterogeneity (p = 0.05, Figure 
4.2). Funnel plot of the outcome on the log scale plotted against study size reveals 
evidence of publication bias with few small studies being published with higher rates of 
pouch failure (Figure 4.3).  
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Figure 4.1 Forrest plot of studies reporting on rates of pouch failure. Point estimates are 
provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size.  
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Figure 4.2 Meta-regression of length of follow-up on rate of pouch failure (ln(odds)). 
Studies with longer follow-up had higher rates of pouch failure, accounting for 16.6% of 
between-study variability (p = 0.05). The area of the circle is proportional to the number 
of patients in each study.  
 
 
 
Figure 4.3 Funnel plot showing rate of pouch failure (ln(odds)) against study size. Lack 
of studies in bottom right hand corner indicates a lack of small studies being published 
with higher rates of pouch failure.    
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Pelvic Sepsis 
 
 Forty-four studies totaling 13,252 patients reported on pelvic sepsis with 
individual study estimates ranging from 0-26%
25-28, 30-32, 34-40, 42-45, 47-51, 53-55, 58-60, 66-70, 73-79, 
83, 86, 89
. The pooled estimate including all studies was 8.0% (95% CI, 6.8%-9.4%) with 
significant heterogeneity p = <0.001 and I
2
 at 84.8% (Table 4.3). Figure 4.4 graphically 
summarizes each study`s point estimate, its 95% confidence interval, and the pooled 
estimate. Studies with ≥85% use of diverting ileostomy had slightly lower rates of pelvic 
sepsis when compared to the overall rate 6.9% (95% CI, 5.7%-8.7%). While studies with 
> 5 years follow-up, and <10% lost to follow-up had slightly higher rates of pelvic sepsis, 
9.1% (95% CI, 6.9-12.2) and 9.0% (95% CI, 7.2%-11.1%) respectively. Restricting the 
analysis to studies with ≥85% J-pouch had little effect on the summary estimate (Table 
4.4). At the study level, only study type was associated with a change in rate of pelvic 
sepsis with a significant increase in the rate of pelvic sepsis among prospective studies in 
both univariable and multivariable meta-regression, accounting for 25.09% of between 
study variability (p = 0.005, Figure 4.5). Prospective studies (13 studies, n = 7,150) 
reported higher rates of pelvic sepsis when compared to the overall rate, 11.4% (95%CI, 
9.3%-14.1%). Funnel plot of the outcome on the log scale plotted against study size 
reveals evidence of publication bias with few small studies being published with higher 
rates of pelvic sepsis (Figure 4.6).  
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 Figure 4.4 Forrest plot of studies reporting on rates of pelvic sepsis. Point estimates are 
provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size.  
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Figure 4.5 Meta-regression of study type (0 = retrospective, 1 = prospective) on rate of 
pelvic sepsis (ln(odds)). Prospective studies reported higher rates of pelvic sepsis, 
accounting for 25.09% of between study variability (p = 0.005). The area of the circle is 
proportional to the number of patients in each study.  
 
Figure 4.6 Funnel plot showing rate of pelvic sepsis (ln(odds)) against study size. Lack 
of studies in bottom right hand corner indicates a lack of small studies being published 
with higher rates of pelvic sepsis. 
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Pouch Fistula 
 
Thirty-six studies totaling 12,155 patients reported on pouch fistula with 
individual study estimates ranging from 1.6-15.8%
25, 26, 28, 32, 34-36, 39, 43-45, 47, 48, 51, 53-55, 58-61, 
64, 66-70, 73-75, 77, 78, 83, 86, 89-91, 93
. The pooled estimate including all studies was 5.1% (95% 
CI, 4.1%-6.5%) with significant heterogeneity p = <0.001 and I
2
 at 88.5% (Table 4.3). 
Figure 4.7 graphically summarizes each study`s point estimate, its 95% confidence 
interval, and the pooled estimate. Studies with at least 5 years of follow-up had higher 
rates of pouch fistula at 6.5% (95% CI, 3.7%-8.9%). Restricting the analysis to studies 
with ≥85% J-pouch, ≥85% diverting ileostomy, or < 10% follow-up had little effect on 
the summary estimate (Table 4.4). At the study level, only outcome criteria definition 
was associated with a change in rate of pouch fistula. In both univariable and 
multivariable meta-regression, studies using clearly defined outcome criteria reported 
higher rates of pouch fistula, accounting for 24.8% of between study variability (p = 
0.003, Figure 4.8). Studies (9, n =2,264)  using clearly defined outcome criteria reported 
higher rates of pouch fistula compared to the overall estimate 9.4% (95% CI,7.2%-
12.3%). Funnel plot of the outcome on the log scale plotted against study size reveals 
evidence of publication bias with few small studies being published with higher rates of 
pouch fistula (Figure 4.9).  
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 Figure 4.7 Forrest plot of studies reporting on rates of pouch fistula. Point estimates are 
provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size. 
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Figure 4.8 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined) 
on rate of pouch fistula (ln(odds)). Studies with clearly defined outcomes reported higher 
rates of pouch fistula, accounting for 29.1% of between study variability (p = 0.003). The 
area of the circle is proportional to the number of patients in each study. 
 
 
 
Figure 4.9 Funnel plot showing rate of pouch fistula (ln(odds)) against study size. Lack 
of studies in bottom right hand corner indicates a lack of small studies being published 
with higher rates of pouch fistula.  
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Anastomotic Stricture 
 
Twenty nine studies totaling 7,533 patients reported on anastomotic stricture with 
individual study estimates ranging from 1.6-33%
25, 30, 32, 35-37, 40, 42-45, 47, 49-51, 53, 58, 59, 64, 66-69, 
73, 76, 78, 79, 89, 93
. The pooled estimate including all studies was 9.1% (95% CI, 6.6%-
11.5%) with significant heterogeneity p = <0.001 and I
2
 at 89.7% (Table 4.3). Figure 4.10 
graphically summarizes each study`s point estimate, its 95% confidence interval, and the 
pooled estimate.  Restricting the analysis to studies with ≥85% J-pouch, ≥85% diverting 
ileostomy, at least 5 years of follow-up, or < 10% follow-up had little effect on the rate of 
anastomotic stricture (Table 4.4). At the study level, only outcome criteria definition was 
associated with a change in rate of anastomotic stricture. In both univariable and 
multivariable meta-regression, studies using clearly defined outcome criteria reported 
higher rates of anastomotic stricture, accounting for 19.4% of between study variability 
(p = 0.014, Figure 4.11). Studies (13, n =2,568)  using clearly defined outcome criteria 
reported higher rates of pouch fistula compared to the overall estimate 12.6% (95% CI, 
9.5%-16.7%). Funnel plot of the outcome on the log scale plotted against study size 
reveals evidence of publication bias with few small studies being published with higher 
rates of anastomotic stricture (Figure 4.12). 
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Figure 4.10 Forrest plot of studies reporting on rates of anastomotic stricture. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size. 
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Figure 4.11 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined) 
on rate of anastomotic stricture (ln(odds)). Studies with clearly defined outcomes 
reported higher rates of stricture, accounting for 19.4% of between study variability (p = 
0.014). The area of the circle is proportional to the number of patients in each study. 
 
 
 
Figure 4.12Funnel plot showing rate of anastomotic stricture (ln(odds)) against study 
size. Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of stricture. 
  
-4
-3
-2
-1
0
ln
(o
d
d
s
)
0 .2 .4 .6 .8 1
outcome definition
0
.2
.4
.6
.8
s
.e
. 
o
f 
ln
o
d
d
s
-4 -3 -2 -1 0
Rate of anastomotic stricture (lnodds)
Funnel plot with pseudo 95% confidence limits
100 
 
 
Pouchitis  
 
Fifty studies totaling 13,003 patients reported on rates of pouchitis with individual 
study estimates ranging from 2-60%
25, 27, 28, 30-32, 35-37, 39-43, 45, 47-59, 61, 63, 64, 66, 67, 69-74, 78, 83-86, 
88-91, 93, 94
. The pooled estimate including all studies was 22.0% (95% CI, 19.4%-26.5%) 
with significant heterogeneity p = <0.001 and I
2
 at 95.3% (Table 4.3). Figure 4.13 
graphically summarizes each study estimate, its 95% confidence interval, and the pooled 
estimate. Studies with at least 5 years of follow-up had higher rates of pouchitis at 28.1% 
(95% CI, 22.3-34.6%). Restricting the analysis to studies with ≥85% J-pouch, ≥85% 
diverting ileostomy, or < 10% follow-up had little effect on the summary estimate (Table 
4.4). At the study level, both outcome criteria definition and length of follow-up were 
associated with a change in the rate of pouchitis. In both univariable and multivariable 
meta-regression, studies using clearly defined outcome criteria reported higher rates of 
pouchitis, accounting for 17.22% of between study variability (p = 0.002, Figure 4.14), 
while the association with length of follow-up was only seen in univariable analysis. 
Studies (26, n =8,360) using clearly defined outcome criteria reported higher rates of 
pouchitis compared to the overall estimate, 28.7% (95% CI, 23.6%-34.5%). Funnel plot 
of the outcome on the log scale plotted against study size reveals evidence of publication 
bias with few small studies being published with higher rates of pouchitis (Figure 4.15).  
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 Figure 4.13 Forrest plot of studies reporting on rates of pouchitis. Point estimates are 
provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size. 
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Figure 4.14 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined) 
on rate of pouchitis (ln(odds)). Studies with clearly defined outcomes reported higher 
rates of pouchitis, accounting for 17.22% of between study variability (p = 0.002). The 
area of the circle is proportional to the number of patients in each study. 
 
 
 
Figure 4.15 Funnel plot showing rate of pouchitis (ln(odds)) against study size. Lack of 
studies in bottom right hand corner indicates a lack of small studies being published with 
higher rates of pouchitis. 
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Small Bowel Obstruction 
 
Thirty-five studies totaling 11,069 patients reported on the rates of small bowel 
obstruction (SBO), with individual study estimates ranging between 1% and 52%
25, 26, 28, 
30-32, 36, 38-40, 43, 45, 47-49, 52-55, 58, 59, 62, 64, 66-69, 73, 74, 77, 78, 83, 86, 89, 93
. The pooled estimate 
including all studies was 11.8% (95% CI, 9.0%-15.3%) with significant heterogeneity p = 
<0.001 and I
2
 at 96.6% (Table 4.3). Figure 4.16 graphically summarizes each study 
estimate, its 95% confidence interval, and the pooled estimate. Studies with at least 5 
years of follow-up, and studies with less than 10% loss to follow-up had higher rates of 
small bowel obstruction at 13.2% (95% CI, 8.3%-20.1%) and 14% (95%CI, 9.8%-19.5%) 
respectively. Restricting the analysis to studies with ≥85% J-pouch, or ≥85% diverting 
ileostomy had little effect on the summary estimate (Table 4.4). In both univariable and 
multivariable meta-regression, studies using clearly defined outcome criteria reported 
higher rates of small bowel obstruction, accounting for 10.4% of between study 
variability (p = 0.04, Figure 4.17). Studies (5, n =1,054) using clearly defined outcome 
criteria reported higher rates of small bowel obstruction compared to the overall estimate, 
22.5% (95% CI, 19.3%-26.5%). Funnel plot of the rate of small bowel obstruction on the 
log scale plotted against study size reveals evidence of publication bias with fewer small 
studies being published with higher rates of small bowel obstruction (Figure 4.18).  
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 Figure 4.16 Forrest plot of studies reporting on rates of small bowel obstruction. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size. 
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Figure 4.17 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined) 
on rate of small bowel obstruction (ln(odds)). Studies with clearly defined outcomes 
reported higher rates of small bowel obstruction, accounting for 10.40% of between study 
variability (p = 0.041). The area of the circle is proportional to the number of patients in 
each study. 
 
 
 
 
Figure 4.18 Funnel plot showing rate of small bowel obstruction (ln(odds)) against study 
size. Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of small bowel obstruction. 
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Sexual Dysfunction 
 
Nineteen studies totaling 5,003 patients reported on the rates of sexual 
dysfunction, with individual study estimates ranging between 0% and 13.6%
25-27, 29, 31, 33, 
35, 36, 39, 43, 47, 52, 54, 58, 78, 83, 89, 93
. The pooled estimate including all studies was 4.6% (95% 
CI, 3.0%-6.8%) with significant heterogeneity p = <0.001 and I
2
 at 95.1% (Table 4.3). 
Figure 4.19 graphically summarizes each study estimate, its 95% confidence interval, and 
the pooled estimate. Studies with at least 5 years of follow-up had higher rates of sexual 
dysfunction at 5.9% (95% CI, 3.5%-9.8%), while studies with ≥85% J-pouch had lower 
rates of sexual dysfunction when compared to the overall rate, 3.1% (95% CI, 1,2%-
9.7%). Restricting the analysis to studies with ≥85% diverting ileostomy or loss to 
follow-up of <10% had little effect on the summary estimate (Table 4.4). Meta-regression 
did not reveal any association between study level factors and rate of sexual dysfunction. 
Funnel plot of the rate of sexual dysfunction on the log scale plotted against study size 
reveals evidence of publication bias with few small studies being published with higher 
rates of sexual dysfunction (Figure 4.20).  
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 Figure 4.19 Forrest plot of studies reporting on rates of sexual dysfunction. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size. 
 
 
 
Figure 4.20 Funnel plot showing rate of sexual dysfunction (ln(odds)) against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of sexual dysfunction. 
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Table 4.3 Results of Meta-Analysis of Complication Rates Following IPAA 
 
Complication Number 
of Studies 
Number of 
Patients 
Pooled % 95% CI Heterogeneity 
I
2
(%) p 
Pouch Failure 46 15,793 5.5 4.7-6.5 77.3 <0.001 
Pelvic Sepsis 44 13,252 8.0 6.8-9.4 84.8 <0.001 
Pouch fistula 36 12,155 5.1 4.1-6.5 88.5 <0.001 
Stricture 29 7,533 9.1 6.5-11.5 89.7 <0.001 
Pouchitis 50 13,003 22.0 19.4-26.5 95.3 <0.01 
SBO 35 11,069 11.8 9.0-15.3 96.6 <0.001 
Sexual 
dysfunction 
19 5,003 4.6 3.0-6.8 95.1 <0.001 
SBO small bowel obstruction 
 
Table 4.4 Subgroup Meta-Analysis of Complications Following IPAA  
Sub-Group No. 
Studies 
No.  
of Patients 
Pooled % 95% CI Heterogeneity 
I
2
 p 
≥85% J-pouch       
  Pouch failure 14 6,535 3.8 2.9-5.1 73.2 <0.001 
  Pelvic sepsis 16 7,425 7.5 5.6-9.9 91.7 <0.001 
  Pouch fistula 13 6,815 4.5 3.5-5.8 73.6 <0.001 
  Anastomotic stricture 10 4,194 9.1 6.1-13.8 93.4 <0.001 
  Pouchitis 18 7,954 21.3 16.2-27.4 92.5 <0.001 
  SBO 13 6,651 12.0 7.3-18.9 98.2 <0.001 
  Sexual dysfunction 5 2,581 3.1 1.2-9.7 89.8 <0.001 
≥85% Diverting ileostomy    115   
  Pouch failure 22 8,350 4.6 3.6-5.9 80.8 <0.001 
  Pelvic sepsis 24 8,985 6.9 5.7-8.7 86.5 <0.001 
  Pouch fistula 20 8,073 4.4 3.0-6.4 83.3 <0.001 
  Anastomotic stricture 17 5,581 8.9 6.6-11.9 91.0 <0.001 
  Pouchitis 30 9,168 24.2 20.0-29.0 95.8 <0.001 
  SBO 19 7,037 11.3 7.5-16.8 97.5 <0.001 
  Sexual dysfunction 12 3,864 5.3 3.4-8.3 87.9 <0.001 
Follow-up ≥ 5yrs       
  Pouch failure 17 8,290 6.3 5.1-7.7 76.8 <0.001 
  Pelvic sepsis 12 5,377 9.1 6.9-12.2 89.5 <0.001 
  Pouch fistula 13 5,338 6.5 3.7-8.9 92.7 <0.001 
  Anastomotic stricture 20 5,659 9.5 7.3-12.4 89.4 <0.001 
  Pouchitis 18 5,349 28.1 22.3-34.6 93.3 <0.001 
  SBO 13 5,123 13.2 8.3-20.1 97.4 <0.001 
  Sexual dysfunction 7 3,017 5.9 3.5-9.8 88.7 <0.001 
< 10% lost to follow-up       
  Pouch failure 26 8,049 5.7 4.6-7.1 79.4 <0.001 
  Pelvic sepsis 23 7,299 9.0 7.2-11.1 86.0 <0.001 
  Pouch fistula 17 6,449 5.8 4.0-8.3 88.5 <0.001 
  Anastomotic stricture 17 3,128 9.4 6.8-12.7 89.7 <0.001 
  Pouchitis 24 5,543 22.4 17.4-28.2 95.3 <0.001 
  SBO 18 5,663 14.0 9.8-19.5 96.4 <0.001 
  Sexual dysfunction 8 3,097 4.0 2.3-8.0 90.3 <0.001 
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4.2.5 Functional Results  
 
Fecal Incontinence 
 
Thirty studies totaling 9,284 patients reported on the rates of fecal incontinence, 
with individual study estimates ranging between 3% and 45%
26-32, 35, 38-40, 43, 44, 46, 47, 50, 52, 
54, 64, 68-70, 74-76, 81, 83, 86, 89, 93
. The pooled estimate including all studies was 13.2% (95% CI, 
9.9%-17.3%) with significant heterogeneity p = <0.001 and I
2
 at 96.0% (Table 4.5). 
Figure 4.21 graphically summarizes each study’s estimate, its 95% confidence interval, 
and the pooled estimate. Studies with at least 5 years of follow-up had higher rates of 
fecal incontinence at 15.9% (95% CI, 9.6%-25.4%), while studies with ≥85% J-pouch 
had lower rates, 9.1% (95%CI, 3.3%-24.5%). Restricting the analysis to studies ≥85% 
diverting ileostomy, or <10% follow-up had little effect on the summary estimate (Table 
4.6). At the study level, outcome criteria definition (p = 0.009, Figure 4.22) and length of 
follow-up (p = 0.009, Figure 4.23) were associated with an increased rate of fecal 
incontinence, accounting for 22.59% and 19.91% of between study variability; while 
proportion of J-pouch (p = 0.009, Figure 4.24) was associated with a decrease rate of 
fecal incontinence, accounting for 22.06% of variability. These associations were seen at 
the univariable level, but lost their significance when subjected to multivariable meta-
regression. Studies (9, n =4,354) using clearly defined outcome criteria reported higher 
rates of fecal incontinence compared to the overall estimate, 21.3% (95% CI, 13.6%-
31.8%). Funnel plot of the rate of fecal incontinence on the log scale plotted against study 
size reveals evidence of publication bias with few small studies being published with 
higher rates of fecal incontinence (Figure 4.25).  
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Figure 4.21 Forrest plot of studies reporting on rates of fecal incontinence. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size. 
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Figure 4.22 Meta-regression of outcome definition (0 =not defined, 1 = clearly defined) 
on rate of fecal incontinence (ln(odds)). Studies with clearly defined outcomes reported 
higher rates of fecal incontinence, accounting for 22.59% of between study variability (p 
= 0.009). The area of the circle is proportional to the number of patients in each study. 
 
 
 
Figure 4.23 Meta-regression of length of follow-up (months) on rate of fecal 
incontinence (ln(odds)). Studies with longer follow-up reported higher rates of fecal 
incontinence, accounting for 19.91% of between study variability (p = 0.02). The area of 
the circle is proportional to the number of patients in each study  
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Figure 4.24 Meta-regression of proportion of patients with J-pouch on rate of fecal 
incontinence (ln(odds)). Studies with a higher proportion of J-pouch reported lower rates 
of fecal incontinence, accounting for 22.06% of between study variability (p = 0.04). The 
area of the circle is proportional to the number of patients in each study. 
 
 
Figure 4.25 Funnel plot showing rate of fecal incontinence (ln(odds)) against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of fecal incontinence. 
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Fecal Urgency 
 
Fourteen studies totaling 3,434 patients reported on the rates of fecal urgency, 
with individual study estimates ranging between 2.5-25%
32, 33, 35, 43, 47, 50, 52, 58, 70, 75, 81, 86, 89, 
91
. The pooled estimate including all studies was 8.8% (95% CI, 6.4%-12.2%) with 
significant heterogeneity p = <0.001 and I
2
 at 88.2% (Table 4.5). Figure 4.26 graphically 
summarizes each study estimate, its 95% confidence interval, and the pooled estimate. 
Studies with <10% loss to follow-up had higher rates of fecal urgency at 11.5% (95% CI, 
6.4%-12.2%), while studies with ≥85% J-pouch had lower rates, 3.9% (95%CI, 2.4%-
6.4%). Restricting the analysis to studies ≥85% diverting ileostomy, or at least 5 years of 
follow-up had little effect on the summary estimate (Table 4.6). At the study level, 
proportion of J-pouch was associated with a decrease rate of urgency, accounting for 
74.65%% of between study variability (p = 0.008, Figure 4.27). Funnel plot of the rate of 
urgency on the log scale plotted against study size reveals evidence of publication bias 
with few small studies being published with higher rates of urgency (Figure 4.28).  
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 Figure 4.26 Forrest plot of studies reporting on rates of fecal urgency. Point estimates 
are provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size. 
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Figure 4.27 Meta-regression of proportion of patients with J-pouch on rate of fecal 
urgency (ln(odds)). Studies with a higher proportion of J-pouch reported lower rates of 
fecal urgency, accounting for 74.65% of between study variability (p = 0.008). The area 
of the circle is proportional to the number of patients in each study. 
 
 
 
 
 
 
 
 
Figure 4.28 Funnel plot showing rate of fecal urgency (ln(odds)) against study size. Lack 
of studies in bottom right hand corner indicates a lack of small studies being published 
with higher rates of fecal urgency. 
-4
-3
-2
-1
ln
(o
d
d
s
)
.2 .4 .6 .8 1
Proportion with J-pouch
0
.2
.4
.6
s
.e
. 
o
f 
ln
o
d
d
s
-4 -3 -2 -1
rate of urgency (lnodds)
Funnel plot with pseudo 95% confidence limits
116 
 
 
Pad Use 
 
Twenty studies totaling 7,341 patients reported on the rates of pad use, with 
individual study estimates ranging between 2.1%-39%
28, 31-33, 37, 39, 44, 46, 50, 52, 54, 58, 70, 75, 78, 
81, 83, 86, 89, 93
. The pooled estimate including all studies was 13.7% (95% CI, 10.6%-
18.1%) with significant heterogeneity p = <0.001 and I
2
 at 94.8% (Table 4.5). Figure 4.29 
graphically summarizes each study estimate, its 95% confidence interval, and the pooled 
estimate. Studies with ≥85% J-pouch had lower rates of pad use, 6.0% (95% CI, 2.1%-
16.5%). Restricting the analysis to studies with at least 5 years of follow-up had little 
effect on the summary estimate, while studies with <10% lost to follow-up had slightly 
higher rate of pad use, as did studies with ≥85% diverting ileostomy (Table 4.6). At the 
study level, proportion of J-pouch (p = 0.02, Figure 4.30) was associated with a decrease 
rate of pad use, accounting for 23.56% of between study variability. Funnel plot of the 
rate of pad use on the log scale plotted against study size reveals evidence of publication 
bias with few small studies being published with higher rates of pad use (Figure 4.31). 
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Figure 4.29 Forrest plot of studies reporting on rates of pad use. Point estimates are 
provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size. 
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Figure 4.30 Meta-regression of proportion of patients with J-pouch on rate of pad use 
(ln(odds)). Studies with a higher proportion of J-pouch reported lower rates of pad use, 
accounting for 23.56% of between study variability (p = 0.02). The area of the circle is 
proportional to the number of patients in each study. 
 
 
 
Figure 4.31 Funnel plot showing rate of pad use (ln(odds)) against study size. Lack of 
studies in bottom right hand corner indicates a lack of small studies being published with 
higher rates of pad use. 
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Anti-Diarrheal Medication Use 
  
Twenty-four studies totaling 6,153 patients reported on the rates of anti-diarrheal 
(AD) medication use, with individual study estimates ranging between 12.6%-60%
26-30, 32, 
33, 37, 39, 43, 44, 47, 50, 52, 58, 64, 70, 78, 81, 83, 86, 89, 91, 93
. The pooled estimate including all studies 
was 32.9% (95% CI, 27.3%-39.4%) with significant heterogeneity p = <0.001 and I
2
 at 
95.1% (Table 4.5). Figure 4.32 graphically summarizes each study estimate, its 95% 
confidence interval, and the pooled estimate. There was little difference between the rates 
of AD medication use among subgroups (Table 4.6). Similarly, no study level factors 
were significantly associated with differences in the rate of AD medication use during 
meta-regression. Funnel plot of the rate of AD medication use on the log scale plotted 
against study size reveals no asymmetry to suggest publication bias (Figure 4.33).   
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Figure 4.32 Forrest plot of studies reporting on rates of AD medication use. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size. 
 
Figure 4.33 Funnel plot showing rate of AD medication use (ln(odds)) against study size. 
No evidence of asymmetry to suggest publication bias.  
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Mean Number of Bowel Movements/ 24 hours 
 
Twenty seven studies totaling 8,336 patients reported on the mean number of 
bowel movements (BM) within 24 hours, with individual study estimates ranging 
between 4.2-7.8 BM/24hrs
25, 27-30, 32, 35, 40, 43, 44, 46, 47, 52-54, 58, 59, 63, 64, 68, 76, 78, 81, 83, 89, 91, 93
. 
The pooled estimate including all studies was 5.6 BM/24 hrs (95% CI, 5.3-5.9) with 
significant heterogeneity p = <0.001 and I
2
 at 99.1% (Table 4.5). Figure 4.34 graphically 
summarizes each study estimate, its 95% confidence interval, and the pooled estimate. 
Studies with ≥85% J-pouch and with follow up of at least 5 years both had slightly higher 
mean number of BM/ 24hrs, 6.1 (95% CI,5.6-6.5) and 5.8 (95% CI, 5.5-6.1) respectively. 
Restricting the analysis to studies with ≥85% diverting ileostomy and < 10% follow-up 
had little effect on the summary estimate (Table 4.6). At the study level, proportion of J-
pouch (p = 0.01, Figure 4.35) was associated with a higher mean number of BM/24 hrs, 
accounting for 17.02% of between study variability, while study type and mid-point year 
lost their association with multivariable meta-regression. Funnel plot of the mean number 
of BM/24 hrs against study size reveals evidence of publication bias with few small 
studies being published with higher mean number of BM/24 hrs (Figure 4.36). 
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Figure 4.34 Forrest plot of studies reporting mean number of BM/ 24 hrs. Point estimates 
are provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size.  
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Figure 4.35 Meta-regression of studies with ≥85% J-pouch (0 =<85% J-pouch, 1 = ≥85% 
J-pouch) on mean number of BM/ 24hrs. Studies with a higher rate of J-pouch had more 
BM in 24hrs, accounting for 17.02% of between study variability (p = 0.01). The area of 
the circle is proportional to the number of patients in each study. 
 
  
 
Figure 4.36 Funnel plot showing rate mean number of BM/ 24hrs against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher number of BM/24 hrs. 
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Mean Number of Bowel Movements/ Night 
 
Fifteen studies totaling 5,594 patients reported on the mean number of bowel 
movements (BM) at night, with individual study estimates ranging between 0.3-1.7 
BM/night
28-30, 35, 44, 46, 54, 58, 63, 64, 76, 78, 83, 89, 91
. The pooled estimate including all studies 
was 1.0 BM/night (95% CI, 0.8-1.2) with significant heterogeneity p = <0.001 and I
2
 at 
99.0% (Table 4.5). Figure 4.37 graphically summarizes each study estimate, its 95% 
confidence interval, and the pooled estimate. Subgroup analysis failed to reveal any 
differences in mean number of BM/ night (Table 4.6). Similarly, univariable meta-
regression failed to identify any significant associations between study level factors and 
mean number of BM/night. Funnel plot of mean number of BM/night did not reveal any 
asymmetry to suggest publication bias.  
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Figure 4.37 Forrest plot of studies reporting mean number of BM/ night. Point estimates 
are provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size.  
 
 
Figure 4.38 Funnel plot of mean number of BM/ night fails to reveal any significant 
asymmetry to suggest publication bias.   
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Table 4.5 Meta-Analysis of Functional Results Following IPAA 
Function Number 
of Studies 
Number of 
Patients 
Pooled % 95% CI Heterogeneity 
I
2
(%) p 
Fecal 
incontinence 
30 9,284 13.2 9.9-17.3 96.9 <0.001 
Urgency 14 3,434 8.8 6.4-12.2 88.2 <0.001 
Pad use 20 7,341 13.7 10.6-18.1 94.8 <0.001 
Anti-diarrheal 
meds 
24 6,153 32.9 27.3-39.4 95.1 <0.001 
Mean number 
of BM/24 hrs 
27 8,336 5.6 5.3-5.9 99.1 <0.001 
Mean number 
of BM/night  
15 5,594 1.0 0.8-1.2 99.0 <0.001 
BM bowel movements 
 
Table 4.6 Subgroup Meta-Analysis of Functional Results Following IPAA  
Sub-Group No. 
Studies 
No.  
of Patients 
Pooled % 95% CI Heterogeneity 
I
2
 p 
≥85% J-pouch       
Fecal incontinence 8 3,350 9.1 3.3-24.5 98.4 <0.001 
Fecal urgency 5 804 3.9 2.4-6.4 47.8 <0.001 
Daily pad use 6 2,754 6.0 2.1-16.5 96.3 <0.001 
Anti-diarrheal medication 6 2,689 35.2 27.6-43.7 90.7 <0.001 
Mean number of BM/24hrs 10 3,878 6.1 5.6-6.5 97.1 <0.001 
Mean number of BM/night 6 2,675 1.1 0.8-1.4 98.8 <0.001 
       
≥85% Diverting ileostomy       
Fecal incontinence 13 5,074 14.9 9.4-22.9 97.7 <0.001 
Fecal urgency 4 589 5.7 2.8-11.5 76.5 <0.001 
Daily pad use 11 4,702 15.8 11.3-21.8 94.8 <0.001 
Anti-diarrheal medication 12 4,091 29.6 21.3-39.6 96.8 <0.001 
Mean number of BM/24hrs 17 6,288 5.4 5.2-5.7 99.1 <0.001 
Mean number of BM/night 10 4,856 1.1 0.8-1.4 98.8 <0.001 
       
Follow-up ≥ 5yrs       
Fecal incontinence 9 5,362 15.9 9.6-25.4 98.4 <0.001 
Fecal urgency 5 2,066 9.8 5.8-16.1 91.7 <0.001 
Daily pad use 10 5,387 13.7 9.4-19.5 90.1 <0.001 
Anti-diarrheal medication 8 3,270 29.9 22.8-38.0 93.8 <0.001 
Mean number of BM/24hrs 11 5,156 5.8 5.5-6.1 98.9 <0.001 
Mean number of BM/night 6 3,905 1.1 0.9-1.4 97.7 <0.001 
       
< 10% lost to follow-up       
Fecal incontinence 20 7,029 13.8 9.5-19.7 97.5 <0.001 
Fecal urgency 9 2,661 11.5 6.4-12.2 88.7 <0.001 
Daily pad use 10 5,000 17.1 12.2-23.5 95.8 <0.001 
Anti-diarrheal medication 15 4,774 32.2 25.2-39.9 95.8 <0.001 
Mean number of BM/24hrs 14 4,851 5.5 5.3-5.8 97.8 <0.001 
Mean number of BM/night 8 3,455 1.0 0.6-1.4 99.5 <0.001 
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4.3 Discussion  
 This systematic review summarizes the literature reporting on clinical outcomes 
following IPAA, and includes 67 studies reporting on 21,882 patients. These studies 
varied greatly in their patient characteristics, operative approaches, and methodologic 
rigor. In an attempt to account for the significant between study heterogeneity, we carried 
out multiple sensitivity analyses and meta-regressions along both clinical variables and 
methodologic criteria.  
One of the most severe complications following this procedure is pouch failure 
resulting in pouch removal and/or permanent ileostomy. The pooled incidence was 5.5%, 
which was significantly lower amongst those studies which predominantly reported on 
patients with J-pouch configuration (pooled incidence 3.8%), and higher amongst those 
studies with at least five years of follow-up (6.3%). No doubt as length of follow-up 
increases, so does the rate of pouch failure as patients may develop pouchitis over time 
necessitating diversion or pouch removal. The influence of pouch type on results was also 
seen for functional outcomes. Studies reporting on patients with J-pouch configuration 
(as opposed to a S- or W- pouch) had improved pouch function as evidenced by lower 
rates of fecal incontinence, fecal urgency, and daily pad use when compared to other 
studies using meta-regression. This finding is supported by a meta-analysis looking 
specifically at pouch configuration that found the J-pouch had higher number of BM/ day 
but lower rates of other complications
95
. Similarly, the mean number of bowel 
movements per 24 hours among studies reporting on patients with J-pouch configuration 
was significantly higher than those reporting on other pouch configurations with a mean 
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of 6.1 BM/24 hrs among those with J-pouch. Given that most surgeons now use the J-
pouch configuration and that a consistent association with this subgroup and most 
functional outcomes reported in this anaysis was observed, we decided to use this 
subgroup of studies to populate our decision aid with functional outcomes.  
Of the methodologic criteria examined using meta-regression, outcome definition 
was consistently associated with an increase in complication rates for most of the clinical 
outcomes (pouch fistula, anastomotic stricture, pouchitis, and small bowel obstruction). 
This implies that studies using well defined outcome criteria are capturing more patients 
with those complications. This likely protects against reporting bias by standardizing the 
assessment of the outcomes and resulting in more reliable complication rates. Other 
methodologic criteria including prospective design, consecutive patient recruitment, 
proportion loss to follow-up, and use of a standardized follow-up protocol were not 
consistently found to influence the rate of complications reported in individual studies. 
There is no empiric evidence available to guide the selection of quality criteria when 
assessing observational studies
6, 7
, although with this analysis we have shown a consistent 
association between the use of clearly defined outcome criteria and rate of most 
complications reported in these studies. Thus, outcome criteria definition should be 
strongly considered as a quality measure when assessing observational studies reporting 
on complications following surgery. 
 Other study level factors we explored using meta-regression included proportion 
of patients with Crohn’s disease, indeterminate colitis, and FAP. Proportions of these 
alternate diagnoses among studies were not associated with rates of outcomes. Studies 
designed to specifically look at the influence of these other diagnoses on the results of 
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restorative pouch procedures have documented higher rates of complications in patients 
with Crohn’s disease and indeterminate colitis75. In a meta-analysis looking specifically 
at patients with Crohn’s disease who had undergone a restorative pouch procedure, the 
failure rate was 32%
96
.Despite a strong association with outcomes in other studies, 
prevalence of Crohn`s disease was not associated with outcomes during our meta-
regression. This lack of association seen at the study level likely reflects the low 
prevalence of Crohn’s disease among the studies included with only 18 of 67 studies 
including patients with Crohn’s disease and of those most accounted for <5% of patients. 
Similarly, the proportion of patients with FAP and indeterminate colitis in the included 
studies was low as well.  
 Study level factors dealing with operative technique examined with meta-
regression included proportion of patients who received a stapled anastomosis and 
proportion of patients with defunctioning ileostomy. No association at the study level 
between the proportion of patients with a defunctioning ileostomy and complication rates 
was identified. A meta-analysis of observational studies comparing patients with and 
without diversion did show that patients who forgo diversion are at increased risk of 
pouch-related septic complications
22
. Most studies included in this review reported 80% 
or greater rates of diversion, thus the un-diverted group likely account for too few 
patients to affect the results. Similarly, no association was found between the proportion 
of patients who underwent a stapled anastomosis and complication rates. 
 Comparing our results to those of the only other systematic review and meta-
analysis of IPAA studies, our overall pooled rates of  complications tended to be slightly 
less than that reported by Hueting et al.
3
 For example, our pooled rate of pouch failure 
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was 5.5% versus 6.8% in the former review. This could be the result of our study 
focusing on larger patient series (100 or greater patients) or more modern series, as their 
review was limited to studies published up to 2000. As surgeons gain experience, results 
will improve and this may be a reflection of this. Other complex surgical procedures have 
been found to have a volume-outcome relationship, with better outcomes arising amongst 
those surgeons with higher volumes
97, 98
. Our review not only updates that of the previous 
authors, but includes an in-depth analysis of between study heterogeneity utilizing 
subgroup analysis, meta-regression, and funnel plots to examine for publication bias.  
With the exception of use of anti-diarrheal medications and mean number of BM/ 
night, every outcome studied showed evidence of publication bias with smaller studies 
predominantly reporting on lower complication rates. Presumably, this results from the 
difficulty or unwillingness to publish smaller studies with poorer results, similar to 
negative comparative trials
99
. By using a random effects model to combine complication 
rates, studies were weighted based on a combination of within study and between study 
variability. Given the high degree of between study variability, smaller studies are given 
more relative weight then they would if the between study variability were less, with 
weights more reflective of study size. This in combination with the lack of smaller studies 
reporting higher complication rates probably lead to an under-estimation of true pooled 
complication rates.  
One way to deal with this problem is to restrict the meta-analysis to larger studies 
whose outcome distributions are more symmetrical
10
. We conducted a sensitivity analysis 
of all outcomes on study size by comparing studies with at least 250 patients to those 
with 100-249 patients and found little difference in pooled outcomes. For example, the 
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pooled pouch failure rate amongst studies with ≥ 250 patients was 5.2% (95% CI, 4.4-
6.1) and 5.6% (95% CI, 4.5-6.9) among those with 100-249 patients. This indicates that 
although the funnel plots suggest publication bias, the degree of between study 
heterogeneity likely outweighs any influence publication bias has on the summary 
estimates. This can be visualized by the number of studies that fall outside the 95% 
confidence limits of the funnel plots (Figure 4.3) which occurs over the entire plot, not 
just at the base.  
Other methods do exist to adjust for the presence of publication bias. Methods 
based on regression equations and adjustment of summary estimates have been 
developed, however they have been found to perform poorly when the I
2
 value reaches 
50%, and thus were not used in this study
100
. Although the funnel plots suggest 
publication bias for most outcomes, with fewer small studies reporting on higher 
complication rates following IPAA, the degree of between study heterogeneity exerts a 
much larger influence on pooled outcomes. 
 Along with pouch failure, one of the more significant complications following 
IPAA is pouchitis. Characterized by poor pouch function, pain, urgency, and multiple 
bloody bowel movements, this complication can be detrimental to a patient’s quality of 
life
101
. The pooled rate of pouchitis was 22%, with individual study ranges from 2-60%. 
When study level factors were explored, the rate of pouchitis was higher among studies 
with at least five years of follow-up (28%) and among studies that utilized clearly defined 
outcome criteria (28%). We were not able to evaluate what specific criteria were used to 
define pouchitis in each individual study as they varied greatly, from no criteria to 
rigorous programs involving endoscopic surveillance and biopsies of the pouch. This 
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highlights one of the limitations of this meta-analysis and likely accounts for some of the 
residual between study heterogeneity that we were unable to account for despite 
sensitivity analyses and meta-regressions. Studies using different outcome criteria will 
result in varying rates of pouchitis, as with other outcomes. The challenge we faced was 
our desire to summarize the literature into point estimates that we could include into a 
decision aid for patients, while running the risk of combining studies that were measuring 
different things. As evidenced by the large I
2
 values, even after sensitivity analyses and 
meta-regression, there clearly remains significant between-study heterogeneity, likely the 
result of un-accounted for study level differences in specific outcome criteria, population 
parameters, and study design.  
 Despite its utility in exploring heterogeneity and guiding our selection of which 
group of studies to include in our decision aid, meta-regression is not without its own 
limitations and cautions. A major limitation is that meta-regression of observational trials 
are still limited by the quality and potential bias inherent in the individual trials
24
. 
Another caution is the use of meta-regression to identify associations between study level 
factors and use this to imply an association at the patient level, a situation known as 
aggregation bias or ecological fallacy
102
. For example, if we had identified an association 
between a higher proportion of diverted patients and pelvic sepsis, then we may have 
concluded that diversion results in a higher risk of pelvic sepsis, when in actual fact, at 
the patient level, all the patients in the studies that had this complication were in the un-
diverted group and differences in other risk factors accounted for the study level 
association. This type of bias is difficult to detect without patient level data, and thus any 
patient level causal inferences made on the basis of study level associations must be 
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viewed with caution
103
.  Another limitation of meta-regression is that it often suffers from 
low power, due to smaller numbers of included studies
103
. To combat this, most authors 
recommend that no more than 1 study level covariate be explored for every 10 studies in 
the meta-analysis
24, 103
. This ratio was used to guide the number of covariates we included 
in our multivariable meta-regression. Another limitation is the potential for data dredging 
and multiplicative testing with possible false positive associations. Most authors 
recommend pre-specifying the covariates to be examined, as we did in this study. 
Another strategy is to apply a Bonferroni adjustment to the significance level
24
 of each 
covariate. We elected not to do this as we had pre-specified our covariates of interest, and 
our analyses were exploratory in nature, trying to explain heterogeneity, not to make 
causal inferences. At the statistical level, certain considerations are important to properly 
conduct a meta-regression. We used a random-effects meta-regression which accounts for 
both between study and within study variance, this the recommend approach as no set of 
covariates will completely explain all the heterogeneity present, thus this must be 
accounted for in the analysis
24
.  
 No established protocol exists for the selection of which studies to include when 
conducting a meta-analysis with a view towards populating a decision aid with outcome 
estimates. We applied a systematic assessment of between study heterogeneity using 
subgroup analyses and meta-regression in an effort to guide the selection of appropriate 
studies to include in the summary estimate destine to be included in the decision aid. For 
those outcomes that were significantly influenced by length of follow-up (pouch failure, 
pouchitis) these point estimates were used, while for studies that showed an association 
with outcome definition (pouch fistula, anastomotic stricture, small bowel obstruction) 
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these subgroups were used. Pelvic sepsis showed an association with prospective design, 
and this was selected as the group for that outcome. While functional results were taken 
from the subgroup of studies reporting on 85% or greater J-pouch patients as there was a 
consistent association with functional outcomes and this subgroup in the meta-regression.   
Despite significant residual between-study  heterogeneity, we executed a large, 
inclusive review with systematic and rigorous exploration of heterogeneity that revealed a 
consistent association with outcome criteria definition and complication rates, thus 
adding some empiric evidence to its use as a quality criterion for the reporting of 
observational surgical trials. We also used the results of the meta-regression to guide the 
inclusion of studies into the decision aid’s point estimates. The next chapter will 
summarize the systematic review of studies reporting on the outcomes following 
ileostomy, while chapter six will outline the methodology necessary in the refinement and 
initial testing of the prototype decision aid.  
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CHAPTER FIVE-SYSTEMATIC REVIEW AND META-ANALYSIS OF OUTCOMES 
FOLLOWING PROCTOCOLECTOMY AND ILEOSTOMY 
 
5.0 Introduction 
 
 The traditional option for patients with ulcerative colitis requiring surgery is total 
proctocolectomy and end-ileostomy. This technique involves suturing the end of the 
small bowel (the ileum) to the skin and everting it along the fashion described by Brooke, 
in an effort to minimize skin based complications
1
. This is touted as the gold standard for 
the management of ulcerative colitis and has been performed since the 1950’s. Despite its 
long history and successful track record, this procedure is not without its own share of 
long-term problems, largely the result of complications related to the ileostomy. In order 
to provide patients with information necessary to decide between having an ileostomy or 
a restorative pouch procedure, it is necessary to summarize the risks of a long-term 
ileostomy. In order to populate our decision aid, we undertook a systematic review and 
meta-analysis of outcomes following protcolectomy and ileostomy with a focus on 
ileostomy-based complications. This information is important to patients who are 
deciding between living with a long-term ileostomy or contemplating conversion to a 
restorative pouch procedure. An ileostomy, although technically simple to construct, is 
fraught with numerous long-term problems which must be balanced by the risks of IPAA 
when patients are deciding between the two options.  
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5.1 Methods 
Search Strategy 
 The overall search strategy is outlined in chapter two of this work. We included 
studies reporting on outcomes following colectomy and ileostomy for patients with 
ulcerative colitis who reported on at least 100 patients. All titles and abstracts were 
independently reviewed by two reviewers and any study that either reviewer deemed as 
potentially eligible was selected for full text review. Study inclusion was then assessed 
independently with any disagreement resolved by consensus. 
Data Extraction 
 Full text papers were reviewed, and for all studies that met our inclusion criteria, 
data was extracted independently by two reviewers with any disagreement resolved by 
consensus using standardized data-abstraction sheets. Study characteristics including size, 
location, time period of patient enrollment, length of follow-up, mean age of patients, 
proportion with Crohn’s disease, FAP, or indeterminate colitis, proportion with prior 
subtotal colectomy, and proportion with excision of rectum were abstracted. Outcomes of 
interest included ileostomy revision (any procedure undertaken to revise the ileostomy 
regardless of method or indication), ileostomy stenosis, ileostomy prolapsed, ileostomy 
fistula, ileostomy retraction, small bowel obstruction requiring surgery, and parastomal 
hernia requiring surgery.  
Quality Criteria 
 A detailed discussion of the rationale behind the selection of quality criteria is 
found in chapter two of this work. We selected specific elements of study design 
reflective of quality and reported on them rather than used established tools as there is no 
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empirical evidence linking any one tool or set of criteria to study validity for 
observational studies
2, 3
. The elements of quality examined included: whether or not the 
patients represented a group of consecutive patients having surgery over a pre-specified 
time period, whether the authors used clearly defined outcome criteria, whether the study 
was retrospective or prospective, proportion loss to follow-up, and whether they 
employed a standardized follow-up procedure.  
Meta-Analysis 
 Each study estimate of a given outcome was recorded and its 95% confidence 
interval was determined using Wilson’s score method4.  In order to combine the 
proportions from individual studies, we converted the individual proportions into odds
5
, 
and the odds was transformed into the log scale using equation 4.1: 
 ln(odds) = ln (no of patients having event/ no of patients not having event)   (4.1) 
This allowed us to generate a variance term which was used in the weighting of studies 
for the meta-analysis(equation 4.2): 
 
var ln(odds) = 1/No of patients having event + 1/ no of patients not having event
5
   (4.2).  
 
Meta-analysis was then carried out of individual study proportions converted to 
the ln(odds) scale according to the random-effects model of DerSimonian and Laird
6
, 
accounting for both within-study variance and between-study variance. This model 
assumes that the outcome measures of each study come from a random distribution of 
outcomes, with the weighting of studies based on the reciprocal of the sum of between 
study variance and within study variance. The statistical package, STATA version 10 
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(Stata inc, Texas, US, 2008) using the procedures meta and metan were used to meta-
analysis the data as described by Sharp
7
. This procedure estimates the between-study 
variance using the non-iterative weighted method of DerSimonian and Laird
6
. Pooled 
results were converted back to the proportion scale and presented along with their 95% 
confidence interval. In case were the study had no events, a continuity correction factor 
was added (0.5) in order to generate an outcome measure for the meta-analysis as ln(0) is 
not a real number. Adding a continuity correction is preferred over excluding studies with 
zero events
8
.  Each outcome was also graphically summarized using Forrest plots. The 
possibility of publication bias was explored using funnel plots of the individual 
outcomes, looking for asymmetry amongst the smaller trials. This was done assuming 
smaller trials might be more apt to get published if they have “better” results, ie lower 
rates of complications following surgery. 
 
Heterogeneity 
 Heterogeneity was assessed for each outcome using the Cochran’s Q chi-squared 
test which is calculated by adding together the squared deviations of each study’s 
outcome from the overall pooled outcome, adjusting each deviation by the study’s weight 
used in the meta-analysis
9
. The degree of heterogeneity was also quantified using the I
2
 
statistic, which is the percentage of total variation across studies that is due to 
heterogeneity rather than chance
10
. The resulting value ranges from 0 (no heterogeneity) 
to 100, with an increasing amount of heterogeneity as the % I
2
 increases. There were too 
few studies to conduct any meaningful subgroup analyses or meta-regression.  
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5.2 Results 
5.2.1 Study Selection 
 We reviewed 3,920 abstracts and titles, of which 411 were selected for full-text 
review. Of these, 11 reported on the outcomes of colectomy and end-ileostomy for 
patients with ulcerative colitis. Agreement between reviewers for this subset of studies 
was excellent (k = 0.78).   
5.2.2 Study Description and Quality  
 The 11 studies included 3,859 patients from five different countries, reporting on 
patients operated on from 1950 to 2005. Most of the studies were retrospective in nature 
and were of non-consecutive patients (Table 5.1). Two of the studies reported on the 
results of patient questionnaires, one from the US and the other from Australia. Only one 
study was prospective and it was also the only study with a standardized follow-up 
protocol. Only 3 of the 11 studies defined some of their outcome criteria, and length of 
follow-up was only recorded in three studies, with mean follow-up of 96, 110, and 139 
months (Table 5.2). Only four of the studies reported exclusively on patients with 
ulcerative colitis. Patients with Crohn’s disease were included in 6 studies with 
proportions ranging from 9.1% to 39.3%, while 3 studies included patients with FAP, 
ranging from 1.3% to 4%. Of the 11 studies, 6 studies exclusively reported on the results 
of total proctocolectomy, while two studies reported on the results of subtotal colectomy 
and ileostomy. The rate of proctocolectomy varied from 54.7% to 90.9% among the 
remaining three studies. Only two of the studies reported on loss to follow-up, the two 
patient questionnaire studies, which had response rates of 51.5% and 53.6%.  
149 
 
 
 
Table 5.1 Characteristics of Studies Reporting on Outcomes Following Colectomy and Ileostomy 
 
Author Location Years of 
Surgery 
Consecutive 
Patients 
Type of Study Outcome 
Defined 
Standardized 
Follow-up 
Morowitz and 
Kirsner
11
, 1981 
US (multiple states) 1960-1970 No Patient 
Questionnaire  
None No 
Albrechtsen et al
12
, 
1981 
Oslo, Norway 1969-1978 No Retrospective Some No 
Bokey et al, 1984
13
 Sydney, Australia 1950-1981 No Patient 
Questionnaire 
None No 
Bauer et al
14
, 1986  New York, US 1973-1984 No Retrospective Some No 
Berry et al
15
, 1986 Oxford, UK 1972-1984 No Retrospective None No 
Carlstedt et al
16
, 
1987 
Goteberg, Sweden 1959-1984 Yes Prospective None Yes 
Leong et al
17
, 1994 London, UK 1971-1980 No Retrospective None No 
Leijonmarck et al, 
1992
18
 
Stockholm, Sweden 1955-1984 No Retrospective None No 
Carlsen and 
Bergan
19
, 1995 
Oslo, Norway 1980-1989 No Retrospective None No 
Karch et al
20
, 1995 New York, US 1988-1993 Yes Retrospective None No 
Brady et a
21
, 2008 Edinburgh, UK 1994-2005 Yes Prospective Some No 
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Table 5.2 Characteristics of Patients in Studies Reporting on Ileostomy and Colectomy. 
 
Author N Patient Mean 
Age (Range) 
y 
% 
Crohn’s 
% 
FAP 
% 
IC 
% Removal 
of Rectum  
% Prior-
subtotal 
Length of 
Follow-up 
(months) 
Loss to 
Follow-up 
(%) 
Morowitz and 
Kirsner
11
, 1981 
1803 35 (3-79) 0 0 0 70.5 NR NR 51.5 
Albrechtsen et al
12
, 
1981 
154 34.7 (12-76) 0 0 0 90.9 0 NR 0 
Bokey et al, 1984
13
 354 49 10 4 0 100 NR NR 53.6 
Bauer et al
14
, 1986 427 NR 9.1 0 0 100 NR NR NR 
Berry et al
15
, 1986 115 33 23.5 0 0 100 18.3 NR 0 
Carlstedt et al
16
, 1987 104 34 0 0 0 100 NR 96 0 
Leong et al
17
, 1994 150 42 (14-76) 39.3 1.3 0 54.7 NR 110 NR 
Leijonmarck et al, 
1992
18
 
255 NR 0 0 0 100 NR 139.2 0 
Carlsen and Bergan
19
, 
1995 
224 NR 24.1 3.5 0 100 NR NR NR 
Karch et al
20
, 1995 114 37 (13-79) 14.9 0 3.5 0 NR NR NR 
Brady et a
21
, 2008 159 41.9 (13-89) 0 0 0 0 NR NR NR 
 
NR not recorded
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5.2.3 Complications 
 
Ileostomy Revision 
 
 Ten studies totaling 3,432 patients reported on the rate of ileostomy revision with 
individual study estimates ranging from 0.6% to 31.2%
11-13, 16-19
. The pooled estimate was 
17.1% (95% CI, 13.1%-22.1%) with significant heterogeneity p = <0.001, I
2
 at 86.4% 
(Table 5.3). Figure 5.1 graphically summarizes each study estimate, 95% confidence 
interval, and pooled estimate. Looking at the largest study, the questionnaire of 1,803 
patients, the rate of revision within that study was 22.4%. Limiting the studies to ones 
that only reported on patients with ulcerative colitis resulted in a pooled rate of ileostomy 
revision of 14.5% (95%CI, 9.1%-22.2%) for 5 studies reporting on a total of 2,475 
patients. A funnel plot (Figure 5.2) shows evidence of publication bias with fewer smaller 
studies being published with higher rates of ileostomy revision. Depending on the study 
the most common causes for revision were either stenosis or retraction of the ileostomy.  
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Figure 5.1 Forrest plot of studies reporting on rates of ileostomy revision. Point estimates 
are provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size.  
 
Figure 5.2 Funnel plot showing rate of ileostomy revision (ln(odds)) against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of ileostomy revision.   
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Ileostomy Stenosis 
 
 Seven studies totaling 3,044 patients reported on the rate of ileostomy stenosis 
requiring therapy with individual study estimates ranging from 0.6% to 13.5% 
11-13, 15-21
. 
The pooled estimate was 5.7% (95% CI, 3.5%-9.5%) with significant heterogeneity p = 
<0.001, I
2
 at 85.5% (Table 5.3). Figure 5.3 graphically summarizes each study estimate, 
95% confidence interval, and pooled estimate. Looking at the largest study, the 
questionnaire of 1,803 patients, the rate of stenosis within that study was 5.6%. Limiting 
inclusion to studies that only reported on patients with ulcerative colitis resulted in a 
pooled rate of stenosis of 7.3% (95%CI, 3.9%-13.3%) for 4 studies reporting on a total of 
2,316 patients. A funnel plot (Figure 5.4) shows evidence of publication bias with fewer 
smaller studies being published with higher rates of ileostomy stenosis.  
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Figure 5.3 Forrest plot of studies reporting on rates of ileostomy stenosis. Point estimates 
are provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size.  
 
Figure 5.4 Funnel plot showing rate of ileostomy stenosis (ln(odds)) against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of ileostomy stenosis  
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Ileostomy Retraction 
 
 Six studies totalling 2,894 patients reported on the rate of ileostomy retraction, 
with individual study estimates ranging from 5.3% to 18.0% 
11-13, 16, 18, 19
. The pooled 
estimate was 6.2% (95% CI, 2.7%-13.3%) with significant heterogeneity p = <0.001, I
2
 at 
95.0% (Table 5.3). Figure 5.5 graphically summarizes each study estimate, 95% 
confidence interval, and pooled estimate. Looking at the largest study, the questionnaire 
of 1,803 patients, the rate of ileostomy retraction within that study was 12.8%. Limiting 
inclusion to studies that only reported on patients with ulcerative colitis resulted in a 
pooled rate of retraction of 11.3% (95%CI, 6.1%-20.1%) for 4 studies reporting on a total 
of 2,316 patients. A funnel plot (Figure 5.6) shows evidence of publication bias with 
fewer smaller studies being published with higher rates of ileostomy retraction.  
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Figure 5.5 Forrest plot of studies reporting on rates of ileostomy retraction. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size.  
 
Figure 5.6 Funnel plot showing rate of ileostomy retraction (ln(odds)) against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of ileostomy retraction  
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Ileostomy Prolapse 
 
 Seven studies totalling 3,044 patients reported on the rate of ileostomy prolapse, 
with individual study estimates ranging from 0.6% to 10.5% 
11-13, 16-19
. The pooled 
estimate was 3.1% (95% CI, 1.5%-6.4%) with significant heterogeneity p = <0.001, I
2
 at 
88.4% (Table 5.3). Figure 5.7 graphically summarizes each study estimate, 95% 
confidence interval, and pooled estimate. Looking at the largest study, the questionnaire 
of 1,803 patients, the rate of ileostomy prolapse within that study was 10.5%. Limiting 
the studies to ones that only reported on patients with ulcerative colitis resulted in a 
pooled rate of prolapse of 3.6% (95%CI, 1.4%-9.8%) for 4 studies reporting on a total of 
2,316 patients. A funnel plot (Figure 5.8) shows evidence of publication bias with fewer 
smaller studies being published with higher rates of ileostomy prolapse.  
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Figure 5.7 Forrest plot of studies reporting on rates of ileostomy prolapse. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size.  
 
Figure 5.8 Funnel plot showing rate of ileostomy prolapse (ln(odds)) against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of ileostomy prolapse. 
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Ileostomy Fistula 
 
Six studies totalling 2,940 patients reported on the rate of ileostomy fistula, with 
individual study estimates ranging from 0.6% to 9.4% 
11-13, 17-19
. The pooled estimate was 
4.8% (95% CI, 2.7%-8.3%) with significant heterogeneity p = <0.001, I
2
 at 85% (Table 
5.3). Figure 5.9 graphically summarizes each study estimate, 95% confidence interval, 
and pooled estimate. Looking at the largest study, the questionnaire of 1,803 patients, the 
rate of ileostomy fistula within that study was 9.0%. Limiting the studies to ones that 
only reported on patients with ulcerative colitis resulted in a pooled rate of ileostomy 
fistula of 3.1% (95%CI, 0.8%-8.3%) for 3 studies reporting on a total of 2,212 patients. A 
funnel plot (Figure 5.10) shows evidence of publication bias with fewer smaller studies 
being published with higher rates of ileostomy fistula.  
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Figure 5.9 Forrest plot of studies reporting on rates of ileostomy fistula. Point estimates 
are provided along with 95% confidence intervals for each study and the pooled estimate. 
Studies are arranged in increasing order of size.  
 
Figure 5.10 Funnel plot showing rate of ileostomy fistula (ln(odds)) against study size. 
Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of ileostomy fistula. 
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Parastomal Hernia 
 
Seven studies totalling 3,005 patients reported on the rate of parastomal hernia 
requiring repair, with individual study estimates ranging from 0.9% to 10.0% 
11-13, 15, 17-19
. 
The pooled estimate was 3.5% (95% CI, 2.0%-6.1%) with significant heterogeneity p = 
<0.001, I
2
 at 80.8% (Table 5.3). Figure 5.11 graphically summarizes each study estimate, 
95% confidence interval, and pooled estimate. Looking at the largest study, the 
questionnaire of 1,803 patients, the rate of parastomal hernia within that study was 6.3%. 
Limiting the studies to ones that only reported on patients with ulcerative colitis resulted 
in a pooled rate of parastomal hernia of 4.1% (95%CI, 2.1%-7.9%) for 3 studies reporting 
on a total of 2,162 patients. A funnel plot (Figure 5.12) shows evidence of publication 
bias with fewer smaller studies being published with higher rates of parastomal hernia.   
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Figure 5.11 Forrest plot of studies reporting on rates of parastomal hernia. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size. 
 
 
Figure 5.12 Funnel plot showing rate of parastomal hernia (ln(odds)) against study 
standard size. Lack of studies in bottom right hand corner indicates a lack of small studies 
being published with higher rates of parastomal hernia  
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Small Bowel Obstruction 
 
Seven studies totalling 2,849 patients reported on the rate of small bowel 
obstruction requiring operation, with individual study estimates ranging from 1.8% to 
18.0% 
11-13, 15, 17, 19, 20
. The pooled estimate was 9.1% (95% CI, 6.5%-12.8%) with 
significant heterogeneity p = <0.001, I
2
 at 78.5% (Table 5.3). Figure 5.13 graphically 
summarizes each study estimate, 95% confidence interval, and pooled estimate. Looking 
at the largest study, the questionnaire of 1,803 patients, the rate of small bowel 
obstruction requiring operation within that study was 12.7%. Limiting the studies to ones 
that only reported on patients with ulcerative colitis resulted in a pooled rate of small 
bowel obstruction of 7.7% (95%CI, 3.8%-15.3%) for 3 studies reporting on a total of 
2,116 patients. A funnel plot (Figure 5.14) shows evidence of publication bias with fewer 
smaller studies being published with higher rates of small bowel obstruction.   
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Figure 5.13 Forrest plot of studies reporting on rates of small bowel obstruction. Point 
estimates are provided along with 95% confidence intervals for each study and the pooled 
estimate. Studies are arranged in increasing order of size. 
 
Figure 5.14 Funnel plot showing rate of small bowel obstruction (ln(odds)) against study 
size. Lack of studies in bottom right hand corner indicates a lack of small studies being 
published with higher rates of small bowel obstruction 
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Table 5.3 Results of Meta-Analysis of Complications Following Colectomy and 
Ileostomy 
 
Complication 
(ileostomy) 
Number 
of 
Studies 
Number of 
Patients 
Pooled % 95% CI Heterogeneity 
I
2
(%) p 
Revision       
  Total 10 3,432 17.1 13.1-22.1 86.4 <0.001 
  UC only 5 2,475 14.5 9.1-22.2 86.2 <0.001 
Stenosis       
  Total 7 3,044 5.7 3.5-9.5 85.5 <0.001 
  UC only 4 2,316 7.3 3.9-13.3 86.6 <0.001 
Retraction       
  Total 6 2,894 6.2 2.7-13.3 95.0 <0.001 
  UC only 4 2,316 11.3 6.1-20.1 91.4 <0.001 
Prolapse 7 3,044 3.1 1.5-6.4 88.4 <0.001 
  Total 7 3,044 3.1 1.5-6.4 88.4 <0.001 
  UC only 4 2,316 3.6 1.4-9.8 86.9 <0.001 
Fistula       
Total 6 2,940 4.8 2.7-8.3 85.0 <0.001 
UC only 3 2,212 3.1 0.8-8.3 84.2 <0.001 
Parastomal 
hernia 
      
Total 7 3,005 3.5 2.0-6.1 80.8 <0.001 
UC only 3 2,162 4.1 2.1-7.9 69.1 0.04 
Small Bowel 
Obstruction 
      
Total 7 2,849 9.1 6.5-12.8 78.5 <0.001 
UC only 3 2,116 7.7 3.8-15.3 78.3 0.003 
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5.3 Discussion 
 
 Although technically simple when compared to reconstructive procedures, 
proctocolectomy and ileostomy can also lead to significant long-term complications 
related to the presence of the ileostomy. Ileostomy revision can be one of the most severe 
problems as patients must have the ileostomy re-fashioned either at the same site or at an 
entirely new site. The pooled rate of ileostomy revision for all studies was 17.1%, and 
among studies limited to patients with ulcerative colitis, the rate was slightly lower at 
14.5%. Of those studies that listed them, the most common indications for revision were 
stenosis
16, 19
, retraction
11, 18
, or obstruction at the ileostomy site
13
. Ileostomy revision can 
occur locally or can necessitate a full laparotomy with re-siting of the stoma to another 
area of the abdominal wall. The rate of local-only repair varied between those studies that 
reported it from 28% to83%
16, 19. Patients with Crohn’s disease have a higher rate of 
ileostomy revision when compared to ulcerative colitis. Carlsen et al reported the need 
for ileostomy revision among Crohn’s patients was 59.3% versus 18.6% among those 
with ulcerative colitis
19
. Similarly, in the only prospective study, Carlstedt et al identified 
the need for revision among patients with Crohn’s disease was 44% versus 24% among 
ulcerative colitis patients
16
.  
 The rate of peristomal fistula has also been found to be higher among patients 
with Crohn’s disease16, 19. This was reflected by the lower rate of peristomal fistula when 
our meta-analysis was restricted to those studies reporting solely on patients with 
ulcerative colitis, 3.1% versus 4.8%. Interestingly, the rates of other stoma-related 
complications were higher in the ulcerative colitis subgroup when compared to Crohn’s 
disease (Table 5.3). Given that many comparative studies have shown that Crohn’s 
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patients are at higher risk of stoma-related complications, this likely results from 
differences in study design or characteristics relating to length of follow-up, outcome 
definition, losses to follow-up, and other study-level factors. Given these differences in 
outcome rates identified in the meta-analysis, we will limit the use of pooled outcomes 
from studies solely reporting on patients with ulcerative colitis for inclusion in the 
decision aid. 
Like patients with restorative procedures, patients who have undergone a 
proctocolectomy and ileostomy are at significant risk of small bowel obstructions 
requiring operative therapy. The pooled estimate among studies solely reporting on 
ulcerative colitis patients was 7.7%. Looking at the study with the longest reported 
follow-up, the rate of small bowel obstruction was 18%
17
. This underscores the ongoing 
risk for small bowel obstruction that carries on beyond the immediate post-operative 
period. Length of follow-up likely plays a role in explaining the different rates of stoma-
related complications, although it was not possible to examine this as only three studies 
reported on the length of follow-up. 
Only one study reported on the most common problem faced by ileostomates, that 
of skin irritation. In Morowitz’s patients questionnaire, 1005 of 1803 (55.7%) patients 
complained of significant skin irritation
11
. Although this rarely leads to ileostomy 
revision, this complication can be distressing to patients and must also be considered by 
those contemplating life with an ileostomy.    
Although proctocolectomy and ileostomy is considered the benchmark to which 
all other procedures for the treatment of ulcerative colitis are to be compared with
22, 23
, 
there is a lack of methodologically sound studies reporting on the complications of this 
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procedure. The quality of the studies reporting on outcomes following proctocolectomy 
and ileostomy are even poorer than those presented in the preceding chapter of studies 
reporting on IPAA. Only three of the studies reported on length of follow-up, only one of 
seven studies was prospective, and very few defined any of their outcomes. In addition, 
many of the studies reported on patients that were operated on in the 1950s and 1960s, 
with less advanced peri-operative care than the modern era. This is important to consider 
as the outcomes reported here will be included in a decision aid and compared to ones 
from restorative procedures which were carried out during the 1980s -2000s. Given the 
large number of patients who choose to undergo restorative procedures, it may be 
difficult to obtain large numbers of patients who have had the conventional treatment of 
proctocolectomy and ileostomy. In a study of over 25,000 ulcerative colitis patients of 
whom 215 had a colectomy, only 29 patients had a total proctocolectomy and end-
ileostomy
24
. This discrepancy in number of patients makes it difficult to compare the 
results of ileostomy to those of IPAA. As was seen in the preceding chapter, there exists a 
wealth of studies reporting on the results of IPAA, while only 11 studies were identified 
that reported on the results of colectomy and ileostomy. This discrepancy is further 
compounded by the very poor quality of the ileostomy studies. Each outcome reported in 
the meta-analysis contained significant heterogeneity (Table 5.3). Unlike the IPAA 
literature, there were too few studies to carry out any meta-regression or any meaningful 
subgroup analyses to explore this heterogeneity.  
 Although severely limited by the small number of studies, historical nature 
of patient cohorts, and poor study quality, we show that patients with ulcerative colitis 
who undergo a total proctocolectomy and end-ileostomy do have a significant risk of 
169 
 
 
ileostomy revision with a pooled estimate of 14.5% (95% CI, 9.1%-22.2%). Most other 
stoma-related complications occur relatively infrequently (<10%); and patients are at risk 
of requiring surgery for a bowel obstruction in the future, as high as 18% among studies 
with longer follow-up. The risks of these potential complications along with the obvious 
changes in body image, daily routine, and lifestyle must be considered by patients who 
are deciding between IPAA and ileostomy.   
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CHAPTER SIX- REFINEMENT AND TESTING OF PROTOTYPE DECISION AID 
 
6.0 Introduction 
 
A patient’s decision between treatment options is complex and requires the 
assimilation of a large volume of information regarding complications and expected 
outcomes.  It is imperative that patients select the surgical procedure that best fits with 
their own expectations and values. There is a paucity of data concerning effective 
communication methods for patients with IBD
1
. Despite a paucity of data, patients with 
ulcerative colitis who require surgery are faced with deciding between a restorative pouch 
procedure or an ileostomy. Decision aids are tools designed to facilitate communication 
of information to patients and enhance their ability to exercise treatment preferences
2, 3
.  
At least 55 randomized controlled trials have evaluated different decision aids for 
various medical decisions
4
. These trials have generally found the use of decision aids to 
lead to improved patient knowledge, reduced decision conflict, and improved patient 
satisfaction with treatment decisions, when compared with traditional methods of patient-
physician interaction
4
. To our knowledge, no decision aids exist to assist patients with 
ulcerative colitis in making this difficult surgical decision.  Our objective is to develop 
and evaluate a decision aid for patients with ulcerative colitis who are undergoing an 
elective proctocolectomy to help them decide between IPAA and ileostomy. The general 
aspects concerning both decision aids and ulcerative colitis and the role of surgery were 
discussed in chapter one of this work. Surgery is generally reserved for patients who fail 
medical management or who develop complications of ulcerative colitis (toxic colitis, 
perforation, cancer or dysplasia). Two main options exist for the patient following 
removal of the colon, either an ileostomy, where bowel movements are expressed into a 
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bag worn on the skin of the abdomen, or formation of a neo-rectum by using the small 
bowel as a pouch, known as ileal pouch-anal anastomosis (IPAA). Both options have 
been shown to have equivalent quality of life as demonstrated by the systematic review of 
these studies in Chapter Three. Despite equivalent quality of life, both options vary 
greatly in their procedure, changes to daily life, and complication profiles. Two separate 
systematic reviews and meta-analyses where conducted of studies reporting on 
complications following either procedure (Chapter 4-IPAA studies, Chapter 5- ileostomy 
studies), the results of which were used to construct a prototype decision aid. This pilot 
aid will then be refined by input from surgeons, enterostomal therapists, and patients. 
Following the refinement process, the aid will be tested for reliability and validity on 
healthy volunteers before being used with patients. This chapter describes the 
methodology behind this process and guides future endeavours aimed at further 
refinement of the aid.  
 
6.1. Methods 
To develop the decision aid we used accepted methodology
5-7
 and followed 
quality criteria established by an international committee on patient decision aids
8
. The 
major steps involved in the development of this aid consist of gathering information, 
initial decision aid prototype construction and refinement, and evaluation of the decision 
aid on healthy volunteers for reliability and validity. Figure 6.1 outlines the major steps in 
the development.  
6.1.1 Information sources 
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In order to determine what information to include in the decision aid we 
conducted a systematic review of the literature for studies of proctocolectomy and either 
ileostomy or IPAA. We have constructed a rough prototype based on the information 
retrieved from the systematic review and plan on presenting this to colorectal surgeons 
and enterostomal therapists to collect their input, and refine the prototype based on their 
recommendations. Finally, we will present the aid to patients with ulcerative colitis who 
have undergone either surgical option to identify information they feel is important in 
reaching a decision and to further refine our prototype.  
 
6.1.2 Systematic Review and Prototype Design 
 Chapters Four and Five detail the methods and results of the systematic reviews of 
studies reporting on outcomes following either the IPAA option or the ileostomy option. 
Given the between study heterogeneity, we selected specific sub-groups of studies to 
include as a source of information for the aid. For the studies summarizing the results 
following ileostomy, we limited the inclusion of the pooled estimates from those studies 
that only reported on patients with ulcerative colitis, as we are dealing with this group of 
patients. For the IPAA studies, we systematically explored both clinical and 
methodologic study level factors for their influence on each outcome by using meta-
regression methods. Those with a significant association and a clinical rationale (for 
example longer follow-up associated with higher rates of pouch failure) were used as the 
subgroup of studies for inclusion into the decision aid.  The following table lists the point 
estimates used in the construction of the aid and the specific subgroup used as the source.  
For each point estimate generated from the literature, we expressed it as x/100 for all 
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outcomes. Utilizing a ratio with a common denominator is recommended by the 
International Patient Decision Aid Standards Collaboration as a way to present 
probabilities
8
. Along with a text-based description of the probabilities, we utilized a 
pictorial representation of the risk of complications. The addition of visual 
representations of risk have been shown to improve how easily and accurately patients 
process quantitative information
9
. In addition, the format of the visual information 
appears to affect the process with horizontally oriented pictographs being superior to 
vertical formats and pie charts
9, 10
.  
 
Table 6.1 Data Sources Used for Construction of the Decision Aid.  
Intervention Outcome Point estimate Subgroup 
Ileostomy  Ileostomy revision 14.5% ~ 15/100  Ulcerative colitis 
Ileostomy  Ileostomy stenosis 7.3%~ 7/100 Ulcerative colitis 
Ileostomy Ileostomy retraction 11.3 ~ 11/100 Ulcerative colitis 
Ileostomy Ileostomy fistula 3.1 ~ 3/100 Ulcerative colitis 
Ileostomy Parastomal hernia 
requiring repair 
 
4.1 ~ 4/10044 Ulcerative colitis 
Ileostomy Small bowel 
obstruction 
 
7.7 ~ 8/100 Ulcerative colitis 
IPAA Pouch failure 6.1 ~ 6/100 Follow-up >5years 
IPAA Pelvic sepsis 11.4~ 11/100 Prospective studies 
IPAA Pouch fistula  9.4%~ 9/100 Defined outcome 
criteria 
IPAA Anastomotic stricture 12.6~ 13/100 Defined outcome 
criteria 
IPAA Pouchitis 28.7% ~ 29/100 Defined outcome 
criteria/ follow-up >5 
yrs 
IPAA Small bowel 
obstruction 
22.5% ~23/100 Defined outcome 
criteria 
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IPAA Sexual dysfunction 4.6% ~5/100 Overall group 
IPAA Fecal incontinence  9.1% ~ 9/100 ≥ 85% J-pouch 
IPAA Fecal urgency 3.9% ~4/100 ≥ 85% J-pouch 
IPAA Daily pad use 5.7% ~ 6/100 ≥ 85% J-pouch 
IPAA Anti-diarrheal 
medication use 
 
32.9% ~ 33/100 Overall group 
IPAA Number of BM/day 6.1 ~ 6 / day ≥ 85% J-pouch 
IPAA Number of BM/ night  1.0 ~ 1/night Overall group 
 
 
We constructed the prototype aid along three categories: information about the procedure, 
potential complications, and changes to daily life. This was constructed as an interactive power 
point presentation that is designed to be used by the surgeon with the patient during the clinical 
encounter. This can easily be modified and adapted into a pamphlet or be uploaded to the internet 
for patient self-study. We selected this format as the aid is not meant to replace the surgeon-
patient interaction, but rather enhance the process of information exchange
11
, and the 
International Patient Decision Aid Standards Collaboration do support the use of the aid in a 
guiding or coaching role during the patient-physician encounter
8
.  In addition to presenting 
information about the procedures, specific values-clarification exercises have been built into the 
aid. The concept of values refers to the qualities that a given patient considers desirable or 
important, and the process of value clarification has become part of decision aids
4
. In the most 
recent systematic review, decision aids incorporating value clarification exercises were found to 
be more effective than simpler aids by improving patients’ decisions and making them more 
congruent with their values
12
.   
Not all authors agree that value clarification has a role in decision aids. Nelson et al 
question whether patients need explicit value clarification, and point out that intuitive decision 
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making on the part of the patient may lead to better decisions as too much introspection and 
attention to detail may disrupt intuitive processes and interfere with a patient’s ability to focus on 
the relevant material, or inhibit the formation of global impressions leading to a decision being 
made
13
. Despite these theoretical concerns, we opted to include a short segment on value 
clarification, as the recent literature has shown it to be effective in improving the decision making 
process. To help clarify a patient’s values, we listed a group of questions regarding various 
attributes of each procedure and asked patients to indicate on a Likert scale how important each 
attribute was to them, with a suggestion at each end of the spectrum corresponding to the 
appropriate treatment option that fit with the value being expressed by the question. For example: 
     
 How important is it to you to avoid a stoma/ ileostomy? 
Not 
important 
    Very 
Important 
0 1 2 3 4 5 
You should consider 
ileostomy 
You should consider pouch  
 
 Throughout our literature review we did not identify any studies that directly compared 
survival between the two surgical options. Although it is not known with certainty, the survival 
following each option is likely to be similar given the same control of disease. Thus we have 
chosen to focus on highlighting the procedure-specific complications with our decision aid, in an 
effort to help patients understand the difference between the two procedures. The prototype aid 
can be found in Appendix B.  
 
6.1.3 Input from Surgeons and Enterostomal therapists 
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Now that a rough prototype has been developed, we will present it to a group of three 
colorectal surgeons and two enterostomal therapists to obtain their feedback on the content, 
format, layout, and practical aspects of the prototype. We will also ask them to describe any 
information they feel is important to the patient interaction that we have omitted from the aid. The 
prototype will then be refined using this feedback. The interview guide for this focus group is 
included in Appendix C.   
 
6.1.4 Input from Patients 
We will conduct focus groups with patients who have had a proctocolectomy for 
ulcerative colitis.  The goal of these groups is to identify information helpful to patients deciding 
between treatment options. In order to generate as much information as possible, we will use 
maximum variation sampling
20
 by including patients that have had both surgical options, and 
patients that did and did not have complications following surgery. We will present the prototype 
to two groups, one of patients who underwent ileostomy and one of patients who underwent 
restorative proctocolectomy. Similar to our interaction with surgeons, we will seek feedback on 
the content, format, layout, and practical aspects of the aid. We will ask patients to describe any 
information they feel is relevant to the decision that we have omitted. Based on the information 
received from the patients we will modify the prototype further to incorporate their suggestions. 
This prototype will then be piloted on three patients who have recently undergone a 
proctocolectomy to further refine the aid for clarity and practicality. These patients will be 
recruited by their surgeon. The interview guide is included in Appendix D.  
6.1.5 Reliability and Validity Testing   
Once we have a refined prototype we will evaluate it in healthy volunteers for reliability 
and validity according to previously published methodology
5, 14, 1521,22
. We have decided to use 
volunteers rather than patients because it is clinically inappropriate and potentially unethical to 
manipulate information concerning therapy and outcomes to patients at the decision point
21,22
.  An 
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interviewer will administer the instrument to 30 volunteers who will then state a preference 
between the two surgical options. In order to establish reliability we will re-administer the 
instrument 2 weeks later to the same volunteers and ask them to state their treatment preferences 
again.  Reliability between treatment preferences will be measured using a kappa statistic. To 
establish validity we will change the information provided in the decision aid and determine if the 
volunteers’ treatment choices change in a predictable manner based on the change in information 
present on the decision aid. For example, if a volunteer prefers the IPAA treatment option we will 
change the information to reflect an increase in pouch failure and see if manipulating the 
information present in the aid can result in a predictable change in decision. Volunteers will be 
recruited by use of posters put up at both the UWO campus, and in University and Victoria 
Hospitals. The datasheet used for this portion of the project is included in Appendix E. University 
ethics approval form for this portion of the project is included in Appendix F.  
 
                                                  Systematic review and data abstraction 
 
 
Creation of rough prototype 
 
 
Presentation of prototype to surgeons and enterostomal therapists 
 
 
 
Presentation of refined prototype to two groups of patients (ileostomy group and restorative 
proctocolectomy group) 
 
 
 
Piloting of Aid to patients who have undergone the decision for clarity   
 
 
 
Evaluation of aid for reliability and validity in healthy volunteers 
 
Figure 6.1 Flow Chart Outlining Steps in the Development of the Decision Aid. 
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6.2 Conclusions and Further Directions  
 
 This work outlines the steps necessary in the design of a decision aid to help 
patients with ulcerative colitis decide between ileostomy and IPAA procedures. Although 
limited by the poor quality and heterogeneous literature, we used a systematic and 
rigorous process of exploring heterogeneity amongst the IPAA studies in order to select 
the most appropriate subgroup of studies to include in the aid. With a valid and reliable 
decision aid, the next step would be its evaluation on patients with ulcerative colitis. The 
aid will be administered to patients with ulcerative colitis who are at the decision point 
and following this several established outcomes for decision aids would be assessed 
including knowledge about the options and their complications, decisional conflict
16
, risk 
perception
12, 17
, preferred role in decision making
18
, and satisfaction with decision 
making
19
. This evaluative process would necessitate a randomized controlled trial and the 
specific methodology is beyond the scope of this work, but is the next step in the 
evaluation of this decision aid.  
 There now exist a wealth of literature supporting the benefits of decision aids in 
enhancing the decision making process for patients. The decision between an ileostomy 
or a restorative pouch procedure is well suited to the use of a decision aid and with a 
rough proto-type now designed, further work will look towards refinement and evaluation 
of this aid with the hope of improving these patients decision making process.  
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APPENDIX A- Search Strategies Used to Identify Primary Studies 
 
 
 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Colitis/ or Colitis, Ulcerative/ or Inflammatory Bowel Diseases/  
2     (inflammatory bowel disease$ or ulcerative colitis or IBD or colitis).mp.  
3     1 or 2  
4     Colonic Pouches/ or Proctocolectomy, Restorative/ or Ileostomy/  
5     (j pouch$ or y pouch$ or w pouch$ or continent pouch$).mp.  
6     (ileo pouch anal-anastomosis or ileo pouch anal anastomosis or IPAA or end-
ileostomy or end ileostomy or ostom$ proctocolectom$ colectom$).mp.  
7     4 or 5 or 6  
8     3 and 7  
9     limit 8 to yr="1978 -Current"  
*************************** 
 
 
  
Database: Cochrane Library 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     ((ulcerative adj2 coliti$) or coliti$ or (inflammatory bowel adj2 disease$) or IBD or 
inflammatory bowel).mp.  
2     (ileo pouch anal anastomosis or ileonalanastomosis or IPAA or anastomosis).mp.  
3     (proctocolectom$ or end-ileostom$ or end ileostom$ or ileostom$ or ostomy).mp.  
4     (colonic pouch$ or continent pouch$ or y pouch or w pouch or j pouch or ileoanal 
reservoir$ or anal reservoir$).mp.  
5     2 or 3 or 4  
6     1 and 5  
7     limit 6 to yr="1978 -Current"  
 
*************************** 
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Database: Embase  
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Colitis/ or Enteritis/ or Ulcerative Colitis/  
2     (inflammatory bowel disease$ or ulcerative colitis or IBD or colitis).mp. (77269) 
3     1 or 2  
4     ileoanal anastomosis/ or ileostomy/ or proctocolectomy/ or continent ileostomy/ or 
Colon Pouch/  
5     colon pouch/ or rectum anastomosis/ or exp rectum resection/  
6     (colon$ pouch$ or ileoanal anastomosis or proctocolectom$ or ileostom$ or colon 
pouch$ or ostomy).mp.  
7     (j pouch$ or y pouch$ or w pouch$ or continent pouch$).mp.  
8     4 or 5 or 6 or 7  
9     3 and 8  
10     limit 9 to yr="1978 -Current"  
11     remove duplicates from 10  
 
*************************** 
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APPENDIX B-PROTOTYPE DECISION AID 
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APPENDIX C-Prototype-Refinement Phase I  
Interview Guide 
Group: Surgeons and Enterostomal Therapists 
 
Moderator: Luc Dubois 
Method: Focus Group 
Goals:  
1) Collect input from surgeons and enterostomal therapists on the 
content, format, and practical aspects of the decision aid. 
2) Seek additional information surgeons or eneterostomal therapists 
find relevant to the decision.  
 
Pre-amble 
“ I would like to thank everyone for agreeing to help with this research project. The goal 
of this project is to develop a decision aid that will help patients with ulcerative colitis 
choose between restorative proctocolectomy with ileal anal-pouch anastomosis or end-
ileostomy. The purpose of this meeting is to discuss and comment on the decision aid we 
have constructed. We are seeking your input into the content, format, and practical 
aspects of the decision aid. 
 
This discussion should take approximately one hour. We will record this discussion and 
analyse the recording to identify any recommendations and refinements for the decision 
aid.  
 
Your answers will be kept confidential and your participation in this group is voluntary, 
you may leave or refuse to participate at any time. 
 
Before we begin are there any questions about this project or the purpose of this meeting? 
” 
 
  
I Present the decision aid prototype to the group 
 
II Seek input from surgeons and enterostomal therapists on the 
following domains:  
 
1) Content 
Framing question: 
 Do you have any comments on the content we have included in the aid?  
 
Follow-up questions:  
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Do you think the information about the procedure, benefits, functional outcomes, and 
risks accurate? 
 
Would you be comfortable presenting this information to your patients? 
 
 
 
Is there any further information you would recommend we include in the aid that we have 
not presented?  
  
Is the language of an appropriate level for your patients?  
 
Should we include graphical representations or pictures of certain aspects of the 
procedure? 
 
 
Is there any information you don’t understand or think patients would have difficulty 
understanding?   
 
Are there any changes you would make to the content of the aid?  
 
2) Format 
 
 Framing question: 
Do you have any comments about the format of the aid?  
 
Follow-up questions:  
Do you think the current format facilitates discussion with patients? 
 
Are there any other formats (board, pamphlet) that you would prefer for the aid?   
 
Are there any changes you would make to the format?  
 
3) Practical Aspects 
 
Framing question: 
Do you have any concerns about the practical aspects of the aid?   
 
Follow-up questions:  
In your opinion, how long should the aid take to administer?  
 
Are there any elements of the aid you think would hamper patient interaction?  
 
Are there any elements that we have omitted that would aid patient interaction?   
 
Are there any changes you would make to the aid to improve its practicality?  
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4) Overall Impression: 
 
Know that you have considered all aspects of the aid, are there any further changes you 
would recommend we make?    
 
 
III Closing Remarks 
 
“Are there any remaining questions or comments? The audio recording will be analyzed 
and the aid will be modified according to your feedback. A modified version of the aid 
will be sent to you once the changes are made. Thank you again for participating in our 
research project.”   
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Prototype-Refinement Phase I 
Data Sheet Group: Surgeons and Enterostomal Therapists 
Date of focus group:  
 
Participant Characteristics 
Surgeon Age Sex Years in Practice 
1    
2    
3    
 
Enterostomal 
Therapists 
Age Sex Years in Practice 
1    
2    
3    
 
Results of Group Discussion 
 
 
Comments Changes Proposed 
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APPENDIX D Prototype-Refinement Phase II  
Interview Guide 
Group: Patients with ileal anal-pouch anastomosis 
Moderator: Luc Dubois 
Method: Focus Group 
Goals:  
1) Collect input from patients on the content, format, and practical 
aspects of the decision aid. 
2) Seek additional information patients find relevant to the decision.  
 
I Pre-amble 
“ I would like to thank everyone for agreeing to help with this research project. The goal 
of this project is to develop a decision aid to assist patients with ulcerative colitis when 
deciding between two surgical options. One is to remove the colon and make a new 
rectum from the small bowel (ileal anal-pouch anastomosis), the other is to bring the 
small bowel out to the skin as an ileostomy. The purpose of this meeting is to discuss and 
comment on the decision aid we have constructed. We are seeking your input into the 
content, format, and practical aspects of the decision aid.” 
 
“This discussion should take approximately one hour. We will record this discussion and 
analyse the recording to identify any recommendations and refinements for the decision 
aid.”  
 
“Your answers will be kept confidential and your participation in this group is voluntary, 
you may leave or refuse to participate at any time.” 
 
“We recognize that discussing aspects of your prior treatment and illness may be 
upsetting, if you feel you need to leave at any moment, please feel free to do so. If you 
feel you require any counselling or other help following this meeting, we will work with 
you to arrange it.” 
 
“Keep in mind that there are no right or wrong answers to these questions.” 
 
“Before we begin are there any questions about this project or the purpose of this 
meeting? ” 
II Present the decision aid prototype to the group 
 
III Seek input from patients on the following domains:  
1) Content 
Framing question: 
 Do you have any comments on the content we have included in the aid?  
 
Follow-up questions:  
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Is the information we have presented in the aid easy to understand? 
 
Would the information in the aid be helpful in making a treatment decision?  
 
Is there any information you think we should add to the decision aid? 
 
Are there any elements of the decision aid we need to clarify?  
 
Would the use of pictures representing the procedures help?  
 
Do you think there is too much information included in the aid?  
 
Do you think there is too little information in the aid?  
 
Is there any language used in the aid that you feel is threatening?  
 
 
2) Format 
 
 Framing question: 
Do you have any comments about the format of the aid?  
 
Follow-up questions:  
Do you think the current format facilitates discussion with a surgeon? 
 
Are there any other formats (board, pamphlet) that you would prefer for the aid?   
 
Are there any changes you would make to the format? 
 
Do you think a take-home version of the aid would be beneficial?  
 
3) Practical Aspects 
 
Framing question: 
Do you have any concerns about the practical aspects of the aid?   
 
Follow-up questions:  
In your opinion, how long do you think it should take you to go through the aid?  
 
Do you think any parts of the aid will prevent discussion with the surgeon?  
 
Is the current layout easy to use?  
 
Is the current layout inviting?  
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Would you recommend any changes to the layout or any other aspects of the aid?  
 
4) Overall Impression: 
 
Know that you have considered all aspects of the aid, are there any further changes you 
would recommend we make?    
 
IV Closing Remarks 
 
“Are there any remaining questions or comments? The audio recording will be analyzed 
and the aid will be modified according to your feedback. Thank you again for 
participating in our research project. If you have any residual questions please feel free to 
contact me.”   
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Prototype-Refinement Phase II  
Data Sheet  
Group: Patients with ileal anal-pouch anastomosis 
Date of focus group:  
 
Participant Characteristics 
Patients Age Sex Years Since 
Surgery 
1    
2    
3    
4    
5    
6    
7    
8    
 
Results of Group Discussion 
 
 
Comments Changes Proposed 
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Appendix E- Reliability and Validity Testing                 
Data Sheet-Page 1 
Participant Number  ___   ___     Date: __ __ __ __-__ __-__ __ 
 
Demographic Information 
1.Age (years)          _____________ 
 
2.Gender         □ Male                   □ Female 
 
3.Relationship 
Status 
          □ Married/ Cohabitating  
          □ Single/ divorced/ widowed 
 
4.Education         □ High School or equivalent or less 
         □ College or University (post-secondary)  
 
 
Decision Information: First Encounter  
Time of administration (mins)          _____________ 
 
Decision with normal probabilities  □ End-ileostomy 
□ Ileal anal-pouch anastomosis  
 
Decision with altered probabilities 
(validity) 
□ End-ileostomy 
□ Ileal anal-pouch anastomosis  
 
How easy was it to understand the 
information presented in the aid?  
□ Very Easy 
□ Somewhat Easy 
□ Somewhat Difficult     
□ Very Difficult 
 
How helpful was the decision aid 
in assisting you when making the 
decision? 
□ Very Helpful 
□ Somewhat Helpful 
□ Somewhat Unhelpful 
□ Very Unhelpful 
Decision Information: Second Encounter (reliability) 
Date of Second Encounter __ __ __ __-__ __-__ __ 
 
Decision with repeated 
administration 
□ End-ileostomy 
□ Ileal anal-pouch anastomosis  
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